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3To the pursuit of Science.
In memory of the work carried out by my aunt Patricia Cody who co-founded DES Action 
in the U.S. and wrote “DES Voices: From Anger to Action”. For decades she worked to 
raise public awareness of the long-term effects of in-utero exposure to diethylstilbestrol
and prevent cervical and other gynecological cancers through intensified screening 
efforts.
This thesis is also dedicated to the memory of my classmate Gretchen Day, whose life 
ended this year due to cervical cancer. Gretchen died just 10 weeks after the birth of her 
first child. Behind every mortality statistic there is a face, and a legacy of life left behind.
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5AbstrAct
Aim: This thesis aims to provide a multidimensional assessment of infection risks and 
to evaluate strategies for HPV prevention including vaccination with quadrivalent HPV-
vaccines, dose-level vaccine effectiveness and condom use in high STI risk situations. 
Methods: Multiple population-based registers and questionnaire responses provided data 
for this thesis. Various multivariable and univariate regression models were fit.
Findings: Overall, quadrivalent HPV-vaccination was highly effective against genital 
warts (GW) also referred to as condyloma, which is the first HPV disease endpoint 
possible to measure. However, effectiveness was contingent upon young age-at-first 
vaccination, with effectiveness declining steadily the older the age-at-first vaccination. 
Among women above 20 years of age there was low to immeasurable effectiveness and 
suggestive evidence vaccinations in this age group tended to reach women at high GW 
risk. There were marked socioeconomic disparities in the opportunistic (on-demand with 
co-pay) vaccination strategy evaluated, with women and girls who have parents with 
the highest education level compared to the lowest having a 15 times greater likelihood 
to be vaccinated (Study III). Once vaccination was initiated, however, high parental 
education level was unrelated to vaccination completion. Maximum protection against 
GW was found among girls vaccinated under the age of 17 who had received three doses 
of the vaccine. No differences in effectiveness were found for girls who received two-
doses between ages 10-16 with that of those who received three-doses between ages 17-
19 (Study IV).  GW affects more men than women in Sweden as of 2010 with 453 per 
100 000 men and 365 per 100 000 women treated. A decline between 25-30% was seen 
between 2006 and 2010 among women in the age groups with the highest vaccination 
coverage. No decline was found amongst men and their GW incidence has steadily 
increased between 2006 and 2010 (Study II). Reported condom use in high risk situations 
was low among both men and women, with 41% of men and 34% of women reporting 
always/almost always condom use with temporary partners. STI risk perception was also 
low, with approximately 10% of sexually active respondents considering themselves at 
large risk of contracting an STI. There was no association between men’s condom use and 
their STI risk perception but there was an association for women (Study I). 
Conclusions: Results suggest that males bear a substantial burden of HPV-related 
condyloma where incidence has dropped among women. When planning HPV-
vaccination among females, efforts should target girls under age 14 for maximum 
effectiveness. Quadrivalent HPV-vaccination offers most protection against condyloma at 
three doses. Gross social inequity was found with opportunistic HPV-vaccination. There 
were large gender differences in factors associated with condom use in high risk situations 
and STI risk perceptions.
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PrefAce: unfoLding ePidemioLogy
Human papillomavirus (HPV) is the most prevalent sexually transmitted infection (STI) 
in the world with an estimated 80% of sexually active individuals infected during the 
course of their lifetime1. Most HPV infections are transient and will clear without external 
intervention. Low oncogenic risk types can lead to cases of genital warts so minor as to 
go undetected while others lead to cases of genital warts so persistent that even after bouts 
of multiple treatment (including surgery) the infections will not clear. High oncogenic 
HPV-types can lead to dysplasia, which thanks to screening and early treatment, may 
never develop into HPV-related cancers. High risk oncongenic HPV-types are a necessary, 
but not sufficient, cause of many cancers, the most common being cervical cancer. HPV 
is not the only cancer-causing virus but it is the most common. Roughly fifteen percent of 
all cancers have been attributed to infectious agents ranging from HPV, Hepatitis B and 
C, Epstein Barr and Helicobacter pylori 2. Though cancer-causing viruses are not new 
discoveries their public health impact and prevention are new. Astrid, one of the women I 
interviewed to discuss HPV risk and prevention said, “Cancer is nothing I’ve ever thought 
about in relation to sex”. 
My original project plan for this thesis was to conduct qualitative assessments of 
quantitative analyses using internet-based focus group methodology. The broad intention 
was to explore how young women and men conceptualized HPV and prevention of HPV-
related diseases after the launch of HPV vaccines. Respondents from a large population 
based survey, “Attitudes toward HPV Vaccination”, were to be the sampling frame for this 
investigation. 
To begin this qualitative investigation, I thought it was important to more closely 
scrutinize respondents’ prevention engagement and risk perceptions. I designed the first 
study in my thesis to examine complex prevention engagement in risk situations: condom 
use with temporary partners. Though it may not sound excessively complicated I believe 
condom use is highly complex as it involves continual decision making in various risk 
situations, with a constant negotiation between individual needs and partner dynamics. I 
also wanted to examine to what extent perceptions of risk are associated with prevention 
engagement. Finally, I wanted to determine if there were gender differences in prevention 
engagement in terms of condom use and STI risk perceptions.
The results from this first study generated more questions for my planned qualitative 
investigations: why were women engaging in high STI risk sexual intercourse (with 
temporary partners and without the use of condoms) when they considered themselves to 
be at risk for contracting an STI?  Why was the prevalence of reported condom use with 
temporary partners higher for men than women? What were men and women doing to 
avoid risks? What did they think of HPV and their HPV risks? Although my qualitative 
investigations were not included as papers in my thesis, I will present some preliminary 
selected results where they pertain to this thesis topic.
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What struck me time and time again in the discussions with the almost 100 men and 
women I interviewed for these qualitative analyses was the gross underestimation of 
men’s HPV risk and burden of HPV-related disease. Some did not understand how men 
were involved with HPV as they assumed it only infected women. Though our HPV 
questions mostly centered around HPV-related cancer, study participants expressed 
concern and had many questions regarding genital warts (GW) and their transmission, 
cure rates, etc. Many were unaware that GW were caused by HPV. Participants’ 
misunderstandings and underestimations of men’s risks reflected the underestimations 
and uncertainty in the field of HPV-research. While examining the scientific literature I 
realized there were no population-based estimations for the burden of GW among men in 
Sweden. A single study from one STI clinic in the 1990s had also reported substantially 
higher GW incidence among women than men3. The natural history of genital HPV 
infections, their clearance, potential for reinfection – all broached by the participants – 
was no easy matter to unpack when examining the literature. Participants asked questions 
to which science is still trying to find answers.
Many women I interviewed expressed feeling like they were shouldering the entire 
burden of HPV-related disease prevention, which many found unfair considering the other 
burdens they expressed shouldering for birth control and STI testing. The considerable 
misunderstanding of men’s HPV-related risk and burden of disease that was found 
convinced me of the need to establish men’s burden of HPV-related disease in Sweden.  
As GW is not one of the reportable STIs in Sweden, establishing accurate estimations 
was not straightforward. I knew podophyllotoxin was used exclusively in the treatment 
of GW and that Sweden’s relatively new prescription drug register would provide insight 
into prescription trends. After discussing the matter with various gynecologists around 
the country who worked in STI clinics, I thought it would be necessary to also examine 
imoquimod prescriptions. As HPV-vaccines had been launched after the availability of 
the prescribed drug register, this second study in my thesis allowed for first glimpses into 
the potential impact of HPV vaccination in Sweden. The short incubation time of GW 
provided opportunity to measure vaccine effectiveness in the population with an actual 
HPV-related disease endpoint.
My ambition to establish GW risk estimations for men and women in Sweden put me 
in the right place at a dynamic time. A researcher in my department was planning to 
study HPV vaccine effectiveness with a non-ecological study design in collaboration 
with Merck Sharp and Dohme Corporation. They had originally intended to use 
podophyllotoxin prescriptions as a proxy for GW and link to individual vaccination status 
using Sweden’s national vaccination register but only in girls ages 13-17. We combined 
forces and expanded the study to include all girls and women ages 10-44 for the third 
study in my thesis.  Involvement in this vaccine effectiveness study allowed me to move 
from an ecological to a cohort design, providing a unique opportunity in the context of 
vaccination effectiveness evaluation. 
Traditionally, observational studies are thought to be a necessary but inferior substitute to 
randomized clinical trials. By design, observational studies are prone to biases that should 
not be present in well-designed randomized trials. Through the randomization process, 
different background characteristics which could influence effect estimations should be 
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evenly distributed throughout the control and treatment groups, allowing for the effect 
of treatment on the event outcome to emerge clearly. However, in the case of measuring 
vaccination effectiveness, these observational studies have a unique advantage over 
clinical trials: real-life situations. Clinical trials create a constrained environment where 
rigorous inclusion and exclusion criteria are delineated, creating a sub-population which 
may not be fully generalizable to the more diverse populations in which the treatment, or 
in this case the vaccinations, will be used. I will continually return to this point throughout 
this thesis. 
Most countries in the world do not have comprehensive population health registers. Those 
which do are usually limited in their capacity to link individual records between various 
registers. In another point I will return to throughout this thesis, the Nordic countries, 
with their extensive population registers and the ability to link to individual-level data, 
can make unique contributions to a global field in terms of measuring vaccination 
effectiveness.  
With the help of advice from statisticians in my department, the vaccine effectiveness 
analysis was designed with vaccine dose as a time-dependent exposure using techniques 
available in survival analysis, also referred to as time-to-event analysis. Many months 
were spent trying to untangle various effects; we knew the vaccines had to be given prior 
to HPV exposure, so essentially prior to sexual debut given the prevalence of HPV, to 
have an effect. We had also learned from our ecological study on men and women’s GW 
risk just how age-sensitive GW occurrence was. Given the relatively short follow-up in 
our study, less than five years, untangling the effects of age-at-vaccination and attained 
age was problematic. To complicate matters, we also had the effect of different vaccine 
dose levels which we could actually account for due to the time-varying exposure design. 
When we had ascertained just how important age-at-first vaccination was for vaccine 
effectiveness, it was decided that we would examine dose-level effectiveness in a cohort 
of younger individuals where we could more precisely ascertain the effects of dose in 
an age-group where we knew there was high vaccine effectiveness. We also understood 
we had to more closely probe our cohort for self-selection biases if we were to draw any 
conclusions on dose-level effectiveness. This dose study became the final study in this 
thesis, which was conducted independently from Merck Sharp and Dohme Corporation 
who were in no way involved in financing, design, data collection, analysis, result 
interpretation or manuscript writing.
In the past years, dose efficacy has emerged as a critical facet of vaccination strategy 
planning. The two competing HPV-vaccines available on the world markets were both 
designed to be administrated in a three-dose schedule over the course of six months. 
Three doses are expensive as is the administration and feasibility of implementing three-
doses in the context of public health programs. Clinical trials have recently emerged 
indicating that one of the vaccines is as protective with a two-dose schedule as a three-
dose schedule4. This trial has not measured HPV-related disease outcomes, however, just 
the presence of HPV infection. Another trial has only been able to show data on antibody 
level responses5. Neither of these measures, antibody response and HPV infection, are 
the disease outcomes which the vaccines are intended to prevent. With the data from 
the Swedish registers on vaccine exposure status and disease outcomes from the entire 
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population, complimentary information to the efficacy trials in terms of actual disease-
outcome measures related to specific vaccine dose-levels can be provided. In this context, 
observational epidemiological studies are necessary compliments, and not merely second-
best substitutes, to clinical trial findings. 
In Journal of Infectious Diseases, Castle and Zhao wrote a commentary: Population 
Effectiveness, Not Efficacy, Should Decide Who Gets Vaccinated Against Human 
Papillomavirus via Publicly Funded Programs 6. Here the authors call for observational 
studies to be used as necessary evidence in planning vaccination strategies. They go so 
far as to say that clinical trials will not suffice as evidence for designing population-based 
vaccination strategies as trial populations are not diverse enough to reflect the real-life 
situations in which vaccines are used. This commentary elucidates a situation where 
multiple risk perspectives and multiple prevention evaluations are needed to best inform 
practice. I started my thesis with the intention of examining HPV risk and prevention 
from multiple perspectives and I find myself ending there as well, except with much 
different measures of risk and prevention than I originally intended. Science should 
not lock itself into one design framework nor should practitioners or policy makers 
draw evidence for practice from one design paradigm. Using observational, reported 
and interview data, this thesis work aims to assess infection risk and evaluate multiple 
prevention strategies and in doing so, highlight strategies with the strongest potential for 
disease reduction in the era of HPV-vaccines. 
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      bAckground
Human papillomavirus
HPV is the most common STI globally. There are over 200 HPV types, of which roughly 
40 are transmitted sexually and a proportion of those are oncogenic. Transmission 
occurs via epitheliotropic, or skin to skin, contact. HPV is known to be a necessary, but 
not sufficient, cause of cervical cancer 7. Besides cervical cancer, high oncongenic risk 
HPV types are associated with cancers of the vulva, vagina, anus, penis and oropharynx 
8. Low-risk types cause genital warts (condylomata acuminata), which are not fatal but 
commonly known to recur and as such are difficult to cure completely, contributing to a 
substantial disease burden among both men and women 9.  
Risk of HPV infection among women after their first male sexual partner has been shown 
to be close to 30% 10.  Most individuals become infected with HPV during the course 
of a lifetime but 90% of HPV infections are spontaneously cleared within 2 years 11. 
Among the relatively small proportion of infections which do persist, most develop into 
precancerous lesions which either clear spontaneously or with treatment, or develop into 
invasive cancer 12.  
Figure 1. HPV infection and development of cervical cancer. Potential risk factors for persistent 
infections include smoking, high parity, long-term oral contraceptive use and infection with other 
STIs.  
Cervical cancer is the second most common cancer among women globally 8. Countries 
with the highest incidences of cervical cancer have the fewest economic resources at their 
disposal, as the following figure from GapMinder indicates.
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Figure 2.  The relationship between cervical cancer incidence and income per capita. 
Colors represent geographical areas by continent, bubble size represents country 
population size. From Gapminder.org.
Higher-resource countries have been able to implement cervical cancer screening, which 
has been the driving factor in the decline seen in many countries over the past decades. 
In Sweden, cervical cancer incidence has declined by 70% over a 40 year period due 
to organized screening 13. The ‘Pap smear’ developed by Papanicolaou in 1943, is still 
used to screen for cervical cancer with the aim of finding disease in early, non-invasive, 
asymptomatic stages. Pap screening programs have been shown to reduce mortality and 
incidence from squamous cell cervical cancer, but such programs are less effective in 
detecting adenocarcinoma of the cervix. Though Pap screening remains common for 
cytology analysis, many programs have migrated to liquid based cytology instead. This 
technology allows for both cytology and HPV-testing. It has been proposed that HPV-
testing be combined with cytology as a primary screening tool 14 as HPV tests have higher 
sensitivity than cytology15.  However, due to the high prevalence of HPV among young, 
sexually active adults, HPV testing in the younger age groups would not be as beneficial. 
Eventual individual or systemic repercussions of detecting HPV positivity have not yet 
been extensively evaluated. Optimization of cervical cancer screening recommendations 
in terms of intervals, ages, HPV-testing and cytology combinations is under continual 
development. The introduction of HPV-vaccines will likely necessitate eventual changes 
in screening recommendations. 
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Hpv vaccines 
The development and subsequent international launch of prophylactic HPV-vaccines has 
transformed HPV-related cancer prevention. As these vaccines are prophylactic, they 
should be given prior to sexual debut to assure maximum protection against HPV. Two 
HPV-vaccines are currently on the market, a bivalent which protects against infection 
with HPV-types 16 and 18 (Cervarix®, GlaxoSmithKline) and a quadrivalent (Gardasil®, 
Merck) which offers additional protection against HPV-types 6 and 11. A nanovalent 
HPV-type vaccine is currently under development and its launch anticipated in the near 
future16. HPV 16 and 18 are high oncogenic types and found in roughly 70% of invasive 
cervical cancers 17. HPV 6 and 11 are considered low oncogenic types and are associated 
with 90% of GW cases18. There is considerable geographic distribution of HPV-type 
prevalence in HPV-related diseases 19, 20. For example, HPV 16 contributes to 23% of 
global HPV infections, but in sub-Saharan Africa it only contributes an estimated 13%; 
in Southern Asia, it contributes to 32% of HPV infections20. Due to this distribution 
and to the fact that exposure to vaccine HPV-types prior to vaccination would render 
the vaccines ineffective, cervical screening will still be necessary for women who have 
been vaccinated21, 22. Cross-protection against some non-vaccine HPV-types has been 
shown but will require further examination 23. Also unknown are whether competing high 
oncogenic types will replace 16 and 18 in prevalence, so called type-replacement24. The 
development of other multivalent HPV vaccines is also progressing, indicating future 
market shifts.      
The quadrivalent-HPV (qHPV) vaccine was approved by the Food and Drug 
Administration in 2006 and became available on the Swedish market in October, 
2006. The bivalent vaccine became available in Sweden in the fall of 2007. Starting 
in May 2007, Sweden began partially subsidizing both vaccines for girls ages 13-17. 
Substantial out-of-pocket costs of approximately 180 euros were required even with 
the subsidies, with costs considerably higher for those ineligible for the subsidy 25. This 
vaccination program was considered opportunistic as the girls and their parents had to 
seek information and find a vaccine provider themselves. The National Board of Health 
and Welfare announced that HPV vaccination for the prevention of cervical cancer should 
be included in the fully subsidized school-based vaccination program for girls between 
10-12 years of age, with a proposed rolled-out in 201026. Tenders were placed by both 
vaccine companies on the market and bivalent Cervarix® won the initial bid. Merck 
opposed the tendering processes due to specific legal technicalities and a subsequent 
bidding process was allowed27. In this bidding process, Merck was allowed to include 
cost-reductions as a result of genital wart protection. Also, the initial choice of a vaccine 
that did not protect against condyloma was criticized by some gynecologists28. Gardasil® 
won this subsequent tendering process and the school-based vaccination program rolled 
out in 2012, with a catch-up program for girls 13-18. Each municipality in Sweden is 
responsible for the procurement and implementation of the program and as this thesis 
goes to print in 2012 there are substantial discrepancies in proportions vaccinated per 
municipality. 
During the time period when both vaccines were available in the opportunistic 
vaccination program at partially subsidized costs, 99% of the vaccinations purchased 
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were Gardasil®. Approximately 30% of 17-year old girls were vaccinated via Sweden’s 
opportunistic vaccination program. Vaccination was approved for men and boys as well, 
but no subsidies were granted and only a few thousand of the over one hundred thousand 
vaccinations sold during opportunistic vaccination were inoculated in males.    
       
Dose efficacy has been widely discussed as a fundamental factor in the vaccine strategy 
decision-making process4, 29-31. Dose evaluation studies will be central to the shaping of 
vaccination strategies. Increased costs and feasibility problems are directly related to an 
increased number of required doses 4, 31. Both bivalent and qHPV vaccines follow a three 
dose schedule over a period of 6 months. There have been discussions regarding the 
necessity of an eventual booster dose32, 33. As invasive cancers take decades to develop, 
measuring such endpoints would be both unethical and unfeasible given the trials’ 
relatively limited follow-up. HPV-infections, cervical, vulvar and vaginal intraepithelial 
neoplasias, adenocarcinoma in situ and genital warts are possible to assess to-date.  Both 
vaccines have shown close to 100% efficacy against CIN outcomes in per-protocol 
populations34, 35.  However in trials comparing the two HPV-vaccines, the bivalent vaccine 
has shown a higher immune response rates in vaccinated women36.  
efficacy versus effectiveness
Besides monitoring safety, randomized controlled clinical vaccine trials provide primary 
outcome measures of vaccine efficacy. Efficacy is a measure of disease risk difference 
between the untreated and treated, which in the case of vaccines is the unvaccinated 
and the vaccinated. Clinical trials provide controlled conditions in which to measure 
effect. Inclusion criteria for these trials provide measures of the vaccine effect in ‘ideal’ 
situations. These ideal situations are the per protocol study populations. Trials also 
include intention to treat populations, which are less than ‘ideal’ and are expected to 
mimic real-life populations more accurately than per protocol populations. However, 
intention-to-treat populations still adhere to inclusion criteria. In the case of the vaccine 
trials, common inclusion criteria for per protocol populations included HPV-negativity 
and specific age limitations, and inclusion criteria for intention-to-treat populations 
include a limited number of sex partners as well as age limitations34, 35. These intention-
to-treat populations do not reflect real-life scenarios of individuals who will be exposed to 
vaccinations. As such, vaccine effectiveness studies are needed to measure the outcome 
of public health strategies 37. Vaccine effectiveness is also known as field efficacy and can 
be measured in the same statistical manner as efficacy, but includes the actual population 
vaccinated and not only clinical trial participants. The advantages of effectiveness 
measures are manifold, foremost that they reflect real life scenarios and can capture shifts 
in herd immunity6, 37. Their external validity to broader populations is superior to those 
of clinical trials37. Effectiveness measures provide accurate measures of public health 
interventions. 
Effectiveness is also known as field efficacy, a term meant to reflect the non-controlled 
environments in which outcomes were assessed37. The real-life situations that 
effectiveness studies measure can capture factors such as vaccine access, distribution and 
herd immunity. Where a finite number of clinical trials are required to assess efficacy, a 
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theoretically infinite number of effectiveness studies are warranted to reflect geographic, 
population, program strategy and economic nuances which will effect disease reduction.
The Nordic registers provide unique data for effectiveness investigations, comparable in 
some aspects to the data possible to capture in clinical trials in terms of hospitalizations, 
potential adverse events, long term follow-up, multiple disease outcomes etc. In many 
countries, access to this individual-level data in an entire population is not possible, 
hence ecological measures of effectiveness are most feasible. Ecological, or aggregate, 
measures of incidence are helpful in assessing total disease burden but causality cannot be 
assessed with individually-based data. Data from registers is potentially biased in a way 
clinical trial data is not due to the randomization process but aided by linkage of multiple 
registers, adjustments based on a priori hypotheses of causal pathways can be made to 
improve quality.
Hpv infection prevention
The HPV-vaccines are prophylactic and as such, should be given to HPV-negative 
individuals for maximum effectiveness. Due to the high prevalence of HPV among 
sexually active individuals, vaccination prior to sexual debut is recommended 38. Current 
HPV-vaccines offer limited protection in terms of HPV-types and will by no means 
eradicate all HPV infections.
HPV is highly transmittable. This combined with its high prevalence creates a contraction 
risk with any type of sexual contact including non-penetrative contacts39. Transmission 
from hand to genitals is also possible 39, 40. Delayed sexual debut will not inhibit infection 
transmission nor will serial monogamy or monogamy, though the latter should reduce 
transmission risk 41. Condoms offer substantial protection if used consistently, reducing 
a woman’s risk of contracting HPV by 70% compared to women whose partners did not 
use condoms 42. Male circumcision has also been indicated in HPV transmission reduction 
and of lower incidence of cervical cancer among female partners 43.  
common Hpv-related diseases and tHeir treatments
Cervical cancer is the HPV-related disease with the highest disease burden globally. As 
cervical cancer can take decades to develop, screening programs have been successful 
in their early detection and treatment. A recent study from Sweden indicated an actual 
curative effect of screening, where women who had followed screening recommendations 
had higher cure proportions of their cancer, not attributable to lead time bias, compared 
to women who were overdue for screening when their cancer was detected 44. Treatment 
for cervical cancer depends on staging at diagnosis, progressing from cervical conisation 
or hysterectomy without lymphadenectomy in very early stages to radical hysterectomy 
including pelvic lymphadenectomy with eventual chemoradiotherapy in later stages.  
When cervical cytology indicates abnormality, clinical response and treatment will vary 
between screening programs and between countries. The treatment of precancerous 
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cervical lesions, referred to in Sweden with nomenclature dysplasia or CIN I-III and in 
the United States as LSIL and HSIL, will range from ‘see and treat’ colposcopy, ablative 
techniques such as cryotherapy or laser ablation and excisional techniques such as 
large loop excision of the transformation zone and cold knife cone biopsy45, 46. “See and 
treat”, or visual inspection with acetic acid and immediate treatment with cryotherapy, is 
common in countries or with populations where organized screening is not possible 47, 48.
Treatment of other HPV-related anogenital and oropharyngial cancers also involve 
surgical and chemoradiotherapy combinations. There are no organized screening 
programs for anal cancers nor FDA approved screening techniques, but some higher 
risk groups for this cancer type, such as men who have sex with men or HIV positive 
individuals, are more frequently examined for lesions49.
treatment of condyloma
Not all individuals with condyloma (frequently referred to as GW) will seek treatment 
and of those who do, a proportion will be receive conservative or wait-and-see therapy. 
Cervical or intra-vaginal warts are treated differently than external genital warts. In cases 
of non-external GW, patient applied therapies are not recommended and specialist care 
is required for their management.  Either colposcopies and proctoscopies and eventual 
subsequent biopsies are recommended for internal GW cases, with cryotherapy or 
electrosurgery as predominant treatment types50.  First hand treatment for external GW is 
patient-applied therapy podophyllotoxin or imiquimod 9, 18, 51. Duration of treatment with 
podophyllotoxin is estimated at 4-6 weeks with cure rates up to 77%52.  Phodophyllotoxin 
is an antimitotic agent which induces local tissue necrosis by hampering cell-division51. 
For imiquimod, treatment duration is 16 weeks with cure rates of up to 54%53. Imiquimod 
is an immune modifier but not an antiviral therapy as it works via the induction of 
cytokines and interleukins51.   Recurrence with podophyllotoxin ranges from 4-38% 
and with imiquimod 13-19% 52. Podophyllotoxin is not recommended before or during 
pregnancies while imiquimod may be used with reservation in these situations 51.  
Provider applied therapies of tri-chloroacetic acid and podophyllin resin are also used for 
non-surgical treatment of GW18. Non-pharmacological treatments include conservative 
therapy, laser, and cryotherapy, with surgical excision options for persistent infections that 
do not respond to pharmacological treatment.
Podophylotoxin is not recommended during pregnancy 51. Imiquimod has not been 
properly tested on humans but has been shown safe for pregnancies and fetal development 
via animal studies. In Sweden, imiquimod is recommended with caution during 
pregnancy51.
demograpHics, practice and infection trends in 
sweden
Income discrepancies in Sweden are relatively small and the country has a high GDP54. 
Health care is provided to all residents through a national health care system. 
Sweden has included sexual education in its school curriculum since the 1950s. There is 
an accepting attitude toward premarital sex for both men and women. Though marriage 
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is common in Sweden, cohabitation without marriage is equally as common and socially 
acceptable. Both birth control and abortions are provided under the health care system.  
Sweden has seen a noticeable increase in STI trends over the past decades, specifically 
chlamydia and gonorrhea but also HPV and HPV positive tonsillar squamous cell 
carcinomas 55-60. Studies have indicated changes in sexual habits, including an increased 
number of reported lifetime partners and acceptance of sexual activities outside steady 
relationships61, 62.
Sweden has had organized cervical cancer screening since the 1960s, which became 
national in 197363.  It is estimated that approximately three-quarters of the target 
population attends the screening program, with large regional variation64. Approximately 
450 women are diagnosed with cervical cancer annually and approximately 150 deaths 
are attributed to the disease annually accounting for roughly 2% of new cancer cases 
in Sweden annually 65. Age standardized incidence rates for cervical cancer are 7/100 
000, giving Sweden the second lowest incidence of the disease in the Nordic countries, 
after Finland with 4/100 000 but lower than Denmark (11/100 000), Norway 9/100 000 
and Iceland 8/100 00063.  Of the over 600,000 cytology tests performed, around 40,000 
are diagnosed with some form of cervical dysplasia 46. One out of ten Swedish women 
report having had genital warts by age 45 66.  Cancers of the male genital organs are rarer, 
accounting for 0.3% of male cancers in Sweden annually and only a proportion of these 
will be triggered by HPV. Rectum and anal cancers are more common, accounting for 
approximately 4% of cancers in men and women with an uncertain proportion attributable 
to HPV65. 
social determinants of HealtH witH focus on ses
Socioeconomic status (SES) has been linked to a substantial proportion of health 
outcomes around the globe and Sweden is no exception67, 68.  As SES appears to play 
such a central role in many health outcomes, it is examined in this thesis as it pertains 
to various health outcomes, from condom use to condyloma, vaccination status and risk 
perception. What is actually captured by measures of SES is debatable. SES reflects, to 
some degree, the fiscal and social environment in which individuals live. SES captures 
some aspects of healthcare access, empowerment, lifestyle, discrimination and culture 
along with certainly other social and behavioral nuances. When significant for a given 
outcome, such as cancer, it is usually unclear of the exact mechanism captured by SES 
variable. What is clear however is that there is some force outside the individual level 
influencing a health state. Education level is common proxy for SES67. A study using 
longitudinal data on SES in Sweden showed that high education level was related 
to ‘good’ occupation, high income and low morbidity69. Other SES proxies include 
composite scores such as income and employment type. The importance of various SES 
component measures will differ geographically, culturally and periodically (period-
effects).   
24
tHeoretical background 
Three theories pertaining to prevention behavior were examined in the context of this 
thesis: Knowledge Attitude Practice (KAP), Health Belief Model (HBM) and Script 
theory.  The two former are generally supported by public education policy and the latter 
is more common within sexual behavior research70-74. 
KAP and HBM linearly associate the perceived threat of a disease with the likelihood 
of taking preventive action75. As the acronym KAP implies, knowledge is thought to 
effect attitudes which in turn effect behavior or practice. This belief that by increasing 
knowledge about disease severity and shifting attitudes then individuals will take  
preventive actions if posed with a threat, underlies many public health awareness efforts. 
KAP and HBM are common undercurrents in sex education curriculums. Though 
these models are similar with their linear association of perceived risk to likelihood of 
behavioral change, the HBM is slightly more complex in that it also allows for perceived 
benefits and perceived barriers to behavioral changes to effect the likelihood of behavioral 
changes 76.  In medical research there is often an unspoken assumption that by assessing 
attitudes, predictions on subsequent behavior will be possible72. A plethora of studies has 
emerged around the globe in recent years measuring attitudes toward HPV-vaccination, 
including one used in this thesis, and questionnaire studies are often designed based on 
KAP principles 77-81.
Figure 3. Knowledge Attitude Behavior/Practice Model (KAP)
Figure 4. Simplified Health Belief Model, similar to KAP model
Sexual behavior, though enacted by individuals, is also determined by relationships and 
group processes. Simon and Gagnon 82 coined the use of the term ‘script’ to describe 
sexual behavior which is regulated by group, gender, and contextual norms. They 
construe sexuality as scripted on three interrelated levels; a collective, cultural level; an 
interpersonal level, related to groups and relationships; and an individual intra-psychic 
level, related to desire management. It has been suggested that existing sexual scripts 
should be studied as a means to better understand and explain STI trends 74, 83. Though 
most studies using sexual script concepts focus on non-disease outcomes related to sexual 
behavior, studies outside of Sweden have looked at scripts in relation to HIV-prevention 
and condom use74, 84.  
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Aims
overall aim 
The aim of this thesis is to provide a multidimensional assessment of infection risks and 
to evaluate strategies for HPV prevention. 
Assessment of infection risks includes epidemiological measures of incidence, risk 
perceptions and risk as described by individuals in situations where infection transmission 
is high. This thesis aims to evaluate multiple prevention strategies, including vaccination 
delivery, quadrivalent-HPV dose-level effectiveness and condom use in high STI risk 
situations.
specific aims 
The primary aim of Study I is to evaluate which factors are associated with utilization of a 
central STI prevention strategy: condom use with temporary partners. The secondary aim 
is to investigate factors associated with STI risk perception with the hypothesis that risk 
perception is indicative of engagement in prevention behavior. 
Using internet-based focus groups, the aim is to further investigate how sexually-
active young adult women reason about risk for STIs and what strategies they use for 
prevention, with particular focus on HPV and HPV-related cancers. The secondary aim of 
these internet-based focus groups is to investigate reasons behind the low prevalence of 
reported condom use in high risk situations.
 
Study II aims to establish population estimates of the disease burden of GW in both men 
and women in order to facilitate understanding the potential public health impact of the 
quadrivalent-HPV vaccination of girls nationally immediately prior to and following 
the commercial availability of the quadrivalent vaccine as well as allow for proper 
discussions of prevention resources and men’s risks.
Study III aims to study vaccine effectiveness to assess the actual population impact of 
opportunistic qHPV vaccination on the incidence of HPV-related disease by assessing 
GW incidence after complete vaccination in Swedish girls and women using individual-
level data from the entire Swedish population. A secondary aim is to assess whether social 
determinants effected vaccination or risk for GW. 
Study IV aims to examine dose-level vaccine effectiveness against GW on a cohort of 
preadolescent and adolescents using individual level data. A secondary aim is to assess 
correlates to adherence to the prescribed dosing schedule.
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mAteriAL And methods
study I II III Iv
Qualitative 
preliminary 
results
research 
questions
What are 
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associated 
with reported 
condom 
use with 
temporary 
partners 
and STI risk 
perception?
What are 
the annual 
incidence 
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of GW 
among men 
and women 
in Sweden 
immediately 
prior to and 
following the 
availability 
of qhpv- 
vaccine?
how effective 
is complete  
qhpv 
vaccination 
in preventing 
GW among 
preadolescent 
girls and 
women? Are 
there social 
determinants 
to vaccination 
or GW?
What is 
the dose 
effectiveness of 
qhpv vaccine 
against GW in 
preadolescents 
and 
adolescents?
Which factors 
are associated 
with completing 
vaccination 
schedule?
What are 
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behind 
the low 
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of reported 
condom use 
in high risk 
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how do 
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prevent 
transmission 
of STIs?
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sectional 
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based 
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cohort
Group and 
individual 
interview 
study 
study 
population
8855 young 
adult women 
and 1712 men
Men and 
women aged 
10-44 living 
in Sweden. 
The study 
population 
ranged from 
4 167 770 
individuals in 
2006 to 
4 190 658  in 
2010.
2 209 263 
women ages 
10-44
1 045 093 
women ages 
10-24. Only 
vaccinations 
occurring from 
ages 10-19 
were examined 
for dose 
effectiveness.
65 young 
adult women
data 
collection 
method
Questionnaire 
and LISA 
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prescription 
Drug and 
patient 
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Multiple 
population- 
based 
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Multiple 
population- 
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based 
discussions
analysis Multivariable-
adjusted 
logistic 
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univariate and 
multivariate 
logistic 
regression
poisson 
multivariate 
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content 
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materials – data source   
 
register data in sweden 
The Nordic region including Sweden is in a unique position globally in terms of ability 
to perform nationwide observational studies. The reasons for this uniqueness are twofold 
but first and foremost related to the broad scale usage of personal identification numbers 
(PIN), assigned to each individual resident85. These PIN numbers are used for health 
care visits, tax purposes, banking, insurance, and education to the point where they are 
essentially ubiquitous when accessing any publically supported service in the Nordic 
countries.  The PIN contains information on birthdate and sex. The PIN is the key to 
linking data from multiple registers.
Because of the PIN and Sweden’s migration to computer-based records in the 1960s, it is 
possible to link data from multiple registers and have decades of follow-up time in which 
to study various exposures and outcomes. Though other countries far surpass the Nordic 
region in terms of population size, few have the infrastructure capacity for linking data 
from multiple registers.
In the context of medical research, ethical approval is essential to obtain before registers 
may be linked. Governmental organizations such as the National Board of Health and 
Welfare provide linkage services if ethical approval is granted. During the linkage, PIN 
are removed and replaced with a random serial number. These governmental agencies 
hold the key identifying the newly assigned serial numbers with their corresponding PIN 
and usually destroy the keys within a matter of years if another agreement is not made 
with individual researchers. This handling of data de-identifies the data in accordance 
with Swedish laws on the public access to information and secrecy (Offtentlighets- och 
sekretesslag in Swedish) and on personal data (Personuppgiftslagen or PUL in Swedish) 
and the movement of data which derive from European Union Directive 95/46/EC. 
Specific Swedish registers used in the studies in this thesis work will be described here in 
brief.
Prescription Drug Register (PDR)
In the summer of 2005 Sweden created a national register for prescription drug 
dispensations. Individual records of all prescriptions dispensed at all pharmacies 
throughout the country are entered into this register in an automated process. Prescriptions 
written but not dispensed will not appear in the register. In-patient prescriptions and 
medical dispensations are not recorded in this register either, nor are school-based 
vaccinations.
In and Out Patient Registers (PR)  
Sweden’s in-patient register has had national coverage since 1987, with region-specific 
and psychiatric in-patient coverage from the 60s and 70s respectively86. Day surgery was 
added in 1997. National out-patient data became part of the PR in 2001 and contains data 
on non-primary outpatient care, including some but not all private specialists. 
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Cause of Death Register
The National Board of Health and Welfare in Sweden is responsible for the PR, the PDR 
and the Cause of Death register among other health registers. The Cause of Death register 
contains information on underlying causes of death for all residents registered in Sweden 
starting in 1952, including contributory factors, using ICD-codes. Deaths occurring 
abroad are also included if the person is a registered in Sweden. It is estimated that 99.5% 
of deaths among registered residents are recorded 87.
Longitudinal integration database for health insurance and labor market studies (LISA) 
Sweden’s LISA register contains detailed and extensive demographic information as 
well as information regarding incomes, subsidies received including social welfare, work 
history, and education. It was started in 2004 but contains information as early as1990. 
This database is maintained by Statistics Sweden, along with the Total Population, 
Education, Multigenerational, and Migration Registers, which are described in more 
detail below.
Total Population Register (TPR)
Sweden’s Total Population Register was formed in 1968 and is the main source for 
updated demographic information often used to link other registers. The data source 
comes from the Swedish Tax Authorities, with continual updates on information including 
address, age, civil status, family information, immigration and emigration status and 
country of origin, changes in citizenship etc. Statistics Sweden imports this data once 
annually for its register, the TPR. The TPR generates Statistics Sweden’s mid-year 
population estimates. These estimates provide an estimation of individuals living in 
Sweden, by age, sex and geographic location. These estimations takes births, deaths and 
migration information into account provide an average of the population in Sweden at the 
beginning and end of each calendar year. 
Migration register
The Migration register was also formed in 1968 when Sweden’s population statistics 
were computerized. Statistics Sweden creates this register from its TPR, with a focus on 
emigration and immigration dates. 
The Swedish Register of Education
The Education register was started in 1985 but contains information on highest 
educational status from decades prior as well. Information prior to 1985 was obtained 
via census and other surveys. The register is updated annually, with education completed 
outside the country obtained through additional survey information to new immigrants. 
Multigeneration Register
A listing of one’s familial relations can be found via Sweden’s Multigenerational 
Register. This register was created in 1991 when the Swedish Tax Authorities took 
over responsibility for address registration from parishes. This register includes family 
information on all individuals born after 1932 who have had a registered address in 
Sweden at any point in time from 1961 onward. Information on adoptive or biological 
parents is also included here.    
30
SVEVAC
A vaccination register, SVEVAC, was initiated locally in 2002 in the region of 
Östergötland for the purpose of registering child vaccinations and expanded gradually 
to other regions in the following decade. In 2006 SVEVAC was expanded under the 
scope of a research project to include all HPV-vaccinations nationally. Coverage of HPV-
vaccinations is estimated to be 85%. Unlike the PDR, which de facto includes vaccine 
registration for all prescription vaccinations dispensed via pharmacies, SVEVAC should 
also theoretically include vaccination data purchased directly from private vaccination 
clinics. As this thesis goes to print, discussions are ongoing for a new national vaccination 
register to be used in lieu of SVEVAC, which will not be used to register girls vaccinated 
in the school-based HPV program. 
Attitudes toward HPV vaccination survey
During January to May 2007, a large-scale questionnaire survey entitled “Attitudes 
toward HPV vaccination” was conducted. This survey, directed toward 40 000 people 
in Sweden, included 16 000 young women and 4000 men aged 18-30, as well as 20 000 
parents to adolescents between the ages 12-15 years old. More women than men were 
sampled in order to facilitate longitudinal analysis of women, the original target group for 
HPV vaccination, in a future follow-up study. The survey aimed at investigating attitudes 
and knowledge about the new HPV vaccine, with questions on sexual habits, HPV, 
cervical cancer and cervical cancer screening.
Individuals with a registered address in Sweden were randomly selected from the 
Swedish Population Register.  Invitation to respond to web-based questionnaires was 
offered to potential participants via a letter and answers were automatically entered into 
a database. In a first reminder, paper questionnaires were offered to those respondents 
unable to answer via Internet. The content of paper-based questionnaires was scanned into 
a database through optical reading. If neither had been completed, a telephone reminder 
was made and the questionnaire answered via a phone interview and the interviewer 
entered the answers via web-based questionnaire. As participation was voluntary, 
respondents provided consent by answering questions in the survey. 
Response rates amongst the young women and men were 55% and 43%, respectively, 
with a total of 8855 women and 1712 men answering. Response rates amongst parents 
were 70% amongst parents of girls and 69% amongst parents of boys. Survey data was 
linked with register data from LISA for more complete familial socio-demographic 
information. This linkage also allowed for a comparison of demographics between non-
respondents versus respondents. 
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metHods 
epidemiology
The discipline of epidemiology and its inherent applications are as dynamic as the world 
that it observes. Though health practitioners such as medical doctor John Snow and nurse 
Florence Nightingale are often cited as pioneers in the discipline’s inception88, 89,  modern 
epidemiologists sometimes don the hats of mathematicians or geneticists. In the field 
of research, epidemiology has become synonymous with sophisticated observational 
research and risk prediction and is not only associated with mitigating the spread of 
communicable diseases as the early pioneers strived to do.     
 
Epidemiology is defined as:
“The study of the occurrence and distribution of health-related states or events in 
specified populations, including the study of the determinants influencing such states, 
and the application of this knowledge to control the health problems. “
- A Dictionary of Epidemiology, 5th Edition
This broad definition further delineates health-related states and events as: diseases, 
causes of death, behaviors, reactions to preventive programs or provision and use of 
health services. Determinants are defined as: physical, biological, social, cultural, 
economic and behavioral factors influencing health90.    
Epidemiological studies can be hypothesis testing (deductive) or hypothesis generating 
(inductive). As the research question itself should dictate the research method used in 
investigation and not vice versa, there are a multitude of methods possible to use in 
the field of epidemiology. This section will provide an overview of the methodologies 
used in this thesis, which focuses on assessing risks and evaluating prevention from 
multiple perspectives. Some basic building blocks frequently discussed within the field 
of epidemiology will be discussed. These building blocks enable the analyses and models 
defined herein.  
Exposure and outcome 
An outcome is something we wish to predict or better understand. In epidemiological 
studies, this is often a disease or death, and in statistics it is known as a dependent 
variable. Data on outcome and exposures can be collected from clinical observations, 
medical records, questionnaires, interviews, registers, administrative databases etc.. An 
outcome variable can be a disease, death, or a belief such as ‘vaccine acceptability’, 
which can be measured from questionnaire data where respondents answer numerous 
questions related to willingness to vaccinate, belief in vaccination safety and 
effectiveness. Depending upon their answers to these questions, they might receive 
a score that is meant to represent their level of vaccine acceptability. In randomized 
control trials (RCT) primary outcomes are often clinical test results such as CD4 count 
or blood-lipid levels. Secondary outcomes could be side effects or adverse reactions. The 
May 4th, 2012 issue of the Centers for Disease Control and Prevention’s Morbidity and 
Mortality Weekly Report (MMWR). is entitled “Sexual Experience and Contraceptive 
Use Among Female Teens – United States 1995, 2002 and 2006-2010”. In that issue, 
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outcome variables were sexual experience levels and types of contraceptive use as the 
title reveals91. 
Exposure variables are  assumed related to the outcome; either causing the outcome or 
being somehow associated with it and in statistics are known as independent variables. 
In RCTs exposure variables would be the therapies under investigation. In observational 
studies exposure variables are correlated with or believed to cause the outcome. In 
the case of cervical cancer or genital warts (outcomes), HPV would be one possible 
exposure variable. Another exposure variable could be sexual activity, which might 
as a proxy measure for HPV exposure. Other exposure variables associated with the 
outcome cervical cancer are age, oral contraceptive use, screening and vaccination. The 
study research question, constructed with a priori knowledge, delineates exposures and 
outcome.    
Minimizing biases: Confounding, effect modification and a note on adjustment
Biases are of primary concerns in scientific studies as they undermine result validity. 
Terms external and internal validity are often used when discussing result biases. 
External validity is related to the concept of generalizability and whether or not study 
results are applicable to any other persons or groups of persons (or other objects of 
measurement) not under investigation. Strict inclusion or exclusion criteria can hinder a 
study’s generalizability to a broader population. Large, population based studies could 
theoretically enhance result generalizability, as long as the population under study is 
comparable with other populations. This thesis examines vaccine effectiveness in the 
entire Swedish female population, making the results generalizable to Sweden or to other 
countries with similar populations (in terms of baseline HPV risk). However, in the two 
vaccine effectiveness studies in this thesis, those with a history of GW treatment prior to 
follow-up were excluded, limiting generalizability to those with no known history of GW.
Self-selection bias of an exposure can also hinder a study’s generalizability; in this thesis 
a question to ponder is whether women who are vaccinated differ in terms of baseline 
HPV-risk compared to other women who are unvaccinated. This type of bias is sometimes 
referred to as participation bias. For example, do women in their 20s who choose to get 
vaccinated have a higher average number of sexual partners than women who do not 
choose to get vaccinated? If this were the case, then the results found here would be valid 
to this group of women studied, but not necessarily to Swedish women with different 
baseline risks.    
If studies are poorly designed, internal validity is threatened. Internal validity is an 
indication of whether or not the association/relationship between the exposure and 
outcome indicated is accurate. An association could be spurious, or the magnitude or 
direction of relationship could be inaccurate.  The problem with threats to internal validity 
is that it is not always possible to predict the direction of the bias or know whether it is a 
true association.
 
By randomization and proper study design it is possible to assess causation, or effects 
of exposures on outcomes with reduced biases. This is based on the principle that in the 
randomization process (with a large enough sample size), only exposure status should 
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differ significantly between groups of study participants. Distribution of other background 
characteristics should be non-differential, making participants in essence exchangeable 
with each other. This quality of exchangeability allows one to draw conclusions about the 
exposure. 
Exchangeability in observational studies is often not plausible. Through some statistical 
techniques such as adjusting for covariates or potential confounders, it is possible 
to approach conditional exchangeability. It becomes more plausible if one accounts 
for covariates, or confounders – variables related to both exposure and outcome. 
Confounding bias occurs when exposure and outcome have common causes that are 
unaccounted for. Statistical adjustment for such confounders, one common method used, 
reduces some of the concern of bias of the exposure-outcome association. 
A typical confounder is age. As one ages, one is more likely to succumb to disease or 
death, two common epidemiological outcomes. Age is also related to eventual exposures, 
such as alcohol intake, smoking levels, and sexual activity. If one were to examine the 
effect of alcohol on cancer and not take into account the effect of age on cancer, the 
results generated would not accurately reflect the effect of alcohol on cancer as they 
would also include the effect of age on cancer. 
When examining the effect of exposure variables on an outcome one must minimize the 
effects of confounding variables or else estimates will be biased. There are four common 
ways to reduce confounding bias: adjustment, stratification, matching and restriction.  
Removing the effects of confounding is also called controlling for confounding variables. 
When one statistically adjusts what one actually does is hold levels of the confounding 
variable constant while assessing the relationship. If age were a confounding variable then 
when assessing the relationship of coffee consumption on cancer one would examine the 
relationship at each level of age (also referred to as ‘holding age constant’). If one would 
also control for smoking in the above example, one would then assess the hypothetical 
coffee-cancer relationship by examining it at each level of smoking status. This 
adjustment can occur in regression modeling or via the process of stratification92.   
When adjusting for a confounder one makes the assumption that association is the 
same across all levels of a variable. When this assumption does not hold, when an 
effect or association is assumed to vary across levels of another variable, one has effect 
modification. When there is known effect modification, stratification can be used to 
properly assess the effects of exposure on outcome. Stratification examines effect sizes of 
a variable across variable levels and accounts for effect modification. Effect modification 
is also called interaction. One can examine the presence of a potential interaction between 
two variables in a regression model, but the actual effects themselves need to be assessed 
via stratification procedures or by introducing an interaction term in the regression 
model92.    
Matching is frequently used in case-control and some cohort studies. Cases, those 
with the disease or outcome, are matched with controls, or individuals with similar 
demographic characteristics such as age, sex, ethnicity, SES etc. or other characteristics 
potentially influencing the outcome  such as hospital where care was received or another 
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pertinent contributory diagnoses. Exposure status is then examined among the cases and 
among the controls to see if there is a difference in outcome/disease risk. Restriction is 
another method used to deal with confounding. RCTs use restriction, or study inclusion 
and exclusion criteria, to avoid results that have biased estimates due to the presence of 
unmeasured confounders. Restriction can limit generalizability if the study population and 
the general population in which the treatment (or vaccine etc.) is used differ because of 
inclusion and exclusion criteria.   
Multiple covariate selection procedures 
As it is infeasible to examine all health related phenomena via RCTs, not to mention 
highly unethical (one cannot expose people to factors that may lead to cancer or pre-term 
death, nor can one withhold treatment that is known to cure), well-designed observational 
studies are imperative.  Multiple confounding variables must be accounted for when 
designing a study. To do this, there exist a number of approaches investigators use to 
decide which covariates to include in their analysis. Some use automated stepwise 
procedures (backward or forward), which relies heavily on p-values. Some look at 
changes in point estimates following adjustment and consider shifts of more than 10% (or 
some other cut point that they decide upon) to retain a variable in the model. Using these 
procedures without careful consideration of underlying mechanisms is not recommended 
as doing so can introduce bias into estimates93.
Directed Acyclic Graph (DAG) 
In the processes of constructing a model, á priori hypothesis should be clearly specified. 
DAGs are graphical representations of causal or associative structures.  DAGs can be 
used to specify  hypotheses before analyses are performed 94. They provide  an overview 
of the relationships between variables under investigation. This in turn aids with covariate 
selection in statistical modeling. DAGs are ‘directed’ because the causal relationship 
between two variables is displayed with an arrow as seen in Figure 5 below. DAGs are 
acyclic as the variables which they display exist in interplay with other variable(s) and are 
the by definition, not closed structures (cyclic). 
Figure 5. Simple DAG showing a relationship between age, HPV and cancer
In Figure 5 HPV acquisition can lead to cancer. In this sketch, one could conceive of 
HPV as the exposure and cervical cancer as the outcome variable. Age increases risk of 
cervical cancer development. Age is also related to HPV acquisition. As HPV is sexually 
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transmitted virus its acquisition will coincide with age of sexual debut and sexual 
activities. In this DAG, age is a confounder, or a common cause of the exposure and the 
outcome.
It is possible to oversimplify relationships between variables by drawing incomplete 
DAGs which lack the presence of unmeasured confounding, or variables relating to 
either the exposure or outcome but that are unknown or impossible to measure. Though 
unmeasured confounding cannot be accounted for, it can still be acknowledged. In the 
case of HPV where HPV is the necessary but not sufficient cause of cancer, a DAG 
that completely describes all causal pathways is unrealistic as there are many unknown 
confounders related to the clearance of HPV infections in some individuals and the 
persistence and development of pre-cancerous lesions in others .
Figure 6. More complex DAG showing a relationship between age, HPV and cancer and 
the presence of unmeasured confounders (variable X) 
Incidence versus prevalence 
Incident cases of a disease are considered new cases of a disease. Prevalent cases of a 
disease are not necessarily new and instead indicate the number of cases of a disease in 
a population at a certain period of time. Incident cancer cases would include new cases 
of cancer diagnosed while prevalent cancer cases would include all cases of cancer in a 
population at some specified time, both the newly diagnosed (incident) and those living 
with the disease for a longer time (disease duration). Simply put, incidence measures risk 
and prevalence is a function of incidence and disease duration: 
 Prevalence = incidence × disease duration
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This relationship holds true if the population has a steady state (in and out migration are 
stable)95. Prevalence is typically greater than incidence as many diseases have a long 
duration. For non-chronic illnesses such as infections with relatively quick clearance, 
incidence and prevalence numbers could be similar due to the short duration of the 
infection. Incidence can be greater than prevalence during epidemic cycles when attack 
rates are at their highest95. 
Although sometimes referred to as a prevalence rate, prevalence is a proportion. It is the 
proportion of individuals with a disease at a specific time or during a specific time period 
and is calculated as:
                  Number of cases of disease in the population at a specific time or time period
                      Number of persons in the population at that specific time or time period  
This proportion can be multiplied by 100,000 to aid interpretation95. However then the 
interpretation would be 648 prevalent cases per 100,000 individuals. 
Whether one wishes to measure incidence or prevalence depends on multiple factors 
including the natural history of the disease under investigation as well as the possibility 
for obtaining data on disease duration. Incidence and prevalence measure different aspects 
of disease burden depending on the natural history of the disease and disease duration. 
Prevalence does provide an important measure of disease burden in a population, such 
as number of individuals living with cancer, and allows for planning of health services. 
Incidence measures provide a measure of risk and new case accrual and are necessary 
when evaluating causality or risk factors, such as the effect of vaccination on disease 
outcome. In this latter case, prevalence measures are not appropriate as issues of 
temporality are paramount; exposure by definition must precede disease outcome. In 
order for this to hold true, the study population must be disease free prior to exposure 
and followed until disease onset, which would provide an incidence and not prevalence 
measure.  
A measure called cumulative incidence is commonly used and is also referred to as risk 
or the incidence proportion. When calculating cumulative incidence, all individuals in 
the population are must be at risk for the outcome of interest. With this assumption, the 
number who get the disease are a proportion of the total at risk. Closed cohorts, where 
the number of people in the study either stays the same or decreases, produce measures 
of cumulative incidence. In open cohorts where individuals enter and exit the study at 
various points in time depending on pre-specified risk criteria (i.e. from ages 10-44 during 
the years 2006-2010 as is the case in Study III), then obtaining measured of cumulative 
incidence is not possible. 
When estimating a denominator is difficult or impossible, as in setting of open cohorts, 
and there is the ability to estimate person-time, incidence rates can be calculated in place 
of risk (or incidence proportion or cumulative incidence). Person-time refers to the time 
an individual is at risk for disease and can be measured in days, months, years etc. Person 
time is measured in cohort studies, both open and closed. Individuals contribute risk time 
until they contract the outcome, until they are censored or until the end of study follow-
up, whichever comes first. If an individual contracts the disease/event in question, the 
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individual would be considered an event/case. Censoring can occur in the case of death 
by other cause than the cause under investigation, emigration, or attaining a pre-specified 
age such as 45 if one were studying disease occurrence in 10-44 year olds as is this case 
in Study III. If one were measuring risk for uterine cancer by establishing incidence rates, 
only women (who at risk because they have uteruses) in a population would be followed 
and typically contribute person time until they get uterine cancer or are no longer at risk 
for uterine cancer because they got a hysterectomy or moved outside the study area or 
died from any cause.  
If a person were to emigrate during the study follow-up, they would contribute person 
time until emigration and then be ‘right censored’. Right censoring refers to when there is 
a lack information on an individual pertaining to the end of study follow-up.  Conversely, 
if a person were to not contribute person time from the start of study follow-up due to 
say living in a geographic area outside the area of investigation but were to move into 
the study area during the investigation, that person would contribute person time starting 
from their immigration date and would be considered ‘left censored’. Left censoring 
refers to when there is a lack of information on an individual pertaining to the beginning 
of or before study follow-up.
Incidence rates are calculated as:
         Number of new cases 
         Person-time at risk  
Incidence rates are interpreted as for example, 923 GW cases per 100,000 person-years of 
follow-up. 
Measures of risk, absolute and relative
The field of epidemiology lacks verbal precision at times. One of those times is when 
discussing risk and rates, which can either be absolute and relative measures.  The 
difference and usefulness of absolute versus relative measures of risk is perhaps more a 
communication limitation than a methodological limitation; but the latter gives rise to the 
former. For health policy decisions, measures of absolute risk are important to consider 
when available. Relative measures can easily be misinterpreted in terms of public health 
risk assessment. 
The incidence of a disease in a population is the absolute risk of the disease in that 
population. Another common measure of absolute risk is risk difference. As the name 
implies, risk difference is calculated by subtracting the incidence rate among the exposed 
from the incidence rate of the unexposed. This difference would provide an absolute 
measure of effect of exposure in the population.
Relative measures of risk compare incidence among exposed and unexposed, but as a 
ratio instead of as the difference. The incidence of disease among exposed individuals 
compared to the incidence of disease among unexposed individuals would be the 
incidence rate ratio (IRR) and looks as follows:
     Incidence among exposed
    Incidence among unexposed  
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IRR is one relative measure of risk, others include  the hazard ratio (HR), and under 
some circumstances the odds ratio (OR). Technically the OR does not measure risk 
in the exposed vs. risk in the unexposed but instead measures the odds of getting the 
disease compared to the odds of not getting the disease. As such, whether the OR is an 
approximation of a risk ratio will depend on multiple factors based on study design (in the 
case of case-control studies where it is necessary to use the OR) or whether the disease in 
question is rare95.   
Effectiveness calculations 
Effectiveness and efficacy measures are calculated as follows:
  1-IRR × 100
Hazard rate ratios such as those generated from Cox proportional hazards models, or 
other relative risk measures including odds ratios can also be used to create measures of 
effectiveness in the same manner as above:  
  1-OR × 100
  1-RR × 100
Effectiveness  is also termed field efficacy37.   
Conversely, the number needed to treat (or vaccinate) to avoid one case of the disease is 
calculated by taking the inverse of the IRD (1/IRD). 
Regression modeling
Regression modeling is appropriate when examining the effect of one or more variables 
(exposures) upon another variable (outcome).    
Linear regression is expressed as follows:
   y = mx+b
  (for Swedish readers, y = kx+m)
 
Y is the outcome or dependent variable and is a function of the exposure or independent 
variable x and another constant, b. The m is the slope and the b is the intercept, or the  
value of y when x is 0.
In regression modeling, the interpretation is that for every unit change in x, the mean 
of y will change accordingly. The linear regression model, which uses a straight line to 
describe the relationship between continuous variables and assumes normal distribution 
of data, can be extended to a multiple regression model to account for multiple predictor 
variables or other covariates:
  y=b + mx1+ mx2 + mx3+…mxK
Logistic regression
When the outcome variable is not a continuous variable but instead binary (0, 1 or yes 
disease/no disease), then logistic regression can be used. An odds ratio (OR) is estimated 
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in logistic regression. A normal distribution is no longer assumed and instead it is 
assumed data follow the binomial distribution. In multinomial logistic regression the 
outcome can have more than two categories, such as never, sometimes or always condom 
use. 
Odds are defined as the probability of occurrence divided by the probability of non-
occurrence or:
      P
              1-P
Instead of modeling the change in mean value of y as a function of x, logistic regression 
models the log of the odds or the logit (logit= log (p/1-p)). The logit is used as it extends 
from negative to positive infinity:
    Logit (y)= mx + b
In multivariable logistic regression, or multiple logistic regression as it is sometimes 
referred to, the equation is:
  Logit (y)= b + mx1+ mx2 + mx3+…mxK
Even though the log odds is modeled in this equation, the predictors can be either 
continuous or categorical and retain the linear function.
Poisson regression
In addition to assessing whether an event, such as cancer, occurred or not, it is also 
interesting to assess the rate at which it occurred. Poisson regression uses discrete count 
data such as number of cases and has a Poisson distribution which allows for assessment 
of the number of events that occur at some rate. Poisson generates incident rate ratios 
(IRR) and provided absolute incidence measures as opposed to just relative measures as 
with the Cox proportional hazards model. 
Rate data have one element in common: time. In order to calculate time to an event, 
which underlies rate calculations, data that allows for estimations of person-time is 
necessary. Time to event analyses estimate incidence rates (IR) and hazard rates (HR) 
and are referred to as survival analyses in health research – even when death is not the 
outcome under investigation.
Poisson regression is a type of time to event analysis. The log hazard is modeled as 
follows:
  Log hazard (time) = b(time) + mx1+ mx2 + mx3+…mxK
As the intercept here (b) depends on time, the model allows the hazard rate to be time 
varying 96. In the above model, the covariates (exposure variables) will not necessarily 
depend on time but can.
The mean of Poisson distribution is the rate (number of events per time-unit), and the 
variance is also equal to the rate. Poisson regression allows for the adjustment of multiple 
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time scales, which is one advantage of using it. The baseline hazard in Poisson does not 
automatically vary as with Cox regression and instead has to be split at intervals to allow 
for fluctuations over time. 
Interpretive description with qualitative analysis
Though not typically associated with epidemiology, qualitative methodology can be 
useful in understanding patterns of risk behavior or for investigating feasibility of health 
promotion strategies. In qualitative research, interviews are commonly the primary unit of 
analysis. As qualitative research is often inductive – that is to say hypothesis generating 
and aims to provide a deeper understanding of phenomena under investigation. The 
primary aim is not to draw conclusions with statistical certainty that can be generalized 
to a specific population, as is the case with quantitative analysis. Sampling usually 
occurs until saturation is reached. Saturation is a term used by researchers that denotes a 
repetition in the patterns of variation constructed from the interviews. Besides expressing 
depth, qualitative inquiry aims to capture and express the variation in responses.
Though generalizations cannot be made with statistical certainty, results from qualitative 
analysis can still be used to inform practice 97, 98.
Interpretive description does not prescribe a specific analysis technique (for example 
content analysis, grounded theory or phenomenology) but instead aims to interpret the 
clinical or public  health issues under investigation in a manner that informs practice or 
can influence policy decisions. Data collection and analysis occur in tandem to inform 
one another, as is common in many forms of qualitative research98.  One interview is 
conducted and a preliminary analysis made, after which subsequent interviews with 
other participants are conducted with eventual new questions based on earlier interview 
preliminary results. 
While clear a priori theorizing is recommended in quantitative methods of scientific 
inquiry, flexibility in a priori theorizing is requested in interpretive description to grant 
the possibility for an a priori theory to be changed through the evidence of the data. The 
aim is not merely to generate hypotheses that can be tested in subsequent studies as is 
sometimes the case with qualitative inquiry, but instead to interpret the data in such a 
manner that has clinical relevance.
Content analysis 
When analyzing text using content analysis, latent or manifest techniques or a 
combination of the two, are often used99. Manifest content analysis places emphasis on 
what is described outright. Latent content analysis interprets the underlying meaning and 
relationships in the text. The process of content analysis involves first reading through 
all text in its entirety. The text is then re-read and coding begins. Coding is a process that 
assigns a label to portions of the text reflecting specific ideas – these are called condensed 
meaning units. Meaning units can be assigned multiple codes depending on the richness 
of the text. Similar codes then form categories. These categories can be presented as 
results. Often themes are also presented as main results. Themes cover multiple categories 
and codes and are meant to express the latent content in the text. Themes themselves can 
be further developed into sub-themes. 
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Focus group discussions as internet based chat discussions 
Focus group discussions (FGD) are often used in health and behavioral research and 
provide a forum for gaining an in-depth understanding of multiple participants’ views 
while simultaneously generating a group dynamic that can highlight cultural or societal 
norms related to the issues under investigation100. This ability to facilitate understanding 
of both individual depths and multilevel dynamics such as relationship or societal issues 
is what makes this method popular. 
Traditionally sensitive, deviant or potentially humiliating topics are not broached in 
face-to-face focus group forums. Developing this method into internet-based discussions 
allowed for anonymity and the ability to broach sensitive topics, while allowing both 
normative and non-normative views to emerge. 
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study i 
material and metHods
A national population-based cross-sectional survey entitled “Attitudes toward HPV 
vaccination” was sent out in the spring of 2007. This survey was sent to adult men and 
women between the ages of 18-30 as well as to parents of boys and girl between the ages 
of 12-15. For this study, only the data from the adults’ survey was used as in addition to 
attitudes, it covered detailed information on prevention utilization and sexual habits. 
The adults’ survey was sent to 4000 men and 16000 women selected randomly from 
Sweden’s TPR. More women than men were sampled due to a planned follow-up design 
involving female participants. As women are the vaccination target group, the original 
intent was to follow trends amongst women over time. The large sample size would 
allow for anticipated drop-out and a response size still large enough to make statistical 
inferences.
Invitations to web-based questionnaires were sent via letter. An initial reminder was sent 
and paper questionnaires were offered to those unable or unwilling to answer via Internet. 
A second reminder was made via telephone and the possibility of answering questions 
via a telephone interview was offered.  Response rates were 55% for women and 43% 
for men, with 8855 women and 1712 men participating. Survey data was linked with 
Statistics Sweden’s LISA database to obtain detailed information on socio-economic 
variables. This also allowed for a comparison of non-responders versus responders. 
The outcome variables for this study were derived from two different survey questions. To 
investigate condom use in high STI risk situations, condom use with temporary partners 
was examined due to the increased risk for contracting an STI from serial or concurrent 
partners. Though non-condom use with steady partners can also lead to STI contraction, 
under monogamous assumptions it is conceivably less of a risk as with temporary sexual 
partners. Also, factors motivating condom use in steady relationships could primarily 
relate to birth control as opposed to STI prevention. Respondents to the question: “When 
you had sex with your temporary partner(s), how often did you use a condom during 
the past year?” were included in the analysis on condom use (n=2594). Responses were 
aggregated into the following categories: 1) Always/almost always, 2) Often/sometimes, 
3) Seldom/never. Individuals who reported not having sex with temporary partners in the 
past year were excluded, as were non-respondents and respondents with missing data on 
this question.
To study STI risk perception, respondents with sexual experience who answered the 
question: “How large a risk do you think you have of contracting an STI” were included 
in the analysis (n=9820). Responses were aggregated into the following categories: 1) No/
small perceived risk or 2) Somewhat large/large perceived risk. Those who responded 
“Don’t know” (n=534) were categorized as missing. Respondents with no sexual 
experience, non-respondents and respondents with who did not answer this question were 
excluded from the analysis. 
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Covariates from questionnaire and registers considered in the models were age, education, 
income, employment type, social welfare status, geographic location, birth country, 
parental birth countries and relationship status, having heard of HPV, belief that men/
women can be infected with HPV, knowledge about reasons for and commonness of 
cervical cancer, knowing cause of genital warts, belief that HPV is sexually transmitted, 
STI risk perception, severity perception of genital warts, predict more unprotected sex 
if vaccinated, pap smear screening attendance (women only), willingness to vaccinate 
against HPV, oral and anal sex habits, types of sexual contact, condom use ever and 
with temporary and steady partners, age at first intercourse, perception of one’s own sex 
partner number compared to others, temporary sex partner number and sex partner gender.
Hypotheses for potential variable relationships were carefully considered and DAGs were 
constructed in order to formulate possible associations and causal pathways.
Figure 7. Example DAG used to delineate hypothesis used in model generation.
An implicit assumption when constructing the DAGs was that risk perceptions would be 
indicative of engagement in prevention practice. It was assumed that knowledge would 
to some degree influence attitudes, which would in turn influence whether or not one 
engaged in prevention practice. This Knowledge Attitude Practice (KAP) assumption was 
operationalized via variables pertaining to STI knowledge, attitudes surrounding STI risk 
and severity perceptions, and condom use with temporary partners as a proxy for safe 
sex practice. It was also assumed that behaviors would be related to other behaviors so 
variables pertaining to sexual behavior were assumed related to prevention practices.  
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Figure 8: Study populations for Study I and internet discussions
study i data analysis
Statistical analyses were performed using SAS version 9.2. Chi-square tests were 
performed between the outcome(s) and variables pertaining to knowledge, attitudes, 
reported behaviors and socio-demographic data. Based on the DAGs, a series of 
univariate regression models assessed the association between exposure variables and 
the outcome variables condom use with temporary partner and STI risk perception. 
Multicollinearity was examined in a correlation matrix for all variables and no serious 
was found except for use of condoms with steady and temporary partners and number 
of sexual partners and number of temporary sexual partners. Variables significantly 
associated with the main outcomes in the univariate analyses were considered for 
inclusion in the multivariable multinomial model (condom use) and the multivariable 
population for IBDs
population 
for Study 1
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logistic regression model (STI risk).Odds Ratios (OR) and 95% confidence intervals (CI) 
were generated.
Variables were retained in the models based on statistical significance (p-value less 
than 0.05), examining confidence intervals, and subject-matter pertinence of the 
covariates to the outcome(s). Exposures were tested first per categories based on KAP 
and demographics. Exposures significant per category were added one at a time to the 
demographic model and all variables excluded were examined separately in a multivariate 
model to ensure their assumed non-effect held true in various multivariate constellations. 
Akaike Information Criteria (AIC) and Bayesian Information Criteria (BIC) were also 
used to examine the fit of the multivariate models.
In the model construction process, significant interaction effects between gender and 
most covariates were found. Stratification, typically used to obtain accurate estimates in 
the presence of interaction, was not sufficient as the model predictive for women was not 
predictive for men. Two separate models were therefore constructed in order to ascertain 
which variables were predictive for women and men with regard to the study outcome(s). 
internet-based focus group material and metHods
To facilitate in-depth investigation on HPV prevention engagement among young adults 
using focus-group methodology, a web-based platform was developed in collaboration 
with an internet consultancy company. This platform allowed participants from 
geographically dispersed areas to attend the same discussion from any computer with 
internet connection. Study participants were able to use their first name or a pseudonym in 
the chat room discussions. Discussions ranged from one to two hours.  
Figure 9. Web-based platform for qualitative investigation 
Focus group methodology was adapted to explore how women reasoned about risk and 
prevention, using internet-based discussions (IBD). Four pilot IBDs were first carried out 
with members of Kärleksakuten (the Love Emergency Room), an STI and contraception 
awareness group working with youth in Sweden. Piloting with this group enabled AL to 
test and adjust an initial open topic discussion guide which was then continually updated 
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during the course of the study. The areas to be covered included HPV and cancer, STI 
risk, condoms, partner responsibility, HPV vaccinations and cervical cancer screening 
with pap smears. The discussion guide was not structured nor was necessary to use in its 
entirety in all subsequent IBDs as the aim was for respondent driven discussions on these 
topics.  
Study participants were derived from the national population-based survey, “Attitudes 
toward HPV vaccination” used in Study I. Women responding to the survey who 1) 
reported sexual activity in the preceding 12 month period, 2) responded to survey 
questions on condom use with temporary partners, and 3) specified their perceived risk 
for contracting an STI, comprised the sampling frame for this study (35% of women 
survey respondents). As we strove for heterogeneity in our sample in relation to factors 
that might affect how women reason, recruitment was based on participants’ survey 
responses concerning risk perceptions, risk taking, and prevention-seeking strategies. 
Women’s responses to questions on self-defined as well as researcher-defined STI risk 
(based on number of reported sex partners during a one-year period and reported condom 
use with sex partners during this period), were charted into strata. A sum score was 
constructed where women with high research defined contraction risk had reported three 
or more sexual partners in the past 12 months and never or seldom condom use with these 
partners. Women with low contraction risk reported one temporary sexual partner in the 
past 12 months and reported always or almost always using condoms with this partner. 
Women with moderate research defined contraction risk had more than one sexual partner 
in the previous 12 month period and inconsistent condom use with temporary partners. 
As we wished to investigate risk and prevention reasoning amongst individuals who were 
at some risk for contracting an STI, we did not include women who reported celibacy in 
the preceding 12 months nor women who reported being in a steady relationship with no 
temporary partners in the preceding 12 months.   
Table 1. Score matrix for research defined STI contraction risk. Individuals with a total of 
2-3 points were defined as low risk, 4 points moderate risk and 5-6 points high risk.
To achieve heterogeneity between strata while maintaining a degree of homogeneity 
within groups, the following matrix was used to define six strata with a total of 3106 
women:
Always/almost always condom use with temporary partner 1
Often/sometimes condom use with temporary partner 2
Seldom/never condom use with temporary partner 3
Greater than 2 sexual partners in past year 3
2 sexual partners in past year 2
Less than two sexual partners in past year (condition that 
one is defined as temporary)
1
Total score for STI contraction risk A + B 
 
 
A
B
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Table 2. IBD strata combining self-defined STI risk with measures of risk based on 
reported sexual behavior (number of partners and condom use with these partners during 
one year period).
Self-defined STI risk
No to low self-defined STI 
risk
Medium-high self-defined 
STI risk
Research-defined STI contraction risk
         Low                     Moderate                        high
 n=11 (N= 556)
Strata 1
n=10 (N=1162)
Strata 3
n=13 (N=646)
Strata 5
n=7 (N=63)
Strata 2
n=10 (N=197)
Strata 4
n=14 (N=475)
Strata 6
Random sampling per strata resulted in 260 study information letters being sent to women 
for whom there was a listed telephone number. One hundred-eighty four women were 
reached by telephone and invited to participate, 89 agreed to participate and 64 attended 
an IBD during the spring of 2010. Eighteen IBDs occurred in groups of 2-6 participants 
recruited from the same strata, while 12 were one-on-one discussions. One additional 
woman was interviewed by telephone due to limited computer access, with data from 65 
participants underlying this analysis. 
Few pre-constructed questions were used and discussions concentrated on sexual risk 
taking, protection and prevention in regard to STIs; follow-up questions were based on 
participant responses.
focus group data analysis 
An inductive analysis approach was used in this exploratory study. While interpretive 
description aided with study design and result interpretation, content analysis procedures 
were used for data analysis. IBD transcripts were automatically generated from the SAVE 
platform for content analysis.
Basic content-analysis procedures were used, with the computer program NVIVO 8.0 used 
to support data coding. Data collection continued until recurring response patterns were 
seen in the data, which were unchanged by analysis of more IBDs. The IBD transcripts 
were initially coded into smaller units based on similar substantive data-derived content, 
i.e. Condom Barriers, Discourse and Disclosure, Health System, Prevention Support 
and Risk Perceptions. Members of the research team read and discussed the coded data, 
comparing content both within and between IBDs. The researcher team then formulated 
categories and theme describing women’s prevention seeking strategies.  
Quotations presented were selected to typify the IBD discussions; these were translated 
by AL fluent in both Swedish and English and verified by other bilingual members of the 
team. Pseudonyms were used for confidentiality. 
No differences in IBD content concerning this subject matter based on participant group 
size could be ascertained. This does not negate possible response differences based on 
group size, only that no differences were found in the areas examined for this study.
Descriptive statistical analysis and logistic regression was used to compare socio-
demographic characteristics of study participants versus survey response participants 
using SAS 9.0.
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study ii 
material and metHods 
The entire population of men and women living in Sweden aged 10-44 between 2006 and 
2010 were included in this study. The study population ranged from 4 167 770 individuals 
in 2006 to 4 190 658 in 2010. Genital wart episodes were identified using the Prescribed 
Drug Register (PDR) and the Patient Registers. Population data were obtained from 
Statistics Sweden on calendar year, age and sex and estimated as the mid-year population 
to incorporate fluctuations due to death, emigration, and immigration. 
For the Patient Registers, International Classification of Disease (ICD)-10 diagnosis code  
A63 was used to locate cases of GW with both main and contributory discharge diagnoses 
allowed. For the PDR, prescriptions for topical pharmaceuticals podophyllotoxin and 
imiquimod were located with ATC codes D06BB04 and D06BB10, respectively. 
Prescription trends for podophyllotoxin revealed a distinct age-specific shape that matched 
with imiquimod trends in the younger age groups. Therefore the study population was 
restricted to those less than 45 years of age. If an individual had a dispensation for 
podophyllotoxin or imiquimod within seven days of a diagnosis via the Patient Registers, 
the pharmaceutical information was used to define the episode, otherwise the sole 
register that picked up the episode was used. This allowed us to estimate the proportion 
of GW episodes not receiving prompt treatment via a prescribed pharmaceutical. Non-
pharmacological treatment includes conservative therapy, laser, cryotherapy, with surgical 
excision options for persistent infections that do not respond to pharmacological treatment. 
An individual was considered a case during the calendar year if they had either a relevant 
dispensation from the PDR or a diagnosis from the Patient Registers with no recorded 
GW episode in the preceding 6 months. Therefore, a 6-month wash-out period was used 
to remove potentially persistent cases from being counted multiple times. Episodes newly 
diagnosed and or treated were estimated in this analysis as a measure of annual incident 
proportions (not first-ever cases exclusively). Only one episode contribution was allowed 
per person per calendar year as the aim was to estimate the proportion of individuals 
seeking or receiving treatment for GW during that year. Individuals could contribute with 
episodes less than 12 months apart, if those episodes were in two different calendar years 
but more than 6 months apart. Due to aforementioned clinical and diagnostic limitations 
it was not possible to assess if some of these new episodes were recurring infections or 
infections with a new HPV-type.
study ii data analysis
SAS 9.2 was used for data analysis.  The aim of the analysis was to estimate annual age-
standardized incidence proportions for men and women from 2006 through 2010. These 
were calculated using Swedish mid-year populations as estimates of the underlying time at 
risk, and then multiplied by 100 000. To assess whether there were significant differences 
across calendar years, Poisson regression was used to model the incidence as a function of 
calendar year for ages 15-25, for men and women separately, using 2006 as the reference 
year. Time trends were also modeled for each age separately, using statistical interaction 
terms to compare changes in 2007, 2008, 2009 and 2010 with 2006. Seasonal incidence 
counts were plotted by quarter and month over the 60 month period of this analysis, per 
age group. 
49
study iii 
material and metHods
This study was based on a nationwide open-cohort of all girls and women aged 10-
44 living in Sweden between January 1, 2006 and December 31, 2010. To assess 
effectiveness against incident GW, all individuals with GW prior to individual follow-
up (15 656) were excluded from the cohort. Individuals were censored at time of 
death (n=3405), or their 45th birthday. As it was not possible for us to obtain updated 
emigration status at the start of follow-up, all women having emigrated up until December 
31, 2002 were left censored (n=152 896). Women who received the bivalent vaccine 
(n=1,384) were censored at vaccination. In total, 2 209 263 women were included in the 
study contributing 9 640 542 person years. The average follow-up time was 4.4 (SD ± 
1.3) years. 
Data were collected using the Swedish population registers. Data management was done 
in SAS version 9. 2. The Total Population Register was used to identify individuals for 
inclusion in the cohort. Data on vaccination exposure status with either the quadrivalent 
or bivalent vaccine were retrieved via the Prescribed Drug Register (PDR) and from 
SVEVAC. The PDR contains all drug prescriptions dispensed at pharmacies in Sweden 
since July 1, 2005. Data on GW case outcome status were obtained from the PDR and 
the Patient Registers (PR) in the same manner as with Study II.  The Cause-of-Death 
Register was used to obtain information on deaths. Emigration status was derived from 
the Migration Register containing all immigration and emigration dates until 2002.  As 
a proxy for socioeconomic status, parents’ education levels were obtained from the 
Education Register and the parents themselves were identified from the Multigeneration 
Register.
GW cases were defined from first diagnosis of GW either via the PR and/or a GW 
treatment prescription identified by the PDR. Age-specific prescription trends for 
podophyllotoxin and imiquimod were identical in the younger age groups.  Imiquimod 
trends differed in the older age groups, likely related to treatment of non-GW ailments, 
hence follow-up was excluded over age 44 as was case in Study II. History of GW prior 
to an individual’s follow-up in study was defined via GW diagnosis in the PR and/or 
imiquimod or podophyllotoxin dispensation in the PDR.  
Vaccination dates from SVEVAC were primarily used to define vaccination status but 
because coverage was incomplete, the PDR was also used to identify prescriptions for 
the quadrivalent and the bivalent vaccines using ATC codes J07BM01 and J07BM02, 
respectively. If a woman had more than three recorded dates for the qHPV-vaccine, it 
was assumed that the first three unique dates matched with the first, second and third 
doses of the vaccine. Nine-hundred-twenty-six women identified via the PDR had more 
dispensations on file than unique dispensation dates. It was assumed that women with 
two unique dates and more than three dispensation dates received their first and second 
dose or their second and third dose at the same date.  Women with only one unique date 
(N=21) listed more than two times were considered to have all three doses on the same 
date. Vaccination status was assessed as a time-varying exposure with full effectiveness 
of the vaccine assumed after three doses.  Using vaccination status as a time-varying 
50
exposure allowed for the same woman to contribute person-time to all or some of the 
dose categories (0, 1, 2, 3) depending on whether the woman received all or any vaccine 
doses during individual follow-up. Age at first-vaccination defined age-at-vaccination.  If 
a woman were to have a case of GW during follow-up and prior to her vaccination, she 
would be censored at time of GW and only contribute person-time in the unvaccinated 
group. 
study iii data analysis
Statistical analyses were done with Stata version 11.Logistic regression with outcome 
vaccination status and exposure parental education level was performed to assess if and 
how socioeconomic status was related to vaccination likelihood SES was also assessed 
as an independent risk-factor for the outcome GW in a logistic model, adjusting for age. 
Those with missing SES were retained in a missing category in the analysis. Highest 
education level of either parent defines variable; if one of them was missing, it was 
assumed that the one with non-missing education had the highest level. 
Kaplan-Meier curves were first constructed to assess proportional hazards. Incidence rates 
(IR) were calculated from the number of cases per accrued person-time for unvaccinated, 
partially vaccinated and fully vaccinated women. To study the effect of vaccination on the 
incidence of GW, incidence rate ratios (IRR) were calculated as the ratio of the incidence 
rate (IR) in fully vaccinated women divided by the IR in partially and unvaccinated 
women. As person-time for the unvaccinated women contributed to 97.5% of total person-
time it was decided to include the partially vaccinated in the reference group as excluding 
them did not alter results and would only serve to diminish the cohort. Poisson regression 
analyses were used to estimate IRRs and 95% confidence intervals (CI) adjusted for 
attained age (time-scale), age-at-vaccination and SES.
Because younger women were more likely to be vaccinated than older women, 
individuals were stratified into six different age groups (age 10-13, 14-16, 17-19, 20-22, 
23-26, and 27-44) splitting person-time based on attained-age and those who received the 
vaccine were categorized based on their age-at-first-vaccination. IRR and 95% confidence 
intervals (CI) were obtained in Poisson regression models adjusting for attained age. 
Vaccine effectiveness was calculated as (1-IRR)*100%, with corresponding 95% CI.  
To assess vaccination self-selection bias, IRs before vaccination availability in Sweden 
were compared with IRs at the end of follow-up amongst those unvaccinated using 
Poisson regression stratified by age with the youngest age group as reference.  
Population-impact was assessed by calculating GW case vaccine-attributable reduction. 
Age-stratified incidence rate differences (IRD) were calculated comparing fully-
vaccinated and not fully-vaccinated and multiplied by 100,000 to display the number of 
avoided cases per 100,000 person-years. Age-stratified IRDs were multiplied by person-
time amongst the fully-vaccinated under age 20 to calculate the actual reduction in the 
cohort and divided by mean follow-up time to obtain annual reduction estimates.
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study iv 
material and metHods
Girls and women between the ages of 10-24 were followed up between January 1, 2006 
and December 31, 2010. Follow-up was individual and based on age. Girls entered the 
open cohort on their 10th birthday or January 1, 2006, whichever came last. They were 
followed until their 25th birthdays or December 31, 2010, whichever came first. 
To assess dose effectiveness against incident, as opposed to prevalent GW, all individuals 
with a GW prior to individual follow-up (N=6 792) were excluded from the cohort. 
Individuals were censored at time of death (N=714). As it was not possible for us to 
obtain updated emigration status at the start of follow-up, all women having emigrated 
up until December 31, 2002 were excluded (N=35 953) as their history and follow-up 
could not be ascertained to the same degree. Women who received the bivalent vaccine 
(n=1 282) were censored at vaccination. In total, 1 045 093 women were included in the 
study. The average follow-up time was 3.8 (SD ± 1.6) years.
Data were collected via the population registers in a manner similar to Study III. Data 
management was done with SAS statistical software version 9.2 (SAS Institute Inc., 
SAS®). As the database coverage was higher in the PDR than SVEVAC for this age-
cohort and as we established that the PDR dispensation dates were an accurate proxy 
for injection dates, the PDR was solely used to obtain information on vaccination status 
in this analysis. Vaccination dates for the quadrivalent and the bivalent vaccines were 
identified in the PDR via ATC codes. If a woman had more than three recorded dates for 
the qHPV-vaccine, it was assumed that the first three unique dates matched with the first, 
second and third doses of the vaccine. 1654 women identified via the PDR had more 
dispensations on file than unique dispensation dates. It was assumed that women with two 
unique dates and more than three dispensation dates received their first and second dose 
or their second and third dose at the same date. Women with only one unique date (N=27) 
listed more than two times were considered to have all three doses on the same date. 
Unique vaccination dose dates were found for 98.6% of individuals.
study iv data analysis
Statistical analyses were done with Stata version 11 (StataCorp). Vaccination dose status 
was used as a time-dependent exposure which allowed for the same woman to contribute 
person-time to multiple dose categories (0, 1, 2, 3) depending on whether she received 
none, some or all vaccine doses during individual follow-up . If a woman were to have 
a case of GW during follow-up and prior to her vaccination, she would only contribute 
person-time in the unvaccinated group. Those who received the vaccine were categorized 
based on their age-at-first-vaccination, creating two groups, one vaccinated between 
10-16 and the other 17-19. Women who were first vaccinated over the age of 19 were 
censored at time of vaccination. Dose effectiveness was measured in girls first vaccinated 
under age 20 compared to the unvaccinated population at the same attained age in order 
to restrict the population to those who were more likely to have limited HPV-exposure 
at the age when they were first vaccinated. Attained-age is a term used here to denote 
individuals’ ages during follow-up (time-dependent). Poisson regression was used to 
estimate incidence rate ratios (IRR) and 95% confidence intervals (CI) of GW by vaccine 
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dose,  adjusting for SES and attained age based on five different attained-age groups 
(10-13, 14-16, 17-19, 20-21 and 22+), among unvaccinated women and women first 
vaccinated before age 20 stratified by age-at-first-vaccination. Dose effectiveness was 
parameterized with the unvaccinated participants as reference group. Using this time-
dependent exposure design, the same individual can contribute person time to all dose-
level categories (if they complete vaccination and do not contract GW before all three 
vaccinations are completed). Vaccine dose effectiveness was calculated as (1-IRR)*100%, 
with corresponding 95% CI.  Comparisons between different levels of vaccination 
(one vs. two doses, two vs. three doses etc.) and age-at-vaccination were based on the 
corresponding linear contrasts between the base parameters.
To assess for vaccination self-selection bias in the population cohort under study, two- 
dose effectiveness was recalculated for those who stopped vaccination at two doses, 
adjusted for age to assess whether these individuals were more likely to get GW at this 
dose level than those who completed all three doses.   
To investigate factors related to three-dose completion, a cohort of individuals who had 
completed all three doses in the vaccine schedule during the follow-up versus individuals 
who did not complete vaccination during follow-up and instead stopped at either one 
or two doses were examined separately. Date of entry into this cohort was date of first 
vaccination; date of exit was end of study follow-up (December 31, 2010) or third 
vaccination-dose, whichever came first. Females included in this cohort were vaccinated 
between 10 and 19 years of age (n=79 441) with no previous history of condyloma and at 
least six months of available follow-up. Analyses with outcome three- dose vaccination 
completion were conducted. Vaccine dose was assessed as a time-dependent outcome 
and GW during follow-up was assessed as a time-varying exposure using multivariable 
Poisson regression, adjusting for age-at-vaccination and SES.  
Population impact was assessed by calculating GW case vaccine-attributable reduction 
per dose level. Incidence rate differences (IRD) were calculated comparing those 
vaccinated at ages 10-16 or 17-19 with unvaccinated in the same age group for three vs. 
zero, two vs. zero and one vs. zero doses and multiplied by 100 000 to display the number 
of avoided cases per 100 000 person years. 
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mAin findings
The findings on infection risk assessment and prevention strategy evaluation in the era 
of HPV-vaccines are taken from Studies I-IV and include some data not presented in the 
papers themselves but which might enhance understanding of the thesis aims. Preliminary 
results from internet-based focus group discussions with women are also presented here. 
The findings are presented under two main themes: assessing infection risk and evaluating 
strategies for prevention.
summary of findings 
Overall, quadrivalent HPV-vaccination was highly effective against GW, the first HPV 
disease endpoint possible to measure. However, effectiveness was contingent upon young 
age at first vaccination, with effectiveness declining steadily the older the age-at-first 
vaccination. Low to immeasurable effectiveness was found in women first vaccinated 
over age 20, with suggestive evidence that vaccinations tended to reach women at 
high GW risk in this age-group. There were marked socioeconomic disparities in the 
opportunistic vaccination strategy evaluated, with women and girls who have parents with 
the highest education level compared to the lowest having a 15 times greater likelihood to 
be vaccinated. Once vaccination was initiated, low parental education level was unrelated 
to vaccination completion, however. Maximum protection against GW was found among 
girls vaccinated under the age of 17 who had received all three doses of the vaccine. 
However, vaccinating older girls with more than one dose will result in considerable 
disease reduction as the burden of GW increases with age from the late teens until 
approximately age 20. No differences in effectiveness were found for girls who received 
two-doses between ages 10 and16 with that of girls who received three-doses between 
ages 17 and 19 (p-value 0.631).  GW affects more men than women in Sweden as of 2010 
with 453 per 100 000 men and 365 per 100 000 women treated. A decline between 25-
30% was seen between 2006 and 2010 amongst women the age groups with the highest 
vaccination coverage. No decline was found among men and their GW incidence has 
steadily increased between 2006 and 2010. Reported condom use in high risk situations 
was low among both men and women, with 41% of men and 34% of women reporting 
always/almost always condom use with temporary partners. STI risk perception was also 
low, with approximately 10% of sexually active respondents considering themselves at 
large risk of contracting an STI. There was no association between men’s condom use 
and their STI risk perception but there was an association for women. Women discuss 
preventing transmission of STIs via partner selection, selective condom use and periodic 
STI testing. Women describe deferring to men to have condoms in first intercourse 
situations so as not to jeopardize the potential for a longer-term relationship, as a woman’s 
condom preparedness reveals that sex might be premeditated and suggests a level of 
sexual experience which women did not feel comfortable expressing to new partners. 
Women found conceptualizing a sex and cancer connection difficult. Due to HPV’s skin-
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to-skin transmission, women expressed preventing HPV contraction via sexual behavior 
changes seemed impossible and outside their control.
assessing infection risks
When assessing infection risk, this thesis examines HPV disease burden via GW 
incidence estimations. Factors associated with excess risk for contracting STIs, including 
HPV, were also identified. Risk perceptions were of central interest and are presented 
here, as are results on navigating competing risks.  
Disease burden and excess infection risk
Age-stratified incidence proportions of GW were highest for 20-year old women (956 
per 100 000 or 1% of women in that age group) while men peaked slightly later at age 24 
(1137 per 100 000). In the same year, 2010, incidence declined to 139/100 000 for women 
aged 44 and 158/100 000 for men aged 44. Crude incidence was marginally higher among 
men than women during 2006-2007 and appeared to later diverge. Figure 10 shows that 
among men overall incidence appeared to increase while incidence in women declined 
between 2008-2010.  
Figure 10. Age specific incidence proportions per sex and year  
Results from Study III showed that women whose parents had the highest education level 
compared to the lowest had an increased risk for GW, or seeking treatment for GW which 
is what was possible to effectively measure (OR 1.33 95% CI 1.28; 1.39) (Table 1). When 
examining age-stratified rates, a slight protective effect of high parental education status 
on GW outcome was seen among girls and teenagers but a substantial excess risk was 
seen among women in their early 20s whose parents had highest education levels. 
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Table 3. Incidence rate ratio (IRR) from Poisson regression modeling effect of parental 
education level on outcome GW, adjusting for age. Highest level of attained education 
defines education level.
IRR, (95% CI)
education level of mother
   Missing 0.59 (0.55-0.63)
   Less than high school Ref
   high school 1.18 (1.14;1.21)
   University studies 1.25 (1.20; 1.29)
education level of father
   Missing 0.68 (0.65-0.72)
   Less than high school Ref
   high school 1.09 (1.06;1.12)
   University studies 1.13 (1.10;1.17)
education level of parents* 
   Missing 0.61 (0.56-0.66)
   Less than high school Ref
   high school 1.25 (1.20;1.30)
   University studies 1.34 (1.28;1.39)
Results from Study III also showed that women with a higher risk for GW were seeking 
vaccination. This self-selection bias was not seen in younger women.
To assess whether there was a self-selection bias amongst those vaccinated, rates of GW 
before commercial availability of qHPV were compared with rates in the unvaccinated 
population at the end-of-follow-up. No significant differences were found in the 
population with highest vaccine coverage (ages 14-19) (IRR 1.00; 95% CI .98-1.02). 
Among women over age 20, the GW rates declined in the unvaccinated population 
compared to the total population before vaccination (IRR 0.96; CI 0.95-0.97) suggesting 
a self-selection bias with individuals at a higher risk for GW being more likely to seek 
vaccination.
Regarding excess infection risk, results from Study I indicate that women who report 
young sexual debut ages were more likely to report seldom or never using condoms with 
temporary partners later in life (OR 1.95;  95% CI 1.46-2.60). Also at increased risk for 
reporting seldom or never condom use with temporary partners are women with low 
education level (OR 1.87; 95% CI 1.30-2.71) and women who come from families who 
have at some point received social welfare (OR 1.59; 95% CI 1.02-2.46). Women with 
Swedish born mothers compared to mother’s born outside the Nordic region also appear 
to be at an increased infection risk as they were almost twice as likely to report seldom or 
never condom use with temporary partners. 
Interestingly, preliminary results from the internet-based focus groups indicate that 
contraction of one infection may potentially reduce risk of subsequent infections in some 
individuals as there were multiple reports of engaging in safer sex practices due to a 
previous STI diagnosis. Women diagnosed with viral STIs attributed the diagnoses to an 
increase in subsequent health seeking behaviors, as the following quote elucidates:  
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Anya: ….I’ve had cell changes. Before I never thought about the risks…Now I stick it 
[condom] in front of the guy’s nose…(I get) comments like ‘Do we have to?’ ‘Yessssssss’ is 
my answer.
Infection risk perceptions
Infection risk perception was generally low for young sexually active men and 
women. Study I showed that over 80% of young, sexually active men and women 
perceived themselves to be at no or small risk for contracting an STI (83.4% vs. 82.7% 
respectively). Correlates to STI risk perception differed between men and women even 
though the prevalence did not. The most notable finding is that men’s STI risk perception 
was not associated with their use of condoms with temporary sexual partners, while 
women’s was strongly correlated. Women who reported seldom or never condom use 
were three times as likely to perceive themselves to be at high STI risk compared to 
women who reported always or almost always using condoms with temporary partners 
(OR 3.1; 95% CI 2.41-4.03). 
 Figure 11. Forrest plot of factors significantly associated with women having 
 high STI risk perceptions.
Many of these factors differ from factors which were significantly correlated for men, 
shown in the following figure (note only significant correlates are shown in plots, many 
other factors were examined but no statistically significant correlates were found).
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  Figure 12. Forrest plot of factors significantly associated with 
  men having high STI risk perceptions.
Results from the Attitude survey used in Study I indicate that both men and women 
are more apt to believe that HPV only infects women. Of those who answered the 
questions on HPV contraction, 83% believed women could be infected with HPV with 
15% reporting they did not know, while only 67% believed that men could be infected 
with HPV and 26% reported not knowing. 79% believed HPV was sexually transmitted 
while 17% report not knowing whether it is sexually transmitted or not (with a higher 
percentage of men than women reporting not knowing).  
The following IBD quote also reveals women perceiving a general lack of awareness 
among men that they can be infected with HPV:
 Kate: it seems like the guys don’t know they can carry it (HPV)
 Lisa: I think so too, they don’t know
 Anne: exactly, as if the woman is the only piece in the puzzle
Navigating HPV risks
Due to HPVs skin-to-skin transmission, women describe preventing HPV contraction 
via sexual behavior changes as impossible and outside their control. Women found 
conceptualizing a sex and cancer connection difficult. The relative newness of the 
awareness that sex and cancer are potentially related is typified in Aili’s quote below: 
 Aili: before I got vaccinated I didn’t know you could get cancer from sex…it  
 was something totally new for me…feels a little like everything in the world is  
 dangerous now…soon there’s no point in going outside :P
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She later rationalizes that HPV risk is too overwhelming to seriously consider in sexual 
encounters:
 Aili: of course you can change your sexual behavior if it will prevent it [HPV]  
 but that’s not exactly what you’re thinking about in those situations…if that were  
 the case you’d have to basically worry about everything
In response to probing, participants reported that the sexually transmitted nature of 
HPV was frightening but beyond their control, with the threat of HPV related-cancers 
too distant in the future to warrant present concern. In contrast to Anya who had been 
diagnosed with dysplasia, Rebecca reasons about the potential oncogenic effects of HPV 
as follows: “you can’t take gigantic precautions to protect yourself from something that 
maybe can develop into cancer”.
When asked if HPV testing would influence them in any way, most women responded 
that they would not change their sexual behavior if they discovered they were HPV 
positive. They motivated this by arguing that it seemed hopeless to protect themselves 
from HPV transmission, commenting that it would be impossible to “live in a little box”  
(Anya) or “cover yourself in plastic wrap” (Melissa). 
When managing multiple risks, such as infection exposure, loss of potential relationship 
and/or tarnished reputation, avoiding infection exposure was not always prioritized. This 
point will be further elucidated when results on condom use in high risk situations are 
presented.
evaluating strategies for prevention 
Prevention strategies under investigation include opportunistic HPV vaccination, 
complete vaccination with the qHPV vaccine among girls and women, effectiveness of 
the qHPV vaccine at various dose levels, reported condom use with temporary partners 
among men and women, as well as women’s own reported strategies for avoiding STI 
risks.
qHpv-vaccination
Among the  2 209 263 women aged 10-44 followed in the study, over 5% received at least 
one dose of the qHPV-vaccine.  Of all vaccinated women 78% were fully vaccinated. 
Highest vaccination coverage was seen in women 17-19 (33%) and 14-16 (26%).
Effectiveness was 75% (95% CI 79-72) among those receiving three doses of the vaccine 
who had received their first dose before age 20. Effectiveness was highest in girls who 
were vaccinated before age 14 (93%; 95% CI 72-98). Effectiveness was  79% (95% 
CI 74-83) for those vaccinated between 14 and 16 years old, 70% (95% CI 64-75)  for 
17-19 years old, and 45% for women vaccinated between 20-22 (95% CI 18-63).  No 
effectiveness was measureable in fully-vaccinated women who received their first dose 
over the age of 22. 
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Figure 13. qHPV-vaccine effectiveness based on incidence of GW by age-at-first 
vaccination
Table 4. Incidence rate ratios (IRR) and effectiveness rates comparing fully vaccinated 
women, with partially and unvaccinated women combined, calculated using Poisson 
modeling. Stratified by age-at-vaccination and adjusted for attained age and SES. Number 
of GW cases amongst fully vaccinated women also presented. Absolute incidence rates 
(IR) among vaccinated and unvaccinated per 100 000 person years shown, along with 
the incidence rate difference (IRD) and corresponding 95% CI, which translates as the 
number of estimated reduced cases per 100 000 persons, shown by age strata.
IRR,
(95%CI)
Effectiveness,
% (95%CI) N*
IR 
vaccinated
IR 
unvaccin-
ated
Estimated 
reduced cases 
(95%CI)
age at 
vaccination
   All ages (10-44) 0.27 (0.23;0.30) 73 (70;77) 259 175.92 346.75 170 (152;187)
   Under age 20 0.24 (0.21;0.27) 76 (73;79) 217 157.03 539.01 382 (367;394)
   10-13 0.07 (0.02;0.29) 93 (71;98) 2 11.97 252.67 240 (211;243)
   14-16 0.21 (0.17;0.25) 79 (75;83) 105 126.41 678.35 551 (536;563)
   17-19 0.29 (0.24;0.35) 71 (65;76) 110 286.34 935.22 648 (603;685)
   20-22 0.52 (0.35;0.78) 48 (22;65) 24 475.15 793.66 318 (97;463)
   23-26 0.78 (0.46;1.32) 22 (<0;54) 14 452.45 483.56 31 (0;207)
   27+ 2.32 (0.87;6.18) <0 (<0;13) 4 450.44 181.19 0 (0;8)
*n=number of fully vaccinated women with GW 
In the previous table, estimated reduced cases was highest for those age 17-19 (648 per 
100 000). Total GW case reduction from qHPV-vaccination among women below 20  is 
estimated as 746 during entire follow-up or approximately 170 cases per year. The total 
population impact of three-dose vaccination in the cohort of 10-19 year olds vaccinated 
was a reduction in 516 cases of GW, the population impact for two-doses was a reduction 
in 249 GW cases and for one dose 104 cases.
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However, the partially subsidized on-demand vaccination strategy evaluated in this study 
showed that having at least one parent with the  highest education level compared to the 
lowest made one 15 times more likely to be vaccinated (OR 15.26 95% CI 14.50;16.07). 
Mothers’ education level had a two-fold higher influence on vaccination status compared 
to fathers’. Once vaccination was initiated, however, high parental education level had 
no positive association with vaccine dose schedule completion. Looking only at the 
vaccinated cohort with at least 6 months of follow-up, those first vaccinated between ages 
17 and 19 were less likely to receive all three doses versus girls first vaccinated between 
ages 10 and 16 (IRR 0.56; 95% CI 0.54-0.57). Contracting GW during follow-up was also 
associated with being less likely to complete vaccination (IRR 0.58; 95% CI 0.46-0.73).
Results from the ecological Study II show a substantial decline in GW incidence among 
young women ages 15-25 during the period 2006 through 2010 (test for trend p-value 
<0.0001 ). No significant trends over time were observed among men (p=0.71). When 
analyzing age-specific trends, women ages 17 and 18 years had over a 25% decline in 
GW rates when comparing 2006 with 2010 (p-value <0.0001), with significant decreases 
through age 25. While no causal relationship could be established with this type of 
ecological data, the quadrivalent vaccination program is likely fueling these declines, as 
we could see in Studies III and IV. 
For girls vaccinated between ages 10 and 16, maximum effectiveness was seen with three 
doses 80% (95% CI 75-83). There was a significant difference between three versus two 
doses in this younger age group (p-value 0.007), with three doses offering 36% more 
effectiveness (95% CI 12-54). 
For individuals vaccinated 
between ages 17-19, maximum 
effectiveness (70%, 95% CI 64-
76) was also seen with three-
doses, offering 26% (95% CI 
0-46) more effectiveness than 
two doses (p-value 0.061), but 
with borderline significance. No 
differences in effectiveness were 
found for girls who received 
two-doses between ages 10 and 
16 with that of individuals who 
received three-doses between 
ages 17 and 19 (p-value 0.631). 
 
Figure 14. Dose effectiveness 
with qHPV by age-at-first vac-
cination. IRR of GW comparing 
girls first vaccinated between 
10-16 or 17-19 respectively, 
with unvaccinated girls adjusted 
for age and parental education. 
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Condom use in high STI risk situations
Study I showed that among men, 41% reported always/almost always using condoms 
with temporary partners while only 34% of women reported the same. 50% of women 
reported never using condoms with temporary partners; the corresponding number among 
men was 40%. 
There were not correlations between condom use and variables related to HPV-related 
cancer or GW awareness, knowledge or disease severity perceptions. Variables associated 
with condom use differed considerably between men and women. The following series of 
Forest plot figures illustrate these gender differences. 
Women were approximately three times as likely to report perceiving a high risk of 
contracting an STI when they report often/sometimes and seldom/never using condoms 
compared to those women who report always/almost always using condoms with 
temporary partners. STI risk perception was not correlated to condom use with temporary 
partners for men. As mentioned in the previous section on infection risk, younger age at 
sexual debut was associated with non-condom use later in life for women but not for men. 
Also associated with non-condom use for women but not for men was coming from a 
family who had ever received social welfare benefits. Mother’s birth country was a factor 
for condom use for women but not for men.
 
Figure 15. Correlates to women’s never use of condoms 
with temporary partners compared to always/almost 
always
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For both men and women, number of temporary partners during the past year was 
associated with increased odds of inconsistent condom use (often/sometimes vs. always/
almost always use). Women were less likely than men to report seldom/never using 
condoms as their number of partners increased. Inconsistent and non-use of condoms 
were more commonly reported in both women and men with lower education levels. 
 
Figure 17. Correlates to men’s sometimes 
use of condoms with temporary partners 
compared to always/almost always.
 
Figure 16. Correlates to men’s never 
use of condoms with temporary partners 
compared to always/almost always.
Women describe exposing themselves to substantial risk for STI contraction in situations 
where they perceive potential for new longer-term relationships. A primary barrier to 
using condoms with temporary partner was gender roles. In the internet-based chat 
discussions, premeditated sexual intentions were described as something that should 
not be revealed to a new partner. As a woman’s preparedness with condoms would 
reveal that sex might be premeditated, thus suggesting a level of sexual experience, 
women described instead deferring to the man to have condoms. The participating 
women described sometimes broaching the subject of condom use immediately prior to 
penetration, although these women were clear in their preference that men raise the issue 
of condom use. The following statements from different discussion groups exemplify how 
women reason about their need to uphold an acceptable facade: 
 Kathrine: It [having a condom] can feel like you’re a little too eager and   
 intentional…I think it’s so hard to show that I’ve intended the evening will end  
 with sex. It’s better if it just “happens”.
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 Tara: You have to act like you didn’t know that you were on your way home   
 to have sex until it’s really obvious. And then it’s supposed to be a little like   
 a surprise, that you absolutely didn’t plan for the night to end this way. If you  
 then pull out a condom or ask the person if they’ve been tested it seems like maybe  
 you’re taking everything too seriously.
The need for covertness appears to be a key element affecting condom use in encounters 
with ‘love potential’, or the potential for a continued longer-term relationship. Women 
describe being covert not only about their sexual desires, but also about their condom 
preparedness. The implication in the discussions with women is that if a woman is not 
covert, she risks not only missing this sexual contact and a potential love relationship, but 
also risks her reputation. Women describe this as one reason why discussions of condom 
use generally occur immediately prior to penetration. It seems they fear that several 
negative consequences may ensue if a woman brings up condom use earlier. First, sex 
will appear premeditated; this is not in line with the script women feel they should act out 
which involves no sexual intention prior to interaction with this particular man. A second 
potentially negative consequence is the risk of embarrassment and possible rejection a 
woman would face by being overt about condom use, before being certain that desire for 
sexual intercourse is mutual. This segment from one discussion illustrates this:
 Kim: many think it’s such a hassle with condoms. Alcohol is involved, no condoms  
 at home, and you don’t want to ask…you don’t want to ask because you don’t  
 know what the answer will be. You maybe want sex and think “if I ask maybe he’ll  
 back away”(…) so it’s embarrassing if you start talking about condoms right  
 away, easier to just avoid it.
 Kerry: I agree. If you ask about condoms then it’s so obvious that your intentions  
 are to have intercourse, and you’re not supposed have those intentions as a girl.
Men who did address condom use were described as unusual, and this characteristic was 
said to indicate an ‘exceptional man’, as illustrated by excerpts from two IBDs: 
 Anya: I’ve met guys who I don’t need to tell. They take the condom initiative           
 themselves. Those guys are real men!
 Amanda: I had a partner who was clear from the beginning that we wouldn’t have  
 sex without protection [condom]. I thought it was so great and felt safe. 
 Astrid: I like when a guy suggests it [condom use]. Feels pretty serious. I would  
 never suggest it myself though.
Women describe what can be conceptualized as ‘symbolic distrust’ related to condom use 
for other reasons than birth control. If condoms were not used at first sexual intercourse 
and the couple continued to have intercourse, it seems that a praxis was established; 
condoms were not described as used later in the same relationship, unless motivated by 
concern about pregnancy. From women’s descriptions it appears that they reason that if 
the potential partner had an STI or thought s/he might be at risk for carrying one, that 
person would hopefully have informed them. This is particularly notable, given the strong 
role that covertness played in women’s own descriptions of decision-making.
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women’s strategies for preventing transmission
One of the aims with the IBDs was to assess how women conceive of HPV and other 
STI related risks as well as gain understanding of what they do to protect themselves 
from STIs. Preliminary results show that women describe managing STI risk via 
partner selection, selective condom use and STI testing. HPV testing specifically and 
HPV vaccinations were notably outside the scripts for risk navigation narrated by IBD 
participants. Women discussed HPV only when asked directly by the researchers and 
did not broach the topic of HPV testing or vaccination spontaneously as they did with 
the aforementioned results on testing for other STIs, condoms and partner selection. As 
selective condom use has been presented in the previous section, a brief presentation of 
how women describe using partner selection and STI testing to prevent transmission will 
be presented here.
Partner selection
Women described avoiding STI exposure through selection of their sexual partners. They 
expressed relative confidence in their ability to ascertain whether a potential partner was 
at high risk for carrying an STI based on multiple cues. Women described conducting 
an initial partner assessment, influenced by a variety of factors including social cues, 
nationality of the potential partner, intuition and alcohol intoxication.  Individuals who 
could be at high risk for carrying STIs were described as external to the women’s social 
spheres.
Sexual intercourse was often described by women as one of the first steps in a dating 
process. In these women’s descriptions, intercourse often appears to function as a means 
of screening for love potential in relationships, rather than as expected only after a 
relationship was established. The participating women often reasoned that if a man were 
likely to have an STI, they would have some indication through their intuition or via 
social cues such as reputation or background; however it is interesting that alcohol and 
other inebriated states affecting judgment were consistently described as the norm in 
initial sexual encounters.
 Tess: i don’t know. It [condoms] ruins the moment like, and it’s better without.  
 Though I usually only have sex with people I know. Otherwise I would maybe be  
 more careful, I don’t know
 Helena: exactly, if someone is known to be a “player” then you’re more careful.
 Jennifer: Exactly!
 Carol: I think so too
 Sandra: yes
Women often appeared to associate the familiar, i.e. Swedish men, with being safer and 
less risky than the less familiar, in this case non-Swedish men:
 Elisabeth: With the risk of seeming racist, I can imagine that Africans and   
 Eastern Europeans are high up on the list [of those with high STI risk].
 Naomi: (…) South Americans too apparently, I got tested a few weeks ago and  
 they were mentioned as a group [at STI risk] .
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This is in line with the view of the woman in the following quote who perceives less risk 
for contracting an STI in Sweden than abroad.
 Andrea: I don’t know if I feel safer in Sweden. On the other hand there are certain  
 countries where I would not have sex. I lived in Tanzania for a while and lived a  
 celibate life there. Very prejudiced I know, it’s just I didn’t dare.
Such risk perceptions were not always in line with the stories told by the participating 
women. The woman in the quote below reported having contracted genital warts in 
Sweden earlier in the IBD, yet here expressed feeling less at risk of contracting an STI in 
Sweden than abroad:
 Jill: If you know the person I think you feel more secure, if you’ve had sex with  
 the person before. I definitely feel safer in Sweden than abroad…Just the fact  
 that a guy ‘offers’ to use a condom makes me feel safer, like a sign that he’s   
 responsible. 
A central theme that permeated scripts involving potential long-term partners with love 
potential (as opposed to ‘sex buddies’) was covertness, i.e. covert sexual premeditations, 
covert condom preparedness, covert STI history. The participating women generally 
described it as imperative that these initial covert issues eventually become overt if 
trust and a steady love relationship were to be established. Intricate timing was said 
to be involved in a transition from the covert to the overt, as women pointed out that 
discussions of condom use or STI history were not able to be broached too early without 
jeopardizing chances of a continued relationship. On the other hand, the participating 
women maintained that if the existence of current or past STIs remained covert for too 
long, this covertness would infringe on trust, described as imperative in love relationships. 
They expressed hope that a man would reveal his current STIs to them as soon as possible 
but did not expect him to at initial intercourse(s) as elucidated below:
 Mikaela: if you’re a couple then you have another [kind of] intimacy and   
 openness. You can maybe even talk about it [STIs]
 Amanda: are we talking about temporary sex, or sex with your partner? I think  
 that if you’re in a relationship you should disclose an eventual STI but with   
 temporary sex then no one wants to know (as long as you’ve been treated).
Periodic STI testing
Women described being periodically tested for STIs to assure disease-free status.  If 
intercourse without condom use occurred and the couple did not continue their contact, 
it was described as likely that the woman would seek STI testing. Women were however 
uncertain of what they were tested for, appearing to instead leave disease and testing 
specifics to health care professionals to determine. Chlamydia was an exception in that 
it was consistently mentioned in conjunction with testing and appears to be the primary 
STI in focus for these women, and according to them, this focus is shared by the health 
system. The central role testing plays in women’s STI risk navigation could be facilitated 
by the trust they express in antibiotics to cure STIs, as described in the following quotes 
from two IBDs: 
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 Naomi…Chlamydia is of course most common and I’ve heard a comment “you  
 just have to take penicillin for 10 days” no problems…  
 Gabriella…I think most people think about Chlamydia and you can of course cure  
 that.
Testing allowed for treatment if one was positive for Chlamydia, as the preceding 
quotes indicate. Women also described that testing results would provide them with the 
information necessary to avoid having unprotected sex during antibiotic treatment.    
If testing confirmed a woman to be disease-free, future sex without condoms would 
not seem overly risk-filled in terms of STIs. Being ‘tested’ (albeit potentially only for 
Chlamydia) and obtaining a ‘disease-free’ status thus seems to act to corroborate the 
effectiveness of women’s previous partner selection strategies for STI avoidance. 
Participants in the IBDs indicated that they might broach the question ‘have you been 
tested?’ with partners, but did not report asking their partners what they had been tested 
for. The vagueness as reported below characterizes the women’s descriptions of testing: 
 Kristin: I remember I asked my boyfriend if he had been tested for any diseases,  
 and he said that he didn’t have any, so then we just used birth control pills.
It appears that testing took place under particular conditions—for example, if neither the 
man nor woman had been tested recently and had had sex with another partner without 
using a condom, testing might occur. Testing was described as functioning as a type of 
relationship rite of passage, from a temporary relationship into one more steady:
 Laura: If you feel like you are a couple and aren’t seeing other people then you  
 hopefully go and get tested [if you haven’t done it before] and then you maybe  
 don’t protect yourself with condoms anymore…
Women wanting to be tested for HIV described difficulties in convincing health care 
professionals that this was justified—this may in part relate to the public financing model 
for health care, with no out-of-pocket costs for this. They reported experiencing a lack of 
health professional support as shown in this excerpt from one IBD:
 Elisabeth: And you can’t be sure they’ll take one [HIV test] even if you ask for  
 it!!!!!
 Naomi: They ask if you’ve been travelling, where and which nationalities you’ve  
 had sex with but then you have to push the issue yourself if you want them to  
 check in any case
 Juliet: They’ll test you for what there’s most risk for, not what you request
 Naomi: so the attitude to HIV is pretty lax within Sweden… 
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discussion
metHodological considerations 
“Science is an anti-narcissistic phenomenon. It assumes a profound human tendency to 
self-deception, employs the scientific method to counteract it, and holds truth higher than 
any personal desire.”
    M. Scott Peck, M.D. 
limitations with gw outcome
Studies II-IV in this thesis share one considerable limitation, they all use treatment- 
seeking behavior as a proxy for HPV-related disease, GW. A proportion of individuals 
with clinical symptoms will not seek treatment or will self-treat with prescriptions 
obtained from friends or via internet purchasing. Sub-clinical infections of GW are 
also missed. As such, these studies will underestimate the actual incidence of GW.  
Participants in clinical trials are followed rigorously and minor GW cases, perhaps 
unnoticed by the individuals, will be detected in these trial settings. 
Furthermore it is not possible to use the available register data to track non-
pharmacological treatment episodes from all private specialist physician settings; only 
a proportion of private specialist clinicians report into the PR. Any physician visits, 
including private physician visits and primary care visits, however, resulting in treatment 
via podophyllotoxin or imiquimod were captured via the PDR. Because these are the 
primary treatment methods we assume that we capture the vast majority of these visits. It 
is not possible to estimate proportions not assessed with any reasonable accuracy.
The primary indication for imiquimod is extragenital warts. However imiquimod is 
sometimes used in practice to treat other skin pathologies such as actinic keratosis, 
intraepithelial carcinoma, and small basal cell carcinoma. Some misclassification of 
episodes identified due to imiquimod dispensing is expected. This misclassification 
should be minimized given the age-restriction imposed after discussing with prescribing 
professionals and examining age-specific curves. Prescription trends for podophyllotoxin 
revealed a distinct age-specific shape that matched with imiquimod trends in the younger 
age groups. Therefore we restricted the study population of interest in Studies II and III to 
those less than 45 years of age.
For Study II, a six month wash-out period was chosen to distinguish new from persistent 
episodes. This time-period was based on the estimated incubation time of GW as well 
as treatment durations51, 52, 101, 102. By using this washout period it was possible to remove 
prevalent episodes from the previous year, which could be considered persistent infections 
under treatment. Sensitivity analyses were performed with a 12 month wash-out period 
and annual incidence proportions decreased by roughly 5% for women and 10% for men.  
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censoring, right and left
In Studies III and IV many individuals will get GW after the end of study follow-up. This 
problem of right censoring is not unique to our study. Follow-up time in these studies was 
similar to that reported from the clinical trials (roughly 5 years). The problem that this 
right censoring presents is expected to be non-differential in terms of exposure.  
As it was not possible for us to obtain updated emigration status at the start of follow-up, 
all women having emigrated up until December 31, 2002 were excluded from the study 
population (i.e. left censored) in the event that they had a GW event elsewhere that we 
could not detect from the available data (n=152 896 in Study III and n=35 953 in Study 
IV). 
As the PDR contains data usable from July 2005 onwards, no data on prescription prior to 
this time could be obtained. This problem of left censoring will lead to an underestimation 
of the variable GW history, used in Studies III and IV. As GW incidence peaks at age 
20, this misclassification of GW history is expected to be more problematic in the older 
cohort. 
Right censoring of exposure status is present in Study IV. Many of the women in that 
study will go on to complete vaccination after end of study follow-up and we will not 
obtain this information nor use it to adjust current estimates. This censoring should be 
non-informative due to the study’s time-dependent exposure design.  
Misclassification and potential inaccuracy of exposure
Using two registers to obtain information on vaccine exposure in Study III allowed us to 
compare differences in coverage between these two registers. The PDR is an automated 
register for prescription dispensations to an individual whereas SVEVAC provides 
information on vaccination injection date. Girls under 18 were partially subsidized for 
the HPV vaccines during the time of the study follow-up, but to receive their subsidies 
they had to purchase the vaccines at a pharmacy. Otherwise, individuals could pay full 
out-of-pocket costs if they purchased the vaccines via the vaccination centers and were 
not reimbursed. All HPV vaccinations are supposed to be registered by the administering 
clinician in SVEVAC, including those vaccinations obtained outside the pharmacy 
system. SVEVAC should cover both prescription retrievals, but as registration is not 
automated and inclusion in the register subject to individual or parental approval, a 
proportion of cases will not be reported in SVEVAC. When comparing the PDR with 
SVEVAC, a large variation in SVEVAC coverage was found throughout the country. As 
SVEVAC is not automated as PDR, its coverage is substantially less. Through the end 
of 2010 for example, the PDR had approximately 20% more complete vaccination cases 
than SVEVAC across all age groups, with even higher completion compared to SVEVAC 
among younger women. 
Study III was first carried out using only PDR data. As women vaccinated age 18 and 
over received no subsidies, it was not necessary for them to purchase via the pharmacy 
system though most did anyway. There was however some increased coverage in 
SVEVAC in women vaccinated over age 20 so it was decided d to complement this study 
with SVEVAC data in order to minimize misclassification of exposure among women 
vaccinated in their 20s, 30s and 40s.   
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There were many incomplete or nonexistent dates in SVEVAC in the younger age group 
compared to the PDR, and as such, PDR was exclusively used in the vaccine dose Study 
IV. There was also the problem of overlapping dates, or dates for partial vaccination that 
existed in one but not the other register. By using the PDR exclusively for the dose study 
we might have missed some vaccinated individuals doing this, thereby underestimating 
our effectiveness by misclassification of exposure, which would lead to more conservative 
vaccine effectiveness estimates.  
By comparing these two vaccination data sources, it was possible to see that the 
prescription dispensation date found in the PDR was an accurate proxy for injection date. 
Comparing those individuals with both SVEVAC records and PDR dispensations showed 
that the PDR dispensation date was an accurate proxy measure for actual vaccination date 
as measured in SVEVAC as the PDR coincided within the same week for approximately 
90% of vaccinations in SVEVAC. 
This became particularly important in Study IV when assessing dose effectiveness as the 
time between doses one and two is relatively short (per schedule 2 months). Amongst 
those fully vaccinated during follow-up, there was an average time of 2.2 months 
(SD±1.2) between doses one and two and an average of 4.2 months (SD±1.6) between 
doses two and three. These dispensation intervals follow recommended dose scheduling 
(0, 2, then four months after the second dose at month 6). 
Figure 18. Number of days from PDR dispensation to injection recording in SVEVAC.
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selection biases
In the case of the vaccine effectiveness evaluations here, a key concern was vaccination 
self-selection bias. Were the women and girls getting vaccinated notably different from 
the general population in terms of HPV-related risk? 
To assess for this the following steps were taken. First and foremost, the time-
dependent exposure design of Studies III and IV allows individuals to contribute 
person time to multiple exposure categories thereby minimizing selection bias.
                                                                                                                                                                                
When comparing dose-level effectiveness for example, individuals move through 
exposure levels and follow-up ceases upon GW diagnosis, even if the individual were to 
go on and get another vaccine dose. This allows for assessment of two-dose effectiveness 
even among individuals who would eventually receive three doses. A concern voiced by 
Merck when they were informed we were going to proceed with a dose-level analysis was 
that it would be inappropriate to compare dose ‘completers’ with ‘non-completers’ as the 
very fact that an individual did not complete the vaccination schedule indicated a different 
baseline risk of HPV via behavioral mechanisms. The time-varying Poisson analysis used 
does not compare completers with non-completers; it compares person-time at each dose 
level. Many of the individuals who are not followed up after GW diagnosis between shots 
will go on to complete vaccination. 
Second, all women with a known history of GW prior to individual follow-up were 
removed from the cohort. It was thought that some women sought vaccination in an 
attempt to treat persistent GW and we wished to exclude these individuals from the 
analysis as their underlying risk is much different. Thirdly, Poisson regression stratified 
by age was used to assess vaccination self-selection bias in the population cohort under 
study by comparing IRs before commercial vaccination availability in Sweden with IRs at 
the end of follow-up amongst those unvaccinated. No significant differences were found 
in the population with highest vaccine coverage (ages 14-19) (IRR 1.00; 95% CI 0.98-
1.02). Among women over age 20, the GW rates declined over time in the unvaccinated 
population compared to the total population before vaccination (IRR 0.96; 95% CI 
0.95-0.97) suggesting a self-selection bias in which individuals at a higher risk for GW 
being more likely to seek vaccination. This is one reason dose analysis in Study IV was 
restricted to those vaccinated under age 20. 
In Study III we found that those vaccinated were much less likely to have parents with 
the lowest levels of education (proxy for SES), indicating a selection bias in exposure. 
When further examining how SES is related to HPV, it was found that individuals with 
higher parental SES were more likely to have the outcome GW. Whether this increased 
risk for GW reflects an actual increased risk or just an increased propensity for treatment 
once infected, is unknown. As a fourth precaution for self-selection bias, this variable was 
included in the multivariable Poisson model in Studies III and IV to adjust estimates for 
some of this bias.  
In Study IV two dose effectiveness was recalculated for those who stopped vaccination 
at two doses, adjusted for age to assess whether these individuals were more likely to get 
GW at this dose level than those who completed all three doses. There was no significant 
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difference in GW incidence after two doses in girls vaccinated with two doses who 
eventually completed their dosing schedule compared to girls vaccinated with two doses 
who did not complete their dosing schedules (p-value 0.372).
The suggested self-selection bias among older women vaccinated found in Study III 
likely reveals that women who considered themselves at risk for contracting an STI were 
more likely to seek vaccination than women who did not consider themselves at risk. 
HPV-vaccines were on-demand only for women over 18 during our study follow-up and 
were not covered by pharmacological subsidies so women in these age groups have to pay 
full out-of-pocket costs themselves. If the entire population of women up to age 45 were 
offered HPV vaccination, it is possible to speculate that effectiveness would be marginally 
better than the zero effectiveness against GW we found in women vaccinated over the 
age of 22. However as qHPV is a prophylactic vaccine, and the prevalence of HPV is 
estimated at approximately 70% in the population, then the likelihood of being HPV-
naïve in an age-group where the majority of women have had multiple sexual partners is 
small103.  This study only measured effectiveness against GW, which are primarily caused 
by HPV-types 6 and 11. Women with exposure to types 6 and 11 but without previous 
exposure to HPV types 16 and 18 when vaccinated should achieve maximum vaccine 
protection against lesions caused by types 16 and 18.
ses, missing and otherwise
SES is examined as an exposure in Studies I, III and IV. In all three studies it appears to 
be a confounder for various outcomes therein. In Study I it was possible to obtain various 
aspects of SES from Sweden’s LISA database including education, disposable income 
in family and individually, social welfare benefits received in the family, employment 
type, own and parental immigration status. When these various aspects were examined 
individually, education and social welfare benefits were most correlated to condom use 
(though social welfare benefits were only influential for women). 
Sweden has a large middle class with little variation in terms of income levels compared 
to many countries with larger income discrepancies. Manual laborers in Sweden who have 
never attended university can easily earn just as much, if not more, than their university 
educated peers. As such, when measuring the influence of SES in Sweden, it may not be 
recommended to use variables that would be clear indicators in other countries, such as 
income. SES is clearly an important factor in health outcomes in Sweden even if income 
discrepancies are minimized 67, 68.
Education level is a good measure for SES in Sweden and is often used as such67, 69. There 
parental education level was used to define SES as many of the girls in Studies III and 
IV were too young to have obtained their highest level of education and because it was 
believed to provide some indication of health-seeking behaviors even in older women. 
The information for parental education level was retrieved from Sweden’s Education 
Register. Individuals who attended Swedish schools will have the data automatically 
recorded in the register. Individuals who attended schools outside of Sweden will not 
have information recorded, unless they answered census data on this variable sent to 
households in 1960, 1970, 1980 and 1990. Due to the ages of the parents examined in 
Studies III and IV (most well under 70 given the ages of the children), the majority of 
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individuals with missing information on this education variable will likely be immigrants, 
or in the case of Studies III and IV, the children of immigrants. As such, the missing status 
in these two studies is informative. How exactly this would effect estimates however is 
unclear. These individuals, or their parents, likely belong to all education levels but the 
very fact that they were not born in Sweden provides another measure of health inequity. 
Rostila explains in his thesis on social-capital in Sweden that “social capital at individual 
level seems important in explaining health inequalities especially between groups based 
on country of birth in Sweden” (p. 7) 104. 
survey biases 
Data collected via questionnaires have limitations. Reported behaviors or attitudes in 
surveys may not reflect real-life behaviors or attitudes of the survey respondent. It is 
assumed that respondents report ‘the truth’, or report with as much accuracy to their 
personal experiences as possible. In the case of our potentially provocative and socially 
embarrassing questions, this assumption may falter in the context of this survey. There is 
no way to assess this potential reporting bias.   
Interestingly, the Attitudes toward HPV vaccination survey data from parents indicated 
that parents with the highest level of education were less likely to be willing to vaccinate 
their children against HPV. This attitude did not reflect real-life behavior that we found 
in Study III. This finding possibly reflects more problems with how attitudes translate 
into behavior than problems with survey accuracy. It also reflects the problematic nature 
of some survey questions in being reliable proxies for the intended outcome. It is also 
a possibility that this finding could reflect a lack of generalizability from the sampled 
survey respondents to the population at large.
External validity, or generalizability, refers to how well results apply to the target 
population. Low survey response rate could effect this validity measure. The survey used 
in this thesis had a population-based sampling frame, which enhances its generalizability 
in Sweden. With consideration given to the sensitive character of the questions and 
healthy young population targeted, the 50% participation rate in the survey can be seen 
as acceptable 78. A demographic analysis of individuals who did not respond to the survey 
was carried out using demographic data from Sweden’s LISA register. A multivariate 
analysis of demographic variables and likelihood of non-response showed that men, 
immigrants, those receiving social welfare, and those with lower education were less 
likely to respond to the questionnaire. Disposable income was not a predictor of non-
response nor was age, living area or population density. There was no indication that 
only a specific demographic group responded, augmenting the study’s generalizability to 
young Swedish adults.
Because the survey was based on a random selection of the population, this helps to 
alleviate some of the problem of selection bias, though not all as seen in the demographic 
analysis of non-responders. There is always the potential for a selection bias, in which 
those who chose not to participate deviated in regard to the outcome variables under 
investigation. The possibility of non-response bias in the sexual habits questions cannot 
be ruled out completely, although the distribution of sexual habits and number of survey 
respondents whom had not made their sexual debut appeared to be reasonable, reflecting 
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the relative heterogeneity expected in the population. Furthermore, both men and women 
proportionally indicated similar risk perception levels. The proportionality of condom 
use responses did differ based on gender, with men more apt to report consistent use. 
Therefore, the potential for non-response bias for that variable cannot be ruled out but 
there was a clear within gender response variation for condom use.
The survey question on STI risk perception might be considered vague, which brings up 
the issue of construct validity.  Is asking participants to estimate their risk for contracting 
an STI an accurate measure of risk perception? This point could be debated. Asking 
participants to estimate their risk can provide an estimate of how individuals perceive of 
their infection likelihood but will provide no indication of how important not contracting 
an infection would be for them. If someone believes that his/her risk for contracting 
influenza is high but is not bothered by the thought of coming down with the flu, they may 
not take any meaningful measures not to contract influenza; this would mean something 
different in terms of prevention engagement compared to a person who responded that 
she/he had a high risk for contracting the flu and was greatly afraid of that actually 
happening. When assessing STI risk perception in the survey, I was under the assumption 
that most sexually active individuals would be afraid to contract an STI.  
Another potential limitation to the survey regarding construct validity is that respondents 
self-define ‘temporary’ when asked about condom use with temporary partners in the past 
year.  Respondents were also asked about steady partners, another construct in which it 
was necessary to rely on self-definition. The term ‘one-night stand’ in the English version 
of the survey was not used in the Swedish version as it was thought that Swedes would 
not recognize their behavior in this type of casual sex but would recognize their situations 
in terms of having ‘temporary’ sex partners.  
Recall bias is a problem when collecting data retrospectively. To avoid this bias, questions 
regarding condom use were limited to only asking about sexual relationships in the past 
year. 
Absolute risk 
In Studies III and IV, absolute measures of risk were generated in addition to relative 
measures. From these absolute measures of incidence, we were able to calculate the 
difference in incidence rates between groups. This absolute calculation was important in 
our result interpretations for the following reason: despite the difference in magnitude of 
the relative incidence in terms of disease prevention, the greatest disease reduction was 
not found in the group with the largest vaccine effectiveness.  The reason for this was that 
the underlying disease rates varied between the strata, with the group with the highest 
incidence showing the greatest reduction in disease after vaccination even though the 
vaccine was more effective when administered to those in a younger group, where the 
underlying disease risk was much lower. This type of information can be important in 
policy decisions regarding public health interventions.
Qualitative limitations
The preliminary results from the qualitative IBDs presented in this thesis were not 
designed to make statistical inferences. The study was designed to gain deeper insight 
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into STI risk perceptions including HPV, as well as gain deeper insight into barriers to 
prevention utilization. Considerations affecting result trustworthiness are often discussed 
in qualitative research105. Quotes are presented to elucidate result findings so the reader 
can follow the process of translating the IBD transcripts into findings and assess the 
accuracy of some of the findings. Validation is an internal process with qualitative 
research. Researchers met on numerous occasions to read interviews and discuss coding 
and results. 
 
Researchers influence content of interview questions. How researchers respond (or not) to 
participants can influence participant response. It is not possible to know what would be 
revealed if different questions were posed to participants or how another level of openness 
to sexual unconventionality would influence the IBDs.
theories applied
Even though KAP and HBM assumptions are supported in research and by public 
education policy on sexual health, they do not appear predictive of the reported practice of 
condom use in both sexes. This thesis reveals that efforts primarily aimed to increase STI 
awareness and/or perceptions of risk will not suffice in influencing this specific prevention 
behavior. Other recent studies have also tested KAP assumptions as predictive of health 
or risk avoidant behavior and found knowledge and attitudes uncorrelated with practice106, 
107. A Swedish report by Herlitz revealed that knowledge and beliefs in condom use being 
protective against STIs increased between 1987 and 2007 but that those increases did not 
correlate to an increase in condom use during the same period70. Another central report on 
health in Sweden recently concluded however that the low awareness of HIV risk found 
amongst Swedish youth would lead to subsequent risk taking behaviors71. Risk awareness 
may not be predictive of prevention behavior for men in terms of condom use, as shown 
in this thesis, but there was a correlation for women’s STI risk awareness and reported 
prevention practice. Study I closely examined gender differences in the KAP assumption, 
as well as other potential factors associated with the practice of condom use in high 
risk situations. A deeper understanding into the actual barriers individuals experience in 
engaging in prevention behavior, with subsequent strategizing to alleviate these barriers, 
is necessary in the sphere of public health epidemiology.
Script theory allowed for a more nuanced understanding of barriers to prevention 
engagement, as well as allowed for an understanding of the contradictions often voiced by 
participants regarding health promoting behaviors. Examining the IBD data through the 
lens of sexual scripting allowed for conceptualizing health barriers on multiple levels. As 
Simon and Gagnon note, “A scripting approach, at best, is not a terminal point but merely 
a beginning, a way of charting that must remain a complex and changing landscape 
of uses and meaning” (p. 496 108). Gender role barriers inhibit women from overtly 
expressing their sexual desires and protection needs. These gender barriers represent 
cultural and interpersonal levels of sexual scripting and are in conflict with women’s 
intrapsychic script.  This conflict is evident in the women’s contradictory descriptions 
of believing in shared responsibility for STI protection and not wanting to be ashamed 
about their sexual desires or safety needs but describing personal situations in which 
they were themselves covert and in which men were allocated responsibility for condom 
preparedness and broaching discussions on use.  Also, collective or cultural barriers 
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regarding professional unwillingness to test for HIV perpetuate a systemic dialogue of 
risk being primarily external. 
These findings concerning the difficulties women express in promoting condom use 
and condom possession are particularly surprising when viewed from a cultural context 
where Scandinavia is associated with open attitudes towards, and legislation supporting, 
sexual expression 109. Despite both efforts and resources, these preliminary results show a 
substantial negative effect of gender barriers in terms of women’s sexual health.
discussion of key findings
GW infection risk and STI risk perception in Sweden
The results on GW incidence presented in this thesis are the first published data on GW 
from registers capturing the entire population of a country. GW incidence estimates to 
date are not usually calculated on a national level and instead are restricted to various 
geographic regions within a country or to certain individuals, such as those visiting sexual 
health clinics or who are covered under an insurance scheme. A German study using an 
insurance claim register to locate new cases of GW via ICD-10 code A63 estimated crude 
incidences of 147 cases/100 000 for men and 191 cases/100 000 for women, although the 
ages of individuals in that study ranged from 10 to 79 years, making comparisons of crude 
estimations inaccurate 110. Peak estimations from the German study were considerably 
lower than estimates reported in this thesis. Not all studies stratify on age and sex, making 
cross-study comparisons difficult. A report from 2008 in the United Kingdom showed 
peaks of GW cases, which included new and recurrent cases, among 20–24-year-olds at a 
similar level as those shown in this thesis111. GW estimates from the United States showed 
a slightly higher burden among men 112. These U.S. estimates are based on more limited 
population data sources or on private insurance claims data and were lower than what was 
found in this thesis, with a range from 162 to 205 cases/100 000 annually.
The first population-based GW incidence proportions for males in Sweden are presented 
in this thesis. The ages during which peak incidence occur are similar to those reported in 
1996 by Persson et al in the only other study in Sweden to-date on men’s GW incidence. 
Persson et al’s study comes from one STI clinic in one smaller town and reported a peak 
incidence of (12 cases/1000 for men aged 20–24 years)3. This thesis work also found 
similar peak trends among women as Persson and colleagues did, however overall rates 
among men were 30% lower than those among women in his study. This thesis did not 
find this sex-based discrepancy, instead crude GW incidence among men and women 
were similar before the vaccine became widely used, although values were slightly higher 
for men even in this early period. It is possible that men are more likely than women 
to seek or receive treatment for GW because of anatomical differences that make warts 
harder to detect in women, despite the equal prevalence of GW.
Estimates presented in this thesis were similar to those from a Nordic study by Kjaer et al 
that provided country-specific estimates from population-based surveys66. There, roughly 
1% of women respondents aged 18–45 years self-reported medical attention for GW in 
the previous year, whereas this thesis shows similar proportions for women aged 18–24 
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years. The response rate for that survey was 63% in the Swedish sample, with a consistent 
age distribution among respondents. These similar results among younger women provide 
some validation for the use of register data in estimating GW episodes. Estimating GW 
episodes by use of prescription dispensation as a proxy measure alone would provide an 
underestimation of incidence, but with the patient registers, peak incidence is comparable 
to clinic and questionnaire data. 
Interestingly, higher parental education status was associated with an excess risk of GW. 
As the GW variable in this thesis is a proxy for treatment seeking behavior, this excess 
risk of GW among those whose parents are well-educated may reflect treatment seeking 
behavior as opposed to actual incidence, as families with high educational status may feel 
more empowered to navigate the healthcare system. It may also be related to differences 
in sexual habits among these groups, with delayed childbearing and longer periods in the 
single and dating culture for women from higher educational backgrounds, which they 
are likely themselves to be if their parents are, with this longer ‘dating’ exposure period 
putting them at higher risk for contracting GW113. 
In societies where health risk exposure information is abundant, as is the case today in 
countries with high GDP per capita such as Sweden or the U.S., few epidemiological 
studies aim to measure how individuals interpret their risk exposure and whether or 
how this is in turn associated with prevention behavior. This thesis shows vast gender 
differences in how STI risk is perceived and correlated with prevention behavior. 
This thesis highlights some women’s descriptions of risk being external to their social 
spheres and external to Sweden. The lack of HIV testing support from health practitioners 
described by some women in the IBDs has also been voiced in mass media 114 and serves 
to strengthen women’s belief of STI risk as irrelevant in Sweden and for themselves. By 
focusing HIV testing on intercourse with men of particular nationalities, the Swedish 
health care system may systematically support women in assuming they will avoid 
STIs in general if they avoid unprotected (non-condom) sex with men with particular 
characteristics. This risk assessment of HIV risk reflects its epidemiology, as HIV 
incidence is relatively low in Sweden with over half of the 500 reported cases in 2009 
reporting infection in higher-prevalence countries before coming to Sweden 115, and men 
who have sex with men and intravenous drug users comprised substantial percentages 
of the remaining infected. However, the praxis of restricted HIV testing described by the 
women in the internet-based discussions could also exacerbate the notion of STI risk as 
external and be used to justify unprotected sex with those deemed ‘safe’. It is conceivable 
a message of HIV as a primarily foreign disease (as reported by women in the IBDs) 
might lead to more unprotected sex domestically.  This trend in turn could possibly prove 
influential to the increase in STI rates at large that have appeared over the last decade 55, 56 
Interestingly, these findings suggest that a positive STI history may function as a 
protective factor by reducing subsequent sexual risk taking and increasing health 
promotion. In Hammarlund’s Swedish study 116, having contracted condyloma was 
reported as a ‘wake-up call’ to disease risk. Another hypothesis generated here is if 
women who report STI experiences also report more health advocacy in terms of condom 
use with temporary partners, as a result of these experiences. Further investigation into the 
potential effects of having received a positive STI diagnosis are warranted.
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Hpv-vaccine effectiveness 
Vaccine effectiveness studies move outside the clinical trial restrictions present in vaccine 
efficacy studies and instead examine reduction of disease burden in the population at 
large. Effectiveness results from this thesis will be compared with efficacy trial results 
as these comparisons prove interesting and are necessary in vaccination program 
assessments. No other effectiveness studies have been published to-date with individual-
level data making effectiveness comparisons impossible. The five-year follow-up in this 
thesis is comparable with trial follow-up34, 117-119.
In the age group fully vaccinated with the  qHPV-vaccine below 14 years of age, where 
there is presumably little prior HPV exposure, the effectiveness against GW found in 
this thesis (93%) was similar to the vaccine-type specific effect reported in HPV-naïve 
subjects in the clinical trials of the qHPV vaccine (96%; CI 93-98) but was somewhat 
higher than the any-type GW reported (83%; CI 75-88) in that group120.  Similarly, the 
effectiveness among all women under the age of 20 (75%), was similar to the vaccine-
type specific GW efficacy (79%; CI 73-84) in the intention-to-treat populations but 
appeared stronger than the any-type GW efficacy reported there (62%; CI 54-69)120. 
However, women in the trials were older at enrollment (age range 16-26). The trials did 
not present age-specific results so age-at-vaccination differences could not be ascertained. 
One could argue that comparisons between efficacy trials and effectiveness studies should 
be focused on any-type infection as this is the only assumption that can be made with 
population data (given that HPV-typing of HPV-related disease outcomes is not standard 
clinical praxis).   A possible explanation for effectiveness being higher than the any-
type efficacy could be that a relatively high prevalence of GW in Sweden is caused by 
vaccine-specific types. Another highly plausible explanation would be if HPV 6/11 are 
preferentially associated with clinically-significant GW and non-vaccine HPVs being 
preferentially associated with minor GW lesions found in the more intense surveillance 
in the clinical trials. Considering that vaccinated individuals are known to be almost 
completely protected against incident HPV infection, indirect protection from herd 
immunity cannot possibly have contributed to further increasing the effectiveness among 
the fully vaccinated younger girls found in this thesis34.
Above the age of 20, the crude estimates of effectiveness are more difficult to interpret, as 
there was evidence suggesting a self-selection bias with women at high risk preferentially 
seeking vaccination. However the trials did limit inclusion to those individuals with fewer 
than four lifetime partners. With this criteria they could have a different risk pattern than 
the women over age 20 who chose vaccination in Sweden where it has become common 
among women with increasing numbers of lifetime partners and decreasing trends in 
condom use with casual partners121.  Also, circumcision is not common among Swedish 
men, increasing the likelihood for HPV transmission to women and thereby making 
comparisons difficult with the efficacy trials regarding baseline HPV risk in countries 
where circumcision is more common43. Nevertheless, failure to find any effectiveness at 
all for women above 22 years of age suggests that this group of women in Sweden had 
exposure to HPV prior to vaccination and thus received less benefit from vaccination. 
It is well known that the vaccine does not alter the course of an already existing HPV-
infection, which means that the vaccine will appear less effective if a woman is already 
infected with one or more of the HPV-types targeted by the vaccine at the time of 
vaccination 122, 123.
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Regarding dose effectiveness for females vaccinated before age 20, disease-specific 
outcomes after q-HPV vaccination per dose level are presented for the first time in this 
thesis. The two dose qHPV trial to-date has reported on measures of HPV-antibody 
responses (Geometric mean antibody titer, or GMT) as an assessment of efficacy124. 
How antibody response translates to disease prevention is currently unknown, though a 
correlation is assumed125, 126. Due to this unknown, it is difficult to compare trial findings 
on immune response with the findings in this thesis on treatment for the purpose of 
assessing whether antibody response translates accurately to actual disease protection 
as this thesis uses observational data with a proxy measure for HPV-infection. Trial 
data containing both antibody response and eventual disease outcomes are needed to 
substantiate and provide accuracy to these translation measures. However the most 
important factor when assessing vaccine effectiveness is actual disease outcomes and not 
antibody responses as a potential proxy for future outcomes.
Alternative dosing schedules of the qHPV-vaccine have shown good immunogenic 
responses127. The Canadian qHPV dose efficacy trial reported differences in mean anti-
HPV type levels5, 124. In that trial, one group was vaccinated between 9-13 years of age 
with a two and three dose schedule while the older group, vaccinated between 16-26 years 
of age, received all three doses. Only girls and women sero-negative at baseline were 
included. Results showed no difference in antibody response for HPV 16, while HPV 18 
response was better with three doses5. 
A non-inferiority in antibody responses for girls in the two dose schedule compared to 
the females vaccinated between ages 16-26 with three doses has been reported124. Though 
this conclusion could not be drawn with this thesis data, differences in effectiveness were 
found depending on age-at-first-vaccination. The trial reported that a three dose schedule 
in girls was superior to a two dose schedule in girls for HPV-types 6 and 18 (but not 16 
and 11)124. HPV-type 6 is found in a higher proportion of GW than HPV-type 11128. 
Quadrivalent HPV-vaccine trials have shown that the vaccine elicits a higher antibody 
response in younger girls fully vaccinated than in older girls and women, all sero-negative 
at baseline126, 129. This initial elevated antibody response could correspond to the higher 
protection seen in this thesis in girls vaccinated at a younger age versus girls vaccinated at 
an older age. Another possible explanation would be a higher incidence of baseline HPV-
positivity among those first vaccinated between 17-19 year olds, a significant proportion 
of whom will have had their sexual debut prior to vaccination. With this register data we 
have no way of controlling for this, but we have excluded women with a history of GW 
before individual follow-up.
The differences in immune responses based on HPV-types, age and dose shown in trial 
data further compel the presence of vaccine dose effectiveness studies to demonstrate if 
and how this response potentially translates into disease protection in real-life situations.
Regarding herd immunity, seminal studies from Australia showed a drastic decrease 
in GW among younger women and to a lesser but substantial degree even men when 
comparing ecological trends before and after vaccine program launch 130-132. While no 
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causal relationship can be established with this type of ecological data, the quadrivalent 
vaccination program is likely fueling these declines.  Australia’s broad school- and 
community-based vaccination program has over 80% coverage among teenage girls, 
while Sweden’s partially subsidized on-demand program has 25-30% coverage for the 
same age cohort 130. 
 
The U.K. also has documented declines in GW post vaccination despite using the bivalent 
vaccine which does not provide coverage for HPV 6&11. Their report suggests some 
ecological cross-protections and herd immunity among boys 133. No such herd immunity 
effects on men in Sweden could be insinuated in this thesis.
Condoms for STI prevention in high risk situations
The rise in multiple STI incidences in Sweden could be related to the relatively low 
prevalence of condom use with temporary partners shown in this thesis, though by study 
design this can merely be speculated56, 59, 60, 134. A report that came out after this thesis work 
on condom prevalence was published showed a positive attitude toward condom use but 
low usage. The same report indicated that young Swedes found not using a condom to 
signify trust in one’s partner72. 
In contrast with Sweden’s reputation for gender and sexual equality 109, women from the 
IBDs describe often deferring to men for condom preparedness and decision-making 
concerning use. A study from the United States also found that sexually active women 
described experiences in which they never initiated or negotiated condom use 135. These 
findings show discordance with other Swedish research showing that women are positive 
about condom use and have intentions of using them with new partners 136. Women in 
the IBDs expressed a need to be covert about pre-meditated sexual intentions with new 
sex-partners with love potential; condom preparedness was said to reveal premeditated 
intentions. 
Acting out ideals based on gender stereotypes of sexually active men and sexually passive 
women was also a theme found in Marston and King’s systematic review 137 on factors 
shaping sexual behavior in young people. In the 268 international qualitative studies they 
reviewed, common gender stereotypes were found where girls and young women who 
expressed wanting sex risked a bad reputation which in turn inhibited communications 
about sex 137. The preliminary results presented here adds data about women up to 
ten years older than those in the aforementioned review, suggesting that these gender 
stereotypes endure into adulthood.
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etHics in science: wHo gets a voice, wHo gets a sHot? 
This last section of this thesis discussion will end with questions and not answers. These 
particular questions have been brought to my attention at various points during my 
doctoral work and continue to perplex me. I have pondered possible answers throughout 
the years though satisfactory answers have yet eluded me. 
1. Who gets a voice? This question is a focal point within qualitative research and 
in medical research. Nursing science in particular frequently asks this question 
and attempts to give voices to the often voiceless (i.e. patients, their families or 
non-medical caregivers). Studies that examine multiple stakeholders’ perspectives 
attempt to make multiple voices heard. Which leads to yet another question in 
medical research: if multiple voices are heard, who is listening? Are certain voices 
still so faint as to be overpowered in discussions? Are certain voices selectively 
tuned-out, and if so, why? 
Through qualitative investigations I was able to ask women and men in STI risk 
situations how they protected themselves and how they felt about HPV-vaccines. 
These individuals are some of the voices of HPV risk and prevention but there are 
many others affected in some way by HPV-vaccinations left unheard.   
2. What voice do people get? Articles using questionnaire-based research often 
report on questionnaire validation studies in order to qualify the choice in 
questionnaire. People will answer questions if asked, but whether or not those 
questions are salient is another matter. I worked with randomized clinical trials for 
surgical techniques, where patient post-operative recovery was imperative to track 
and I was frequently disappointed with how little of what patients experienced 
in their recovery process was actually assessed using standard questionnaires. 
Even in this thesis work based on questionnaire data from Attitudes toward HPV-
vaccination wonders which attitudes experienced by respondents toward HPV-
vaccination were even presented to answer in the questionnaire. 
Could some of the decreasing trends in response rates seen in questionnaire 
studies reflect people’s impatience with inappropriate survey questions – 
inappropriate for their specific circumstances138?   
3. Who gets a shot? Of all the questions listed here, this one makes me most 
uncomfortable. I wonder who will be held accountable by future generations for 
the death of millions when it becomes apparent that vaccinations were available 
but that they never reached many of the people who needed them most. GAVI 
initiatives are to be credited with attempting to prevent disease and mortality 
by funding vaccinations in very low-resource settings139. The development, 
testing and distribution of new vaccinations and treatments all require copious 
financial resources. Will disease prevention measures and treatments ever be more 
equitably distributed? Will treatments with low potential return on investments 
even make it to the development phase140? 
81
A frequently asked question regarding who gets an HPV-shot is ‘what about 
men’? This came up time and time again in my internet-based discussions with 
women and comes up frequently at conferences and in public health debates. 
Will men carry any of the responsibility for HPV prevention? Will men be able 
to capitalize on any of the benefit of HPV-vaccinations outside of what will 
eventually come to them via herd immunity? What about MSM who are at high-
risk for HPV-related anal cancers? 
4. Who is left out, who gets let in? In the preface I mentioned one limitation with 
RCTs: their inclusion and exclusion criteria may not reflect the real-life situations 
in which treatments or vaccinations are used. Also, their follow-up length is 
limited by financial constraints, eliciting the question, ‘which outcomes are even 
possible to assess’? Rarer outcomes or adverse advents that take years to develop 
will not be possible to assess. Of all the questions here, this is the only one where 
I have found the start of an answer which provides some satisfaction: 
Nordic population-based registers should be used for continued investigations 
into possible long-term effects of treatments – not to instill fear with possible 
risk factors but to do what trials cannot do: investigate long-term follow-up in 
a more comprehensive population. Effectiveness and safety studies based on 
observational research provide necessary compliments to RCTs. 
5. If there is a voice, will there be a microphone?  Second to the ‘who gets a shot’ 
question, this one also makes me very uneasy. Publication bias is known and 
discussed in scientific literature 141, 142. The peer-review system for publication 
is not fool-proof. How often do important negative or contradictory results get 
silenced?  What will the scientific community do to give fiscally detrimental or 
unpopular science a voice? 
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concLusions 
Study I revealed that condom use with temporary partners was not associated with STI 
risk perception for men whereas it was for women, despite a higher percentage of men 
reporting consistently having used condoms with temporary partners. Correlates to STI 
risk perception differ substantially between men and women. Awareness and severity 
perceptions of HPV and HPV-related cancer were not associated with either condom 
use or risk perception, whereas education level was positively associated with condom 
use. Women who were youngest at sexual debut also had two-fold increased odds of 
reporting non-condom use with temporary partners compared to women with later sexual 
debuts. Also, women with immigrant mothers were almost twice as likely to report using 
condoms consistently with temporary partners compared to women with Swedish-born 
mothers. Number of reported temporary partners was the only common factor associated 
for both men and women with condom use and STI risk perception.
Preliminary results based on analysis of data generated by internet-based discussions with 
women aged 21-34 years old in Sweden indicate that in situations where women perceive 
potential for a love relationship, they describe behaving in ways that expose them to 
substantial risk for STI contraction. The gender roles described subvert these women’s 
own desires and health promotion and thereby act to hinder women’s potential condom 
advocacy. Managing HPV infection risk via behavioral changes was described as virtually 
impossible. However, these preliminary results suggest that previous diagnosis with a 
viral STI may function as a protective factor by reducing subsequent sexual risk taking 
and increasing health-promoting behaviors.
 
Study II showed that the incidence of GW peaked at a younger age for females and that 
males accounted for a higher overall proportion of episodes. Podophyllotoxin was the 
most common first-line treatment for new GW episodes for both sexes, while imiquimod 
was prescribed to females more often than to males. The incidence of GW peaked at a 
younger age for females and males accounted for a higher overall proportion of episodes. 
There was a downward trend of GW incidence among younger females between 2006 
and 2010. Among females aged 17–18 years, the GW incidence decreased by more than 
25% post HPV-vaccine availability. Such declines were not observed among females 
over age 25 or under age 16 or among males overall. The burden of GW in Sweden is 
high, and this study indicates that GW is the second-most-common STI in Sweden after 
chlamydial infections. This study provides a reasonable estimation of the incidence of 
GW in the Swedish population by use of register data, with results comparable to those 
from previous smaller studies. 
Study III is the first vaccine effectiveness study of an entire population and showed that 
qHPV vaccination had high protection against disease among women fully vaccinated 
under the age of 20, with particularly high effectiveness for girls below 14 years of age. 
By including more than 2.2 million women ranging from ages 10-44, nuanced effects 
84
of age-at-vaccination could be discerned for the first time in this study. Effectiveness 
declined as age-at-first-vaccination increased. For women above age 22, there is 
suggestive evidence that vaccinations tended to reach women already exposed to HPV 
and there was no measurable effectiveness in these age groups. There is also evidence of 
inequity in vaccine use, with individuals from families with higher socioeconomic status 
being 15 times more likely to receive vaccines compared to individuals from families 
with lower socioeconomic status. It is important to consider that just because this study 
did not find qHPV-vaccine effective in women vaccinated over age 22, does not mean it is 
ineffective in all women vaccinated over the age of 22. Also, the outcome in this study is 
GW, not cervical dysplasia, which is the primary indication for vaccinations.
Study IV revealed maximum protection against GW with three doses, and two-doses is 
less effective than three doses. No differences in effectiveness were found for girls who 
received two-doses between ages 10-16 with that of individuals who received three-doses 
between ages 17-19. This study does not account for HPV-disease outcomes other than 
GW in measures of dose effectiveness. What is measured is a proxy for GW in terms of 
treatment-seeking behavior, which in itself is a proxy for HPV infection. More studies 
with longer follow-up are needed to assess other HPV-related disease outcomes such as 
CIN.
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imPLicAtions for PrActice
Focusing HPV-vaccination efforts on vaccinating girls under age 14 will provide 
maximum protection. Vaccinating women over 20 will not lead to substantial reductions 
in GW disease burdens. The results from the dose Study IV should contribute to the 
HPV vaccine dose discussions but should by no means be solely decisive in regards to 
effectiveness of less than three qHPV-vaccine doses. Following a three-dose schedule for 
qHPV provides maximum protection against GW. 
Opportunistic or on-demand vaccination programs exacerbate social disparities in 
negative health outcomes.  Social inequities emerge with on-demand vaccination 
programs, to an extent not anticipated with school-based programs.
With the harmful and sometimes deadly health effects of STIs, proper condom use as a 
primary prevention measure should remain a top priority for health officials. This thesis 
concludes, however, that campaigns with a primary aim to increase STI knowledge and 
awareness with the intention of influencing risk perceptions among those sexually active 
may not effectively translate into an increase in prevention behaviors. To
reach the public health goal of reducing STI prevalence, barriers to engaging in STI 
prevention need to be addressed. Discourse on detrimental effects of gender-stereotypical 
behavior should be integrated into sex education curriculums.
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sAmmAnfAttning På svenskA
Syfte: Att ge en flerdimensionell bedömning av infektionsrisker och utvärdera strategier 
för HPV-prevention inklusive opportunistisk vaccination med tetravalent HPV-vaccin, 
effektivitet på dos-nivå och kondomanvändning när det finns hög risk för att överföra en 
könssjukdom.  
Metoder: Flera populationsbaserade register och enkätsvar används som underlag 
för denna avhandling. Kvinnor som besvarade enkät och som uppgav något mått av 
riskbeteende i förhållande till könssjukdomar intervjuades vid senare tillfälle via internet-
baserad diskussion.
Resultat: Tetravalent HPV-vaccination var mycket effektiv mot kondylom, den första 
HPV-relaterade sjukdomen efter HPV-exponering som är möjligt att mäta. Effektiviteten 
var dock knuten till ung ålder vid första vaccination, med en stadig minskning av 
effektivitet ju äldre åldern var vid första vaccinationen. Bland kvinnor som var över 20 år 
vid den första vaccinationen hittades det låg till omätlig effektivitet och indikationer på 
att vaccinationer i denna åldersgrupp tenderade att nå kvinnor som redan exponerats för 
HPV-typer associerade med kondylom. Stora socioekonomiska skillnader hittades i vem 
som vaccinerades i det opportunistiska programmet, med 15 gånger större sannolikhet 
att vaccineras hos kvinnor och flickor som har föräldrar med högsta utbildningsnivå 
jämfört med den lägsta (Studie III). Maximalt skydd mot kondylom hittades bland flickor 
som vaccinerades under 17 år som hade fått tre doser av vaccinet. Inga skillnader i 
effektivitet hittades mellan flickor som fick två doser mellan åldrarna 10-16 och de som 
fick tre doser mellan åldrarna 17-19 (Studie IV). Kondylom drabbar fler män än kvinnor 
i Sverige med 453 fall per 100 000 män och 365 fall per 100 000 kvinnor under 2010. 
En nedgång mellan 25-30% sågs mellan 2006 och 2010 bland kvinnor i åldersgrupperna 
med den högsta vaccinationstäckningen. Ingen nedgång hittades bland män och deras 
kondylomincidens har stadigt ökat mellan 2006 och 2010 (Studie II). Redovisad 
kondomanvändning i högrisksituationer var låg bland både män och kvinnor, där 41% av 
männen och 34% av kvinnorna rapporterar att de alltid / nästan alltid använder kondom 
med tillfälliga partners. Infektionsriskuppfattningen var också låg, där cirka 10% av alla 
sexuellt aktiva respondenter anser sig ha stor risk att smittas av en könssjukdom. Det 
fanns inget samband mellan mäns kondomanvändning och deras STI-riskuppfattning men 
det fanns ett samband för kvinnor (Studie I).Kvinnor diskuterade att förhindra överföring 
av sexuellt överförbara sjukdomar genom val av sexpartner, selektiv kondomanvändning 
och regelbunden könssjukdomstestning. Kvinnor beskriver dock att männen får ansvara 
för att ha kondomer vid första samlaget för att inte äventyra möjligheterna till en 
långsiktig relation. De säger att en kvinnas kondomberedskap visar att de planerat att ha 
samlag och visar en nivå av sexuell upplevelse som kvinnor inte känner sig bekväma med 
att uttrycka till en ny partner. Kvinnor tyckte att sambandet mellan sex och cancer var 
svårt att föreställa sig. På grund av HPVs hud-mot-hud-överföring, uttalade kvinnorna att 
förebyggande av HPV-spridning genom sexuellta beteendeförändringar verkade omöjligt 
och utanför deras kontroll (preliminära resultat). 
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Slutsatser: Resultaten tyder på att män har en betydande incidens av HPV-relaterad 
kondylom och att incidensen har sjunkit bland kvinnor. Vid planeringen av HPV-
vaccination bland kvinnor, bör insatserna inriktas mot flickor under 14 års ålder för 
maximal effektivitet. Tetravalent HPV-vaccination ger mest skydd mot kondylom vid 
tre doser. Stora sociala skillnader hittades i den opportunistiska HPV-vaccinationen. 
Integrering av könsspecifika förebyggande strategier i kursplaner för sexualundervisning, 
inklusive diskurs om skadliga effekter av könsstereotypiska beteenden för att kunna öka 
kondomanvändning i höga risksituationer.
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Appendix mAteriAl
Questionnaire for men and women in Swedish and English 
1
THE STUDY OF HPV VACCINE’S ACCEPTABILITY IN SWEDEN 
QUESTIONNAIRE FOR MALE ADULT AGED 18-30 YEAR OLDS  
001  QUESTIONNAIRE IDENTIFICATION NUMBER   [_A_|_M_|___|___|___|___] 
002  DATE OF FILLING IN QUESTIONNAIRE (mm/dd/yyyy):  ____/ ____ / 2006 
Section 1: Background characteristics 
No. Questions and filters Coding categories Skip to 
Q101 What is your age? Age:    [__|__] 
Q102 From what country were you born? Sweden     1 
Iceland, Denmark, Finland or Norway     2 
Outside the Nordic countries     3 
Q103 What is your current marital status? Use Swedish version as in CCS study, add 
registered partner to Married
Q104 Are you currently in a relationship? Yes     1 
No     2
Q105 Which is your current state of 
employment? 
(Please select only one choice) 
Full-time employed     1 
Part-time employed     2 
Un-employed     3 
Retired     4 
Parental leave     5 
Student     6 
Other     7 
Please specify: ……………………………
……………………………
Q106 What is your annual income level? 
(Please select only one choice) 
Include arbetslöshetsunderstöd, 
sjukpension, etc. Do not include 
studielån och studiebidrag 
Less than 50000 kronor/year     1 
50000 – 100000 kronor/year     2 
100000 – 150000 kronor/year     3 
150000 – 200000 kronor/year     4 
200000 – 250000 kronor/year     5 
250000 – 300000 kronor/year     6 
300000 – 400000 kronor/year     7 
400000 – 500000 kronor/year     8 
More than 500000 kronor/year     9 
Q107 What is the highest level of school 
you completed? 
(Please select only one choice) 
Use Swedish version as in CCS study 
If not going to school then skip to next 
section
 2 
 
Q108 
 
How many total years of education 
have you completed up to now? 
 
 
# Years completed  [__|__] 
                                           
 
 
Section 2 Now we would like to ask you some questions about your sexual habits. Your answers are very 
important in helping us understand how certain diseases can be prevented. All answers will be kept 
confidential, so please answer each question honestly and accurately. 
 
No. Questions and filters Coding categories Skip to 
 
Q201 
 
Who have you ever had sex (of any 
type) with? 
(Several choices can be given) 
 
A man     1 
A woman     2 
Never had sex     3 
 
 
 
Q301 
 
Q202 
 
Did you ever have vaginal sex? 
Yes     1 
No     2 
Don’t know 998 
 
Q301 
Q301 
 
Q203 
 
If you have ever had vaginal sex, 
how old were you at your first 
experience? 
 
Years of age     [__|__] 
 
Don’t know     998 
 
 
Q204 
 
Have you ever had other types of sex 
than vaginal sex? 
 
(Several choices can be given) 
 
Oral sex     1 
Anal sex     2 
Other type of sex    3 
Only vaginal sex     4 
Don’t want to reply 999 
 
 
 
 
Q206 
 
Q205 
 
What age were you when you had 
any of the above mentioned types of 
sex for the first time? 
 
Years of age     [__|__] 
 
Don’t know     998 
 
 
Q206 
 
How many sexual partners did you 
have in the last year? 
 
(If none, please write 0) 
 
Sexual partners include steady 
partners (wife/girlfriends/registered 
partner) and one-night stands 
 
Number of sex partners [__|__|__]  
 
 
 
 
Q207 
 
Among them, how many were one-
night stand? 
 
(If none, please write 0) 
 
Number of one-night stands [__|__|__] 
 
 
Q208 
 
Have you ever used condoms? 
 
Yes     1 
No     2 
Don’t know     998 
 
 
Q211 
 3 
 
    
 
Q209 
 
With regards to sex with your steady 
partners, with what frequency did 
you and your steady partner(s) use 
condoms over the last year? 
 
(If you did not have a steady partner, 
please circle number 9) 
 
Every time (100% of the time)     1  
Almost every time (75-99%)     2  
Often (50-74%)     3 
Sometimes (25-49%)     4 
Rarely (1-24%)     5 
Never (0%)     6 
No steady partner over last year     7 
Don’t know     998 
 
 
Q210 
 
With regards to sex with your one-
night stands, with what frequency did 
you and your one-night stands use 
condoms over the last year? 
 
(If you did not have one-night stand 
partner, please circle number 9) 
 
Every time (100% of the time)     1  
Almost every time (75-99%)     2  
Often (50-74%)     3 
Sometimes (25-49%)     4 
Rarely (1-24%)     5 
Never (0%)     6 
No one-night stand over last year     7 
Don’t know     998 
 
 
Q211 
 
Compared to other women of your 
age, do you consider your-self as 
having had more, fewer, or about the 
same number of sex partners? 
 
More     1 
Fewer     2 
About the same     3 
Don’t know     998 
 
 
Q212 
 
What level of risk of sexually 
transmitted infections do you think 
you are having? 
 
Not at risk     1 
Low risk     2 
Medium risk     3 
High risk     4 
Don't know     998 
 
 
 
 
 
Section 3 Now we would like to ask you some questions about certain health conditions. There is no 
right or wrong, good or bad answers. Please truly tell us what you know or think. 
 
 
No. Questions and filters Coding categories Skip to 
 
Q301 
 
Before you participated in this study, 
have you ever heard about cancers of 
the cervix (cervical cancer)? 
 
Yes     1 
No     2 
 
 
Q303 
 
Q302 
 
Do you believe that cervical cancer is 
a common cancer among women? 
 
Very common     1 
Rather common     2 
Not so common     3 
Very uncommon     4 
Don't know     998 
 
 
 
 4 
 
 
 
No. Questions and filters Coding categories Skip to 
 
Q303 
 
Have you ever heard about any 
possible cause(s) of cervical cancer? 
 
Yes     1 
No     2 
 
 
 
 
Q304 
 
Have you ever heard of Condyloma, 
also called Genital Warts? 
 
Yes     1 
No     2 
 
 
Q307 
 
Q305 
 
Do you believe that Condyloma is a 
serious disease? 
 
Very serious     1 
Rather serious     2 
Not so serious     3 
Not serious at all     4 
Don't know     998 
 
 
Q306 
 
Have you ever heard about any 
possible cause(s) of Condyloma? 
 
Yes     1 
No     2 
 
 
Q307 
 
Before you participated in this study, 
have you heard about a virus called 
Human Papillomavirus (HPV)? 
 
Yes     1 
No     2 
 
 
Q401 
 
 
Q308 
 
Do you believe that HPV may cause 
cervical cancer? 
 
Yes     1 
No     2 
Don't know     998 
 
 
Q309 
 
Do you believe that HPV may cause 
other types of cancer than cervical 
cancer? 
 
Yes     1 
No     2 
Don't know     998 
 
 
Q310 
 
Do you believe that HPV may cause 
Condyloma? 
 
Yes     1 
No     2 
Don't know     998 
 
 
Q311 
 
Do you believe that HPV is sexually 
transmitted? 
 
Yes     1 
No     2 
Don't know     998 
 
 
Q312 
 
Do you believe that women can be 
infected by HPV? 
 
Yes     1 
No     2 
Don't know     998 
 
 
Q313 
 
Do you believe that men can be 
infected by HPV? 
 
Yes     1 
No     2 
Don't know     998 
 
 
Q314 
 
Are you aware if there is a vaccine 
against HPV caused disease? 
 
 
A vaccine is available     1  
A vaccine is being tested     2 
There is no such vaccine     3 
 
 5 
SELECT ONE Don’t know     998 
 
 
 
Section 4 In this section, we will ask for your general opinions about vaccination. Again, there is no 
right or wrong answer. Please let us know what you think. 
 
No. Questions and filters Coding categories Skip to 
 
Q401 
 
In general, do you believe that 
vaccination is an effective way 
against diseases?  
 
(Please circle one choice only) 
 
Very effective     1 
Rather effective     2 
Not so effective     3 
Not effective at all     4 
Don’t know     998 
 
 
Q402 
 
Do you think that vaccination is a 
cost-efficient way against diseases? 
 
Very cost-efficient     1 
Rather cost-efficient     2 
Not so cost-efficient     3 
Not cost-efficient at all     4 
Don’t know     998 
 
 
Q403 
 
In your opinion, is vaccination 
generally a safe way against disease? 
 
Very safe     1 
Rather safe     2 
Not so safe     3 
Not safe at all     4 
Don’t know     998 
 
 
Q404 
 
If there is a vaccine that is coming out 
that concern you, how would you like 
to know about it?  
 
(Several choices may be given) 
 
Via health workers     1 
Educational programs on TV, radios     2 
Health education at work/school     3 
Booklet, brochure, leaflet     4 
Authorized websites     5 
Others     6 
…………………………………………. 
Don’t know     998 
 
 
Q405 
 
Which of the above ways would be 
the best way you want to know about 
a new vaccine?  
 
(Please select only one choice) 
 
Via health workers     1 
Educational programs on TV, radios     2 
Health education at work/school     3 
Booklet, brochure, leaflet     4 
Authorized websites     5 
Others     6 
…………………………………………. 
Don’t know     998 
 
 
 
Section 5  
 
For your information, an effective three-dose vaccine against HPV has been developed and will soon be 
ready for use. Please do not go back and “correct” any answer given previously. We would like to ask 
for your opinion about the usage of this new HPV vaccine. 
 
 6 
No. Questions and filters Coding categories Skip to 
 
Q501 
 
If the vaccine is free, would you be 
willing to vaccinate yourself? 
 
Yes     1 
No     2 
Don’t know     998 
 
 
Q505 
 
Q502 
 
What if the vaccine is only given at 
some extra cost, would you still be 
willing to vaccinate yourself? 
 
Yes     1 
No     2 
Don’t know     998 
 
 
Q504 
Q504 
 
Q503 
 
What is the maximum cost that you 
think you can afford? (Three doses 
are considered to give full protection) 
 
(If you will vaccinate yourself at all 
cost, please circle number 9) 
 
Price per dose (in SEK)     
………………………… 
 
Vaccination at any cost     2 
 
 
 
 
Q504 
 
At what age would you consider 
vaccinate yourself? 
 
(Please circle number 9 if you don’t 
consider vaccinating yourself at any 
age) 
 
Age to start HPV vaccination [__|__] 
 
I don’t consider HPV vaccination     9 
 
 
Q505 
 
You may have concerns about the 
new vaccine. If so, please mark what 
you would like to know more about 
this new HPV vaccine? 
 
(You can select more than one choice 
if necessary) 
 
If the vaccine is really protective     1 
If there are any side effects (safety)     2 
If vaccine needs to be repeated with more 
doses in the future     3 
Others     4 
Please specify:_____________ 
_________________________________ 
I have no concerns     5 
Don’t know     998 
 
 
 
 
 
 
 
 
Q507 
 
Q506 
 
If it may, what of those concerns 
could MOST likely make you NOT 
vaccinate yourself against HPV? 
 
(Please circle only ONE choice) 
 
If the vaccine is really protective     1 
If there are any side effects (safety)     2 
If vaccine needs to be repeated with more 
doses in the future     3 
Others     4 
Please specify:_____________ 
_________________________________ 
I would get vaccinated despite concerns     
5 
Don’t know     998  
 
 
Q507 
 
If you are vaccinated, do you think 
that you would be fully protected 
against condyloma? 
 
Yes     1 
No     2 
Don’t know     9 
 
 
Q508 
 
would you consider having more 
unprotected sex (=not using a 
 
Yes     1 
No     2 
 
 7 
condom) if you get vaccinated? Don’t know     9 
 
 
 
End of the questionnaire 
Thank you very much for taking time to answer these questions. We highly appreciate your help! 
F101	 Hur	gammal	är	du?	
F102	 I	vilket	land	är	du	född?
	 1.	 	 Sverige	 2.	 	 Danmark,	Finland,	Island	eller	Norge	 3.	 	 Annat	land
F103	 Vilket	är	ditt	nuvarande	civilstånd?
	 1.	 	Gift/sambo/registrerad	partner	-	Gå	till	F105	 3.	 	 Änkeman
	 2.	 	 Ensamstående		 	 	 	 999.	 	 Vill	ej	svara
F104	 Har	du	för närvarande	ett	förhållande?
	 1.	 	 Ja	 2.	 	 Nej
F105	 Vilken	är	din	huvudsakliga	sysselsättning?		Välj endast ett alternativ
	 1.	 	 Heltidsarbetande	 3.	 	 Arbetslös	 5.	 	 Föräldraledighet
	 2.	 	 Deltidsarbetande	 4.	 	 Sjukpensionär	 6.	 	 Studerande	
	 7.	 		Annat	(ange	vad)	 	..................................................................................................................................
F106	 Vilken	är	din	årliga	inkomst	före	skatt?	Inkludera	arbetslöshetsunderstöd,	sjukpension,	etc.		
	 	 Inkludera	inte	studielån	och	studiebidrag		Välj endast ett alternativ
	 1.	 	Mindre	än	50	000	kr/år	 4.	 	 150	000–200	000	kr/år	 7.	 	 300	000–400	000	kr/år
	 2.	 	 50	000–100	000	kr/år	 5.	 	 200	000–250	000	kr/år	 8.	 	 400	000–500	000	kr/år
	 3.	 	 100	000–150	000	kr/år	 6.	 	 250	000–300	000	kr/år	 9.	 	Mer	än	500	000	kr/år
	 	 	 	 	 	 	 998.	 	 Vet	ej
F107	 Vilken	är	din	högsta	avslutade	utbildning?		Välj endast ett alternativ
	 1.	 	Grundskola	år	1–9	 5.	 	 Folkhögskola
	 2.	 	Yrkesskola	 6.	 	Högskola/universitet	upp	till	2	år
	 3.	 	Gymnasium	 7.	 	 Högskola/universitet	mer	än	2	år
	 4.	 	Vuxenutbildning	
	 	 	 	 8.	 	Annat	 	........................................................................................
F108	 Hur	många	år	har	du	sammanlagt	studerat	fram	till	idag?	
	 	 Antal	(hela)	studieår	 	 998.	 	 Vet	ej
	
UNDERSÖKNING OM INSTÄLLNINGEN TILL ETT NYTT VACCIN
FRÅGEFORMULÄR FÖR MÄN MELLAN 18 OCH 30 ÅR
Fyll i de förtryckta fälten eller kryssa in det alternativ som du anser passar bäst
Del 1. Bakgrund
	 	 		
Nr	 Frågor	 	
F201	 Med	vilka	av	följande	har	du	någon	gång	haft	någon	typ	av	sexuellt	umgänge?		Flera alternativ kan anges
	 1.	 	Man	 2.	 	 Kvinna	 3.	 	 Har	aldrig	haft	sexuellt	umgänge	-		
	 	 	 	 	 	 	 	 	 Gå	till	F301
F202	 Har	du	haft	vaginalt	samlag	någon	gång?
	 1.	 	 Ja	 2.	 	 Nej	-	Gå	till	F204	 998.	 	 Vet	ej	-	Gå	till	F204
F203	 Om	ja	på	ovanstående	fråga,	hur	gammal	var	du	första	gången	du	hade	vaginalt	samlag?
	 	 Ålder	 	 998.	 	 Vet	ej
F204	 Har	du	någonsin	haft	annan	typ	av	sexuellt	umgänge	än	vaginalt	samlag?		Flera alternativ kan anges 
	 	 	 	 	 	 	
	 1.	 	Oralsex	 3.	 	 Annan	typ	av	sex	
	 2.	 	 Analsex	 4.	 	 Endast	vaginalt	samlag	-	Gå	till	F206
	 	 	 	 999.	 	 Vill	ej	svara
F205	 Hur	gammal	var	du	när	du	hade	någon	av	ovan	nämnda	typer	av	sex	första	gången?
	 	 Ålder	 	 998.	 	 Vet	ej
F206	 Hur	många	sexpartners	har	du	haft	det	senaste	året?	Räkna	med	fasta	partners	och	tillfälliga		
	 	 förbindelser.	(Om ingen, ange 0)
	 	 Antal	sexpartners	 	 998.	 	 Vet	ej
F207	 Hur	många	av	dina	sexpartners	det	senaste	året	var	tillfälliga	förbindelser? (Om ingen, ange 0)
	 	 Antal	tillfälliga	förbindelser	 	 998.	 	 Vet	ej
F208	 Har	du	någonsin	använt	kondom?
	 1.	 	 Ja	 2.	 	 Nej	-	Gå	till	F212	 998.	 	 Vet	ej
Fyll i de förtryckta fälten eller kryssa in det alternativ som du anser passar bäst
Del 2.  Nu följer några frågor om sexualvanor. Dina svar kan hjälpa oss att förstå hur vissa  
 sjukdomar kan förhindras. Vi ber dig besvara frågorna så noggrannt som möjligt. 
	 	 		
Nr	 Frågor	 	
F209	 När	du	hade	sex	med	din(a)	fast(a)	partner(s),	hur	ofta	använde	ni	kondom	under	det	senaste	året?	
	 	 (Välj	nummer	7	om	du	inte	hade	någon	fast	partner	det	senaste	året?)
	 1.	 	 Varje	gång	(100%	av	tillfällena)	 	 5.	 	 Sällan	(1-24%)
	 2.	 	 Nästan	varje	gång	(75-99%)	 	 	 	 6.	 	 Aldrig	(0%)
	 3.	 	Ofta	(50-74%)	 	 	 	 7.	 	 Har	inte	haft	någon	fast	partner	senaste	året	
	 4.	 	 Ibland	(25-49%)	 	 	 	 998.	 	 Vet	ej
F210	 När	du	hade	sex	med	din(a)	tillfällig(a)	partner(s),	hur	ofta	använde	ni	kondom	under	det	senaste	året?	
	 	 (Kryssa	nummer	7	om	du	inte	hade	någon	tillfällig	partner	det	senaste	året?)
	 1.	 	 Varje	gång	(100%	av	tillfällena)	 	 5.	 	 Sällan	(1-24%)
	 2.	 	 Nästan	varje	gång	(75-99%)	 	 	 	 6.	 	 Aldrig	(0%)
	 3.	 	Ofta	(50-74%)	 	 	 	 7.	 	 Har	inte	haft	någon	tillfällig	partner	senaste	året
	 4.	 	 Ibland	(25-49%)	 	 	 	 998.	 	 Vet	ej
	F211	 Jämfört	med	andra	män	i	din	ålder,	tror	du	att	du	har	haft	fler,	färre	eller	ungefär	lika		
	 	 många	sexpartners	(totalt	sett)?
	 1.	 	 Fler	 3.	 	 Ungefär	lika	många
	 2.	 	 Färre		 998.	 	 Vet	ej
F212	 Hur	stor	risk	att	råka	ut	för	sexuellt	överförbara	sjukdomar	tror	du	att	du	har?
	 1.	 	 Ingen	risk	 3.	 	Ganska	stor	risk
	 2.	 	 Liten	risk	 4.	 	 Stor	risk	 998.	 	 Vet	ej
Fyll i de förtryckta fälten eller kryssa in det alternativ som du anser passar bäst
	 	 		
Nr	 Frågor	 	
Fyll i de förtryckta fälten eller kryssa in det alternativ som du anser passar bäst
Del 3. Nu följer några frågor om hälsoförhållanden. Det finns inga riktiga eller felaktiga svar.  
 Vi ber dig svara uppriktigt vad du vet eller tror.	
	 	 		
Nr	 Frågor	 	
F301	 Hade	du	hört	talas	om	livmoderhalscancer	innan	du	deltog	i	denna	studie?
	 1.	 	 Ja	 2.	 	 Nej	-	Gå	till	F304
F302	 Tror	du	att	livmoderhalscancer	är	en	vanlig	cancerform	bland	kvinnor?
	 1.	 	Mycket	vanlig	 3.	 	 Inte	så	vanlig
	 2.	 	Ganska	vanlig	 4.	 	Mycket	ovanlig	 998.	 	 Vet	ej
F303	 Känner	du	till	möjliga	orsaker	till	livmoderhalscancer?
	 1.	 	 Ja	 2.	 	 Nej
F304	 Har	du	någonsin	hört	talas	om	kondylom,	även	kallade	könsvårtor?
	 1.	 	 Ja	 2.	 	 Nej	-	Gå	till	F307
F305	 Hur	allvarligt	är	kondylom	enligt	din	uppfattning?	
	 1.	 	Mycket	allvarligt	 3.	 	 Inte	så	allvarligt
	 2.	 	Ganska	allvarligt	 4.	 	 Inte	alls	allvarligt	 998.	 	 Vet	ej
F306	 Känner	du	till	möjliga	orsaker	till	kondylom?
	 1.	 	 Ja	 2.	 	 Nej
F307	 Hade	du	hört	talas	om	ett	virus	kallat	humant	papillomvirus	(HPV)	innan	du	deltog	i	denna	studie?
	 1.	 	 Ja	 2.	 	 Nej	-	Gå	till	F401
F308	 Tror	du	att	HPV	kan	orsaka	livmoderhalscancer?
	 1.	 	 Ja	 2.	 	 Nej	 998.	 	 Vet	ej
F309	 Tror	du	att	HPV	kan	orsaka	annan	cancer	än	livmoderhalscancer?
	 1.	 	 Ja	 2.	 	 Nej	 998.	 	 Vet	ej
F310	 Tror	du	att	HPV	kan	orsaka	kondylom?
	 1.	 	 Ja	 2.	 	 Nej	 998.	 	 Vet	ej
F311	 Tror	du	att	HPV	kan	smitta	genom	sexuellt	umgänge?
	 1.	 	 Ja	 2.	 	 Nej	 998.	 	 Vet	ej
F312	 Tror	du	att	kvinnor	kan	smittas	av	HPV?
	 1.	 	 Ja	 2.	 	 Nej	 998.	 	 Vet	ej
F313	 Tror	du	att	män	kan	smittas	av	HPV?
	 1.	 	 Ja	 2.	 	 Nej	 998.	 	 Vet	ej
F314	 Känner	du	till	om	det	finns	något	vaccin	mot	sjukdom	orsakad	av	HPV?		Välj endast ett alternativ
	 1.	 	 Ett	vaccin	finns	tillgängligt	 3.	 	 Det	finns	inget	vaccin	mot	HPV
	 2.	 	 Ett	vaccin	testas	för	närvarande	 998.	 	 Vet	ej	
Fyll i de förtryckta fälten eller kryssa in det alternativ som du anser passar bäst
Del 4. Nu följer några frågor om din inställning till vaccination.  
 Återigen finns det inga rätta eller felaktiga svar. Ange bara din åsikt.	
	 	 		
Nr	 Frågor	 	
F401	 Tror	du	att	vaccination	kan	vara	ett	effektivt	sätt	att	förebygga	sjukdomar?		Välj endast ett alternativ
	 1.	 	Mycket	effektivt	 3.	 	 Inte	så	effektivt
	 2.	 	Ganska	effektivt	 4.	 	 Inte	alls	effektivt	 998.	 	 Vet	ej
F402	 Tror	du	att	vaccination	kan	vara	ett	kostnadseffektivt	sätt	att	förebygga	sjukdomar?		Välj endast  
  ett alternativ
	 1.	 	Mycket	kostnadseffektivt	 3.	 	 Inte	så	kostnadseffektivt
	 2.	 	Ganska	kostnadseffektivt	 4.	 	 Inte	alls	kostnadseffektivt	998.	 	 Vet	ej
F403	 Tror	du	att	vaccination	är	en	säker	metod	att	förebygga	sjukdomar?		Välj endast ett alternativ
	 1.	 	Mycket	säker	 3.	 	 Inte	så	säker
	 2.	 	Ganska	säker	 4.	 	 Inte	alls	säker	 998.	 	 Vet	ej
F404	 Om	det	lanseras	ett	vaccin	som	du	skulle	kunna	ha	nytta	av,	hur	skulle	du	helst	vilja	få	reda		
	 	 på	det?		Flera alternativ kan anges
	 1.	 	 Via	sjukvårdspersonal	 	 5.	 	 Via	Internet
	 2.	 	 Utbildningsprogram	på	TV	eller	radio	 6.	 	 Annat	sätt	(Ange	vad)	 	.............................................
	 3.	 	 Hälsoundervisning	på	arbete/skola	 	 	 	
	 4.	 	 Informationsfolder,	broschyr,	häfte	 	 	 	..................................................................................
	 	 	 	 	 	 	 998.	 	 Vet	ej	-	Gå	till	F501
F405	 Vilket	av	ovanstående	sätt	skulle	vara	det	bästa	för	dig	att	få	information	om	ett	nytt	vaccin?		
	 	 Välj endast ett alternativ
	 1.	 	 Via	sjukvårdspersonal	 	 5.	 	 Via	Internet
	 2.	 	 Utbildningsprogram	på	TV	eller	radio	 6.	 	 Annat	sätt	(Ange	vad)	 	.............................................
	 3.	 	 Hälsoundervisning	på	arbete/skola	 	 	 	
	 4.	 	 Informationsfolder,	broschyr,	häfte	 	 	 	..................................................................................
	 	 	 	 	 	 	 998.	 	 Vet	ej
Fyll i de förtryckta fälten eller kryssa in det alternativ som du anser passar bäst
Del 5. Vi vill informera dig om att HPV är ett sexuellt överförbart virus som kan orsaka kondylom hos  
 män och kvinnor och livmoderhalscancer hos kvinnor. Ett effektivt HPV-vaccin har utvecklats  
 och är klart för användning. Vi ber dig att inte gå tillbaka och ändra något  
 av de tidigare avgivna svaren.  
 Nu  vill vi fråga om din åsikt angående användning av det nya HPV-vaccinet.
 
	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 		
Nr	 Frågor	 	 	 	 	 	 	 	 	 	 	 	 	 	
F501	 Skulle	du	vilja	vaccinera	dig	mot	HPV	om	vaccinet	är	gratis?
	 1.	 	 Ja	 2.	 	 Nej	-	Gå	till	F505	 998.	 	 Vet	ej
F502	 Skulle	du	vilja	vaccinera	dig	mot	HPV	om	vaccinet	kostar	pengar?
	 1.	 	 Ja	 2.	 	 Nej	-	Gå	till	F504	 998.	 	 Vet	ej	-	Gå	till	F504
F503	 Vilken	är	den	högsta	kostnad	du	kan	tänka	dig	att	betala	för	att	vaccinera	dig	mot	HPV?		
	 	 (Tre	doser	anses	ge	ett	fullgott	skydd).
	 Pris	för	vaccination	per	dos	(i	kr)	 ..............................	 2.	 	 Vaccination	oavsett	kostnad
F504	 Vid	vilken	ålder	anser	du	att	man	ska	vaccinera	mot	HPV?
	 Ålder	för	att	påbörja	HPV-vaccination	 	 	 9.	 	 Jag	överväger	inte	HPV-vaccination
F505	 Vilken	information	skulle	du	vilja	ha	om	det	nya	vaccinet?		Flera alternativ	kan anges
	 1.	 	Om	vaccinet	verkligen	skyddar	 5.	 	 Jag	har	inga	frågor	-	Gå	till	F507
	 2.	 	Om	vaccinet	har	biverkningar	 998.	 	 Vet	ej
	 3.	 	Om	vaccinationen	behöver	upprepas
	 4.	 	 Annat	(Ange	vad)	 	...................................................................................................................................
	 	 	........................................................................................................................................................................
F506	 Skulle	någon	av	ovanstående	frågor	kunna	få	dig	att	avstå	från	att	vaccinera	dig	mot	HPV?	
	 	 Välj endast ett alternativ
	 1.	 	Om	vaccinet	verkligen	skyddar	 5.	 	 Jag	skulle	vaccinera	mig	oavsett	frågor
	 2.	 	Om	vaccinet	har	biverkningar	 998.	 	 Vet	ej
	 3.	 	Om	vaccinationen	behöver	upprepas
	 4.	 	 Annat	(Ange	vad)	 	...................................................................................................................................
	 	 	........................................................................................................................................................................
F507	 Tror	du	att	du	skulle	vara	fullständigt	skyddad	mot	kondylom	om	du	vaccinerade	dig	mot	HPV?
	 1.	 	 Ja	 2.	 	 Nej	 998.	 	 Vet	ej
F508	 Skulle	du	kunna	tänka	dig	att	ha	mer	oskyddat	sex	än	idag	(=utan	att	använda	kondom)		
	 	 om	du	vaccinerar	dig	mot	HPV?
	 1.	 	 Ja	 2.	 	 Nej	 998.	 	 Vet	ej
Slut på frågeformuläret 
Ett stort tack för att Du tog dig tid att svara på dessa frågor. Vi uppskattar verkligen din hjälp!
Fyll i de förtryckta fälten eller kryssa in det alternativ som du anser passar bäst
	 	 		
Nr	 Frågor	 	
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THE STUDY OF HPV VACCINE’S ACCEPTABILITY IN SWEDEN 
 
QUESTIONNAIRE FOR FEMALE ADULT AGED 18-30 YEAR OLDS  
 
 
001  QUESTIONNAIRE IDENTIFICATION NUMBER   [_A_|_M_|___|___|___|___] 
 
002  DATE OF FILLING IN QUESTIONNAIRE (mm/dd/yyyy):  ____/ ____ / 2006 
 
Section 1: Background characteristics 
 
No. Questions and filters Coding categories Skip to 
 
Q101 
 
What is your age? 
 
Age:    [__|__] 
 
 
 
Q102 
 
From what country were you born? 
 
Sweden     1 
Iceland, Denmark, Finland or Norway     2 
Outside the Nordic countries     3 
 
 
 
Q103 
 
What is your current marital status? 
 
Use Swedish version as in CCS study, add 
registered partner to Married 
 
 
Q104 
 
Are you currently in a relationship? 
 
Yes     1 
No     2 
 
 
Q105 
 
Which is your current state of 
employment? 
 
(Please select only one choice) 
 
Full-time employed     1 
Part-time employed     2 
Un-employed     3 
Retired     4 
Parental leave     5 
Student     6 
Other     7 
Please specify: …………………………… 
…………………………… 
 
 
Q106 
 
What is your annual income level? 
 
(Please select only one choice) 
 
Include arbetslöshetsunderstöd, 
sjukpension, etc. Do not include 
studielån och studiebidrag 
 
Less than 50000 kronor/year     1 
50000 – 100000 kronor/year     2 
100000 – 150000 kronor/year     3 
150000 – 200000 kronor/year     4 
200000 – 250000 kronor/year     5 
250000 – 300000 kronor/year     6 
300000 – 400000 kronor/year     7 
400000 – 500000 kronor/year     8 
More than 500000 kronor/year     9 
 
 
Q107 What is the highest level of school 
you completed? 
 
(Please select only one choice) 
Use Swedish version as in CCS study 
If not going to school then skip to next 
section 
 
 2 
 
Q108 
 
How many total years of education 
have you completed up to now? 
 
 
# Years completed  [__|__] 
                                           
 
 
Section 2 Now we would like to ask you some questions about your sexual habits. Your answers are very 
important in helping us understand how certain diseases can be prevented. All answers will be kept 
confidential, so please answer each question honestly and accurately. 
 
No. Questions and filters Coding categories Skip to 
 
Q201 
 
Who have you ever had sex (of any 
type) with? 
(Several choices can be given) 
 
A man     1 
A woman     2 
Never had sex     3 
 
 
 
Q301 
 
Q202 
 
Did you ever have vaginal sex? 
Yes     1 
No     2 
Don’t know 998 
 
Q301 
Q301 
 
Q203 
 
If you have ever had vaginal sex, 
how old were you at your first 
experience? 
 
Years of age     [__|__] 
 
Don’t know     998 
 
 
Q204 
 
Have you ever had other types of sex 
than vaginal sex? 
 
(Several choices can be given) 
 
Oral sex     1 
Anal sex     2 
Other type of sex    3 
Only vaginal sex     4 
Don’t want to reply 999 
 
 
 
 
Q206 
 
Q205 
 
What age were you when you had 
any of the above mentioned types of 
sex for the first time? 
 
Years of age     [__|__] 
 
Don’t know     998 
 
 
Q206 
 
How many sexual partners did you 
have in the last year? 
 
(If none, please write 0) 
 
Sexual partners include steady 
partners (wife/girlfriends/registered 
partner) and one-night stands 
 
Number of sex partners [__|__|__]  
 
 
 
 
Q207 
 
Among them, how many were one-
night stand? 
 
(If none, please write 0) 
 
Number of one-night stands [__|__|__] 
 
 
Q208 
 
Have you ever used condoms? 
 
Yes     1 
No     2 
Don’t know     998 
 
 
Q211 
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Q209 
 
With regards to sex with your steady 
partners, with what frequency did 
you and your steady partner(s) use 
condoms over the last year? 
 
(If you did not have a steady partner, 
please circle number 9) 
 
Every time (100% of the time)     1  
Almost every time (75-99%)     2  
Often (50-74%)     3 
Sometimes (25-49%)     4 
Rarely (1-24%)     5 
Never (0%)     6 
No steady partner over last year     7 
Don’t know     998 
 
 
Q210 
 
With regards to sex with your one-
night stands, with what frequency did 
you and your one-night stands use 
condoms over the last year? 
 
(If you did not have one-night stand 
partner, please circle number 9) 
 
Every time (100% of the time)     1  
Almost every time (75-99%)     2  
Often (50-74%)     3 
Sometimes (25-49%)     4 
Rarely (1-24%)     5 
Never (0%)     6 
No one-night stand over last year     7 
Don’t know     998 
 
 
Q211 
 
Compared to other women of your 
age, do you consider your-self as 
having had more, fewer, or about the 
same number of sex partners? 
 
More     1 
Fewer     2 
About the same     3 
Don’t know     998 
 
 
Q212 
 
What level of risk of sexually 
transmitted infections do you think 
you are having? 
 
Not at risk     1 
Low risk     2 
Medium risk     3 
High risk     4 
Don't know     998 
 
 
 
 
 
Section 3 Now we would like to ask you some questions about certain health conditions. There is no 
right or wrong, good or bad answers. Please truly tell us what you know or think. 
 
 
No. Questions and filters Coding categories Skip to 
 
Q301 
 
Before you participated in this study, 
have you ever heard about cancers of 
the cervix (cervical cancer)? 
 
Yes     1 
No     2 
 
 
Q304 
 
Q302 
 
Do you believe that cervical cancer is 
a common cancer among women? 
 
Very common     1 
Rather common     2 
Not so common     3 
Very uncommon     4 
Don't know     998 
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No. Questions and filters Coding categories Skip to 
 
Q303 
 
Have you ever heard about any 
possible cause(s) of cervical cancer? 
 
Yes     1 
No     2 
 
 
 
 
Q304 
 
Have you ever heard of Condyloma, 
also called Genital Warts? 
 
Yes     1 
No     2 
 
 
Q307 
 
Q305 
 
Do you believe that Condyloma is a 
serious disease? 
 
Very serious     1 
Rather serious     2 
Not so serious     3 
Not serious at all     4 
Don't know     998 
 
 
Q306 
 
Have you ever heard about any 
possible cause(s) of Condyloma? 
 
Yes     1 
No     2 
 
 
Q307 
 
Before you participated in this study, 
have you heard about a virus called 
Human Papillomavirus (HPV)? 
 
Yes     1 
No     2 
 
 
Q401 
 
 
Q308 
 
Do you believe that HPV may cause 
cervical cancer? 
 
Yes     1 
No     2 
Don't know     998 
 
 
Q309 
 
Do you believe that HPV may cause 
other types of cancer than cervical 
cancer? 
 
Yes     1 
No     2 
Don't know     998 
 
 
Q310 
 
Do you believe that HPV may cause 
Condyloma? 
 
Yes     1 
No     2 
Don't know     998 
 
 
Q311 
 
Do you believe that HPV is sexually 
transmitted? 
 
Yes     1 
No     2 
Don't know     998 
 
 
Q312 
 
Do you believe that women can be 
infected by HPV? 
 
Yes     1 
No     2 
Don't know     998 
 
 
Q313 
 
Do you believe that men can be 
infected by HPV? 
 
Yes     1 
No     2 
Don't know     998 
 
 
Q314 
 
Are you aware if there is a vaccine 
against HPV caused disease? 
 
 
A vaccine is available     1  
A vaccine is being tested     2 
There is no such vaccine     3 
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SELECT ONE Don’t know     998 
 
 
 
Section 4 In this section, we will ask for your general opinions about vaccination. Again, there is no 
right or wrong answer. Please let us know what you think. 
 
No. Questions and filters Coding categories Skip to 
 
Q401 
 
In general, do you believe that 
vaccination is an effective way 
against diseases?  
 
(Please circle one choice only) 
 
Very effective     1 
Rather effective     2 
Not so effective     3 
Not effective at all     4 
Don’t know     998 
 
 
Q402 
 
Do you think that vaccination is a 
cost-efficient way against diseases? 
 
Very cost-efficient     1 
Rather cost-efficient     2 
Not so cost-efficient     3 
Not cost-efficient at all     4 
Don’t know     998 
 
 
Q403 
 
In your opinion, is vaccination 
generally a safe way against disease? 
 
Very safe     1 
Rather safe     2 
Not so safe     3 
Not safe at all     4 
Don’t know     998 
 
 
Q404 
 
If there is a vaccine that is coming out 
that concern you, how would you like 
to know about it?  
 
(Several choices may be given) 
 
Via health workers     1 
Educational programs on TV, radios     2 
Health education at work/school     3 
Booklet, brochure, leaflet     4 
Authorized websites     5 
Others     6 
…………………………………………. 
Don’t know     998 
 
 
Q405 
 
Which of the above ways would be 
the best way you want to know about 
a new vaccine?  
 
(Please select only one choice) 
 
Via health workers     1 
Educational programs on TV, radios     2 
Health education at work/school     3 
Booklet, brochure, leaflet     4 
Authorized websites     5 
Others     6 
…………………………………………. 
Don’t know     998 
 
 
 
Section 5  
 
For your information, an effective three-dose vaccine against HPV has been developed and will soon be 
ready for use. Please do not go back and “correct” any answer given previously. We would like to ask 
for your opinion about the usage of this new HPV vaccine. 
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No. Questions and filters Coding categories Skip to 
 
Q501 
 
If the vaccine is free, would you be 
willing to vaccinate yourself? 
 
Yes     1 
No     2 
Don’t know     998 
 
 
Q505 
 
Q502 
 
What if the vaccine is only given at 
some extra cost, would you still be 
willing to vaccinate yourself? 
 
Yes     1 
No     2 
Don’t know     998 
 
 
Q504 
Q504 
 
Q503 
 
What is the maximum cost that you 
think you can afford? (Three doses 
are considered to give full protection) 
 
(If you will vaccinate yourself at all 
cost, please circle number 2) 
 
Price per dose (in SEK)     
………………………… 
 
Vaccination at any cost     2 
 
 
 
 
Q504 
 
At what age would you consider 
vaccinate yourself? 
 
(Please circle number 9 if you don’t 
consider vaccinating yourself at any 
age) 
 
Age to start HPV vaccination [__|__] 
 
I don’t consider HPV vaccination     9 
 
 
Q505 
 
You may have concerns about the 
new vaccine. If so, please mark what 
you would like to know more about 
this new HPV vaccine? 
 
(You can select more than one choice 
if necessary) 
 
If the vaccine is really protective     1 
If there are any side effects (safety)     2 
If vaccine needs to be repeated with more 
doses in the future     3 
Others     4 
Please specify:_____________ 
_________________________________ 
I have no concerns     5 
Don’t know     998 
 
 
 
 
 
 
 
 
Q507 
 
Q506 
 
If it may, what of those concerns 
could MOST likely make you NOT 
vaccinate yourself against HPV? 
 
(Please circle only ONE choice) 
 
If the vaccine is really protective     1 
If there are any side effects (safety)     2 
If vaccine needs to be repeated with more 
doses in the future     3 
Others     4 
Please specify:_____________ 
_________________________________ 
I would get vaccinated despite concerns     
5 
Don’t know     998  
 
 
Q507 
 
Do you think that you would be fully 
protected against cervical cancer if 
you get vaccinated? 
 
Yes     1 
No     2 
Don’t know     998 
 
 
Q508 
 
Do you think that you would be fully 
protected against condyloma if you 
 
Yes     1 
No     2 
 
 7 
get vaccinated? Don’t know     998 
 
Q509 
 
Would you consider having more 
unprotected sex (=not using a 
condom) if you get vaccinated? 
 
Yes     1 
No     2 
Don’t know     998 
 
 
 
Section 6 Cervical cancer screening program 
 
No. Questions and filters Coding categories Skip to 
 
Q601 
 
Have you ever heard about the 
cervical cancer screening program? 
 
Yes     1 
No     2 
 
 
Q604 
 
Q602 
 
Have you ever participated in a 
cervical cancer screening program? 
 
Yes     1 
No     2 
Don’t know     998 
 
 
Q604 
Q604 
 
Q603 
 
How would your behavior regarding 
cervical cancer screening be affected 
if you get vaccinated against HPV? 
 
I would stop having Pap smears     1 
I would have Pap smears less frequently 
than today     2 
I would have Pap smears as usual     3 
Don’t know     998 
 
 
Q604 
 
If the answers is No or Don’t know in 
Q601 or Q602, do you think you will 
participate in a cervical cancer 
screening program in the future, even 
if you are vaccinated against HPV? 
 
Yes I will     1 
No I will not     2 
I don’t know     998 
 
 
 
 
 
End of the questionnaire 
Thank you very much for taking time to answer these questions. We highly appreciate your help! 
F101	 Hur	gammal	är	du?	
F102	 I	vilket	land	är	du	född?
	 1.	 	 Sverige	 2.	 	 Danmark,	Finland,	Island	eller	Norge	 3.	 	 Annat	land
F103	 Vilket	är	ditt	nuvarande	civilstånd?
	 1.	 	Gift/sambo/registrerad	partner	-	Gå	till	F105	 3.	 	 Änka
	 2.	 	 Ensamstående		 	 	 	 999.	 	 Vill	ej	svara
F104	 Har	du	för närvarande	ett	förhållande?
	 1.	 	 Ja	 2.	 	 Nej
F105	 Vilken	är	din	huvudsakliga	sysselsättning?		Välj endast ett alternativ
	 1.	 	 Heltidsarbetande	 3.	 	 Arbetslös	 5.	 	 Föräldraledighet
	 2.	 	 Deltidsarbetande	 4.	 	 Sjukpensionär	 6.	 	 Studerande	
	
	 7.	 		Annat	(ange	vad)	 	..................................................................................................................................
F106	 Vilken	är	din	årliga	inkomst	före	skatt?	Inkludera	arbetslöshetsunderstöd,	sjukpension,	etc.		
	 	 Inkludera	inte	studielån	och	studiebidrag		Välj endast ett alternativ
	 1.	 	Mindre	än	50	000	kr/år	 4.	 	 150	000–200	000	kr/år	 7.	 	 300	000–400	000	kr/år
	 2.	 	 50	000–100	000	kr/år	 5.	 	 200	000–250	000	kr/år	 8.	 	 400	000–500	000	kr/år
	 3.	 	 100	000–150	000	kr/år	 6.	 	 250	000–300	000	kr/år	 9.	 	Mer	än	500	000	kr/år
	 	 	 	 	 	 	 998.	 	 Vet	ej
F107	 Vilken	är	din	högsta	avslutade	utbildning?		Välj endast ett alternativ
	 1.	 	Grundskola	år	1–9	 5.	 	 Folkhögskola
	 2.	 	Yrkesskola	 6.	 	Högskola/universitet	upp	till	2	år
	 3.	 	Gymnasium	 7.	 	 Högskola/universitet	mer	än	2	år
	 4.	 	Vuxenutbildning	
	 	 	 	 8.	 	Annat	 	........................................................................................
	 	 	 	 	 	
F108	 Hur	många	år	har	du	sammanlagt	studerat	fram	till	idag?	
	 	 Antal	(hela)	studieår	 	 998.	 	 Vet	ej
	
UNDERSÖKNING OM INSTÄLLNINGEN TILL ETT NYTT VACCIN
FRÅGEFORMULÄR FÖR KVINNOR MELLAN 18 OCH 30 ÅR
Fyll i de förtryckta fälten eller kryssa in det alternativ som du anser passar bäst
Del 1. Bakgrund
	 	 	 	 	 	 	 	 	 	 	 	 	 	 	
Nr	 Frågor	 	 	 	 	 	 	 	 	 	 	 	 	
F201	 Med	vilka	av	följande	har	du	någon	gång	haft	någon	typ	av	sexuellt	umgänge?		Flera alternativ kan anges
	 1.	 	Man	 2.	 	 Kvinna	 3.	 	 Har	aldrig	haft	sexuellt	umgänge	-		
	 	 	 	 	 	 	 	 	 Gå	till	F301
F202	 Har	du	haft	vaginalt	samlag	någon	gång?
	 1.	 	 Ja	 2.	 	 Nej	-	Gå	till	F204	 998.	 	 Vet	ej	-	Gå	till	F204
F203	 Om	ja	på	ovanstående	fråga,	hur	gammal	var	du	första	gången	du	hade	vaginalt	samlag?
	 	 Ålder	 	 998.	 	 Vet	ej
F204	 Har	du	någonsin	haft	annan	typ	av	sexuellt	umgänge	än	vaginalt	samlag?		Flera alternativ kan anges 
	 	 	 	 	 	 	
	 1.	 	Oralsex	 3.	 	 Annan	typ	av	sex	
	 2.	 	 Analsex	 4.	 	 Endast	vaginalt	samlag	-	Gå	till	F206
	 	 	 	 999.	 	 Vill	ej	svara
F205	 Hur	gammal	var	du	när	du	hade	någon	av	ovan	nämnda	typer	av	sex	första	gången?
	 	 Ålder	 	 998.	 	 Vet	ej
F206	 Hur	många	sexpartners	har	du	haft	det	senaste	året?	Räkna	med	fasta	partners	och	tillfälliga		
	 	 förbindelser.	(Om ingen, ange 0)
	 	 Antal	sexpartners	 	 998.	 	 Vet	ej
F207	 Hur	många	av	dina	sexpartners	det	senaste	året	var	tillfälliga	förbindelser? (Om ingen, ange 0)
	 	 Antal	tillfälliga	förbindelser	 	 998.	 	 Vet	ej
F208	 Har	du	någonsin	använt	kondom?
	 1.	 	 Ja	 2.	 	 Nej	-	Gå	till	F212	 998.	 	 Vet	ej
Fyll i de förtryckta fälten eller kryssa in det alternativ som du anser passar bäst
Del 2.  Nu följer några frågor om sexualvanor. Dina svar kan hjälpa oss att förstå hur vissa  
 sjukdomar kan förhindras. Vi ber dig besvara frågorna så noggrannt som möjligt. 
	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 		
Nr	 Frågor	 	 	 	 	 	 	 	 	 	 	 	 	 	
F209	 När	du	hade	sex	med	din(a)	fast(a)	partner(s),	hur	ofta	använde	ni	kondom	under	det	senaste	året?	
	 	 (Välj	nummer	7	om	du	inte	hade	någon	fast	partner	det	senaste	året?)
	 1.	 	 Varje	gång	(100%	av	tillfällena)	 	 5.	 	 Sällan	(1-24%)
	 2.	 	 Nästan	varje	gång	(75-99%)	 	 	 	 6.	 	 Aldrig	(0%)
	 3.	 	Ofta	(50-74%)	 	 	 	 7.	 	 Har	inte	haft	någon	fast	partner	senaste	året
	 4.	 	 Ibland	(25-49%)	 	 	 	 998.	 	 Vet	ej
F210	 När	du	hade	sex	med	din(a) tillfällig(a) partner(s),	hur	ofta	använde	ni	kondom	under	det	senaste	året?	
	 	 (Kryssa	nummer	7	om	du	inte	hade	någon	tillfällig	partner	det	senaste	året?)
	 1.	 	 Varje	gång	(100%	av	tillfällena)	 	 5.	 	 Sällan	(1-24%)
	 2.	 	 Nästan	varje	gång	(75-99%)	 	 	 	 6.	 	 Aldrig	(0%)
	 3.	 	Ofta	(50-74%)	 	 	 	 7.	 	 Har	inte	haft	någon	tillfällig	partner	senaste	året
	 4.	 	 Ibland	(25-49%)	 	 	 	 998.	 	 Vet	ej
	F211	 Jämfört	med	andra	kvinnor	i	din	ålder,	tror	du	att	du	har	haft	fler,	färre	eller	ungefär	lika		
	 	 många	sexpartners	(totalt	sett)?
	 1.	 	 Fler	 3.	 	 Ungefär	lika	många
	 2.	 	 Färre		 998.	 	 Vet	ej
F212	 Hur	stor	risk	att	råka	ut	för	sexuellt	överförbara	sjukdomar	tror	du	att	du	har?
	 1.	 	 Ingen	risk	 3.	 	Ganska	stor	risk
	 2.	 	 Liten	risk	 4.	 	 Stor	risk	 998.	 	 Vet	ej
Fyll i de förtryckta fälten eller kryssa in det alternativ som du anser passar bäst
	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 		
Nr	 Frågor	 	 	 	 	 	 	 	 	 	 	 	 	 	
Fyll i de förtryckta fälten eller kryssa in det alternativ som du anser passar bäst
Del 3. Nu följer några frågor om hälsoförhållanden. Det finns inga riktiga eller felaktiga svar.  
 Vi ber dig svara uppriktigt vad du vet eller tror.	
	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 		
Nr	 Frågor	 	 	 	 	 	 	 	 	 	 	 	 	 	
F301	 Hade	du	hört	talas	om	livmoderhalscancer	innan	du	deltog	i	denna	studie?
	 1.	 	 Ja	 2.	 	 Nej	-	Gå	till	F304
F302	 Tror	du	att	livmoderhalscancer	är	en	vanlig	cancerform	bland	kvinnor?
	 1.	 	Mycket	vanlig	 3.	 	 Inte	så	vanlig
	 2.	 	Ganska	vanlig	 4.	 	Mycket	ovanlig	 998.	 	 Vet	ej
F303	 Känner	du	till	möjliga	orsaker	till	livmoderhalscancer?
	 1.	 	 Ja	 2.	 	 Nej
F304	 Har	du	någonsin	hört	talas	om	kondylom,	även	kallade	könsvårtor?
	 1.	 	 Ja	 2.	 	 Nej	-	Gå	till	F307
F305	 Hur	allvarligt	är	kondylom	enligt	din	uppfattning?	
	 1.	 	Mycket	allvarligt	 3.	 	 Inte	så	allvarligt
	 2.	 	Ganska	allvarligt	 4.	 	 Inte	alls	allvarligt	 998.	 	 Vet	ej
F306	 Känner	du	till	möjliga	orsaker	till	kondylom?
	 1.	 	 Ja	 2.	 	 Nej
F307	 Hade	du	hört	talas	om	ett	virus	kallat	humant	papillomvirus	(HPV)	innan	du	deltog	i	denna	studie?
	 1.	 	 Ja	 2.	 	 Nej	-	Gå	till	F401
F308	 Tror	du	att	HPV	kan	orsaka	livmoderhalscancer?
	 1.	 	 Ja	 2.	 	 Nej	 998.	 	 Vet	ej
F309	 Tror	du	att	HPV	kan	orsaka	annan	cancer	än	livmoderhalscancer?
	 1.	 	 Ja	 2.	 	 Nej	 998.	 	 Vet	ej
F310	 Tror	du	att	HPV	kan	orsaka	kondylom?
	 1.	 	 Ja	 2.	 	 Nej	 998.	 	 Vet	ej
F311	 Tror	du	att	HPV	kan	smitta	genom	sexuellt	umgänge?
	 1.	 	 Ja	 2.	 	 Nej	 998.	 	 Vet	ej
F312	 Tror	du	att	kvinnor	kan	smittas	av	HPV?
	 1.	 	 Ja	 2.	 	 Nej	 998.	 	 Vet	ej
F313	 Tror	du	att	män	kan	smittas	av	HPV?
	 1.	 	 Ja	 2.	 	 Nej	 998.	 	 Vet	ej
F314	 Känner	du	till	om	det	finns	något	vaccin	mot	sjukdom	orsakad	av	HPV?		Välj endast ett alternativ
	 1.	 	 Ett	vaccin	finns	tillgängligt	 3.	 	 Det	finns	inget	vaccin	mot	HPV
	 2.	 	 Ett	vaccin	testas	för	närvarande	 998.	 	 Vet	ej	
F401	 Tror	du	att	vaccination	kan	vara	ett	effektivt	sätt	att	förebygga	sjukdomar?		Välj endast ett alternativ
	 1.	 	Mycket	effektivt	 3.	 	 Inte	så	effektivt
	 2.	 	Ganska	effektivt	 4.	 	 Inte	alls	effektivt	 998.	 	 Vet	ej
F402	 Tror	du	att	vaccination	kan	vara	ett	kostnadseffektivt	sätt	att	förebygga	sjukdomar?		Välj endast  
  ett alternativ
	 1.	 	Mycket	kostnadseffektivt	 3.	 	 Inte	så	kostnadseffektivt
	 2.	 	Ganska	kostnadseffektivt	 4.	 	 Inte	alls	kostnadseffektivt	998.	 	 Vet	ej
F403	 Tror	du	att	vaccination	är	en	säker	metod	att	förebygga	sjukdomar?		Välj endast ett alternativ
	 1.	 	Mycket	säker	 3.	 	 Inte	så	säker
	 2.	 	Ganska	säker	 4.	 	 Inte	alls	säker	 998.	 	 Vet	ej
F404	 Om	det	lanseras	ett	vaccin	som	du	skulle	kunna	ha	nytta	av,	hur	skulle	du	helst	vilja	få	reda		
	 	 på	det?		Flera alternativ kan anges
	 1.	 	 Via	sjukvårdspersonal	 	 5.	 	 Via	Internet
	 2.	 	 Utbildningsprogram	på	TV	eller	radio	 6.	 	 Annat	sätt	(Ange	vad)	 	.............................................
	 3.	 	 Hälsoundervisning	på	arbete/skola	 	 	 	
	 4.	 	 Informationsfolder,	broschyr,	häfte	 	 	 	..................................................................................
	 	 	 	 	 	 	 998.	 	 Vet	ej	-	Gå	till	F501
	 	 	 	
F405	 Vilket	av	ovanstående	sätt	skulle	vara	det	bästa	för	dig	att	få	information	om	ett	nytt	vaccin?		
	 	 Välj endast ett alternativ
	 1.	 	 Via	sjukvårdspersonal	 	 5.	 	 Via	Internet
	 2.	 	 Utbildningsprogram	på	TV	eller	radio	 6.	 	 Annat	sätt	(Ange	vad)	 	.............................................
	 3.	 	 Hälsoundervisning	på	arbete/skola	 	 	 	
	 4.	 	 Informationsfolder,	broschyr,	häfte	 	 	 	..................................................................................
	 	 	 	 	 	 	 998.	 	 Vet	ej
	 	 	 	
Fyll i de förtryckta fälten eller kryssa in det alternativ som du anser passar bäst
Del 4. Nu följer några frågor om din inställning till vaccination.  
 Återigen finns det inga rätta eller felaktiga svar. Ange bara din åsikt.	
	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 		
Nr	 Frågor	 	 	 	 	 	 	 	 	 	 	 	 	 	
F501	 Skulle	du	vilja	vaccinera	dig	mot	HPV	om	vaccinet	är	gratis?
	 1.	 	 Ja	 2.	 	 Nej	-	Gå	till	F505	 998.	 	 Vet	ej
F502	 Skulle	du	vilja	vaccinera	dig	mot	HPV	om	vaccinet	kostar	pengar?
	 1.	 	 Ja	 2.	 	 Nej	-	Gå	till	F504	 998.	 	 Vet	ej	-	Gå	till	F504
F503	 Vilken	är	den	högsta	kostnad	du	kan	tänka	dig	att	betala	för	att	vaccinera	dig	mot	HPV?		
	 	 (Tre	doser	anses	ge	ett	fullgott	skydd).
	 Pris	för	vaccination	per	dos	(i	kr)	 ..............................	 2.	 	 Vaccination	oavsett	kostnad
F504	 Vid	vilken	ålder	anser	du	att	man	ska	vaccinera	mot	HPV?
	 Ålder	för	att	påbörja	HPV-vaccination	 	 	 9.	 	 Jag	överväger	inte	HPV-vaccination
F505	 Vilken	information	skulle	du	vilja	ha	om	det	nya	vaccinet?		Flera alternativ	kan anges
	 1.	 	Om	vaccinet	verkligen	skyddar	 5.	 	 Jag	har	inga	frågor	-	Gå	till	F507
	 2.	 	Om	vaccinet	har	biverkningar	 998.	 	 Vet	ej
	 3.	 	Om	vaccinationen	behöver	upprepas
	 4.	 	 Annat	(Ange	vad)	 	...................................................................................................................................
	 	 	........................................................................................................................................................................
F506	 Skulle	någon	av	ovanstående	frågor	kunna	få	dig	att	avstå	från	att	vaccinera	dig	mot	HPV?	
	 	 Välj endast ett alternativ
	 1.	 	Om	vaccinet	verkligen	skyddar	 5.	 	 Jag	skulle	vaccinera	mig	oavsett	frågor
	 2.	 	Om	vaccinet	har	biverkningar	 998.	 	 Vet	ej
	 3.	 	Om	vaccinationen	behöver	upprepas
	 4.	 	 Annat	(Ange	vad)	 	...................................................................................................................................
	 	 	........................................................................................................................................................................
Fyll i de förtryckta fälten eller kryssa in det alternativ som du anser passar bäst
Del 5. Vi vill informera dig om att HPV är ett sexuellt överförbart virus som kan orsaka kondylom hos  
 män och kvinnor och livmoderhalscancer hos kvinnor. Ett effektivt HPV-vaccin har utvecklats  
 och är klart för användning. Vi ber dig att inte gå tillbaka och ändra något  
 av de tidigare avgivna svaren.  
 Nu  vill vi fråga om din åsikt angående användning av det nya HPV-vaccinet.
 
	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 		
Nr	 Frågor	 	 	 	 	 	 	 	 	 	 	 	 	 	
F601	 Har	du	någonsin	hört	talas	om	gynekologisk	cellprovskontroll	för	att	förebygga	livmoderhalscancer?
	 1.	 	 Ja	 2.	 	 Nej	-	Gå	till	F604
F602	 Har	du	någonsin	tagit	ett	gynekologiskt	cellprov?
	 1.	 	 Ja	 2.	 	 Nej	-	Gå	till	F604	 998.	 	 Vet	ej	-	Gå	till	F604
F603	 Hur	skulle	ditt	beteende	beträffande	gynekologisk	cellprovskontroll	påverkas	om	du	vaccinerar	dig	mot	HPV?
	 1.	 	 Jag	skulle	helt	sluta	ta	cellprov	 	 	 	 3.	 	 Jag	skulle	forsätta	ta	cellprov	som	tidigare
	 2.	 	 Jag	skulle	ta	cellprov	mer	sällan	än	idag	 998.	 	 Vet	ej
F604	 Denna fråga gäller endast dig som svarade nej eller vet ej  i någon av frågorna F601 eller F602 
	 	 Om	du	vaccinerar	dig	mot	HPV,	tror	du	att	du	kommer	att	ta	gynekologiska	cellprov	i	framtiden?
	 1.	 	 Ja	 2.	 	 Nej	 998.	 	 Vet	ej
Slut på frågeformuläret 
Ett stort tack för att Du tog dig tid att svara på dessa frågor. Vi uppskattar verkligen din hjälp!
Del 6  Nedan följer några frågor om deltagande i gynekologisk cellprovskontroll. 
	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 		
Nr	 Frågor	 	 	 	 	 	 	 	 	 	 	 	 	 	
Fyll i de förtryckta fälten eller kryssa in det alternativ som du anser passar bäst
	 	 	 	 	 	 	 	 	 	 	 	 	 	 	
	
Nr	 Frågor	 	 	 	 	 	 	 	 	 	 	 	 	
	
F507	 Tror	du	att	du	skulle	vara	fullständigt	skyddad	mot	livmoderhalscancer	om	du	vaccinerade	dig	mot	HPV?
	 1.	 	 Ja	 2.	 	 Nej	 998.	 	 Vet	ej
F508	 Tror	du	att	du	skulle	vara	fullständigt	skyddad	mot	kondylom	om	du	vaccinerade	dig	mot	HPV?
	 1.	 	 Ja	 2.	 	 Nej	 998.	 	 Vet	ej
F509	 Skulle	du	kunna	tänka	dig	att	ha	mer	oskyddat	sex	än	idag	(=utan	att	använda	kondom)		
	 	 om	du	vaccinerar	dig	mot	HPV?.
	 1.	 	 Ja	 2.	 	 Nej	 998.	 	 Vet	ej
